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Abstract 
3 
ifidobacterium is an important genus of the human gastrointestinal microbiota, affecting 
several host physiological features. Despite the numerous Bifidobacterium related health-
promoting activities, there is still a dearth of information about the molecular mechanisms at the 
basis of the interaction between this microorganism and the host. Bacterial surface associated 
proteins may play an important role in this interaction because of their ability to intervene with 
host molecules, as recently reported for the host protein plasminogen. Plasminogen is the 
zymogen of the trypsin-like serine protease plasmin, an enzyme with a broad substrate specificity. 
Aim of this thesis is to deepen the knowledge about the interaction between Bifidobacterium and 
the human plasminogen system and its role in the Bifidobacterium-host interaction process. As a 
bifidobacterial model, B. animalis subsp. lactis BI07 has been used because of its large usage in dairy 
and pharmaceutical preparations. 
We started from the molecular characterization of the interaction between plasminogen and one 
bifidobacterial plasminogen receptor, DnaK, a cell wall protein showing high affinity for 
plasminogen, and went on with the study of the impact of intestinal environmental factors, such 
as bile salts and inflammation, on the plasminogen-mediated Bifidobacterium-host interaction. 
According to our in vitro findings, by enhancing the activation of the bifidobacterial bound 
plasminogen to plasmin, the host inflammatory response results in the decrease of the 
bifidobacterial adhesion to the host enterocytes, favouring bacterial migration to the luminal 
compartment. Conversely, in the absence of inflammation, plasminogen acts as a molecular bridge 
between host enterocytes and bifidobacteria, enhancing Bifidobacterium adhesion. Furthermore, 
adaptation to physiological concentrations of bile salts enhances the capability of this 
microorganism to interact with the host plasminogen system. 
The host plasminogen system thus represents an important and flexible tool used by 
bifidobacteria in the cross-talk with the host. 
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The Gut Microbiota 
 
A huge amount and a wide range of microorganisms populate the human body. It has been 
estimated that the components of this human-associated microbiota outnumber human somatic 
and germ cells by a factor of ten, leading to reconsider human beings as “supraorganisms”. This 
microbial community contains members of the three domains of life, Eukarya, Bacteria and 
Archaea, with their relative viruses. Among the different regions of the human body where these 
microbial communities are present, the gastrointestinal tract (GIT) represents the most densely 
populated habitat (Gill et al., 2006; Turnbaugh et al., 2007; Ley et al., 2008; Neish, 2009). 
The human gut microbiota 
The GIT is a complex ecosystem composed of several host cells, lining the whole structure, and the 
intestinal microbiota, dominated by bacteria. Different kinds of eukaryotic cells constitute the 
intestine: absorptive enterocytes, mucus-secreting goblet cells, antimicrobial peptides-producing 
Paneth cells and neuroendocrine enterochromaffin cells (Daneman and Rescigno, 2009). In addition 
to their physiological role in digestion and absorption, these cells and their products constitute the 
intestinal epithelial barrier that, together with immune cells, interact with microorganisms and 
components present in the gut (Rescigno, 2011). 
The human intestine harbours a highly complex microbial ecosystem, populated with as many as 
100 trillion cells belonging to more than 1000 different species (Ley et al., 2006a; Rajilid-Stojanovid 
et al., 2007; Qin et al., 2010) (Fig. 1). It has been estimated that the collection of all the microbial 
genomes present in the gut, the microbiome, contains more than 100 times the number of genes in 
the human genome (Bäckhed et al., 2005). 
 
 
 
 
 
 
 
 
 
Fig. 1. Representation of the 
diversity of bacteria in the 
human intestine. Phylogenetic 
tree of the domain Bacteria 
based on 8903 representative 
sequences of the 16S rRNA gene. 
Wedges represent divisions 
(superkingdoms): those 
numerically abundant in the 
human gut are indicated in red, 
rare divisions are green, and 
undetected are black. Wedge 
length is a measure of 
evolutionary distance from the 
common ancestor. Scale bar 
indicates the degree of diversity 
(evolutionary distance) within a 
division, in terms of the fraction 
of the 16S rRNA gene 
nucleotides that differ between 
member sequences. CFB, 
Cytophaga-Flavobacterium-
Bacteroides (Bäckhed et al., 2005). 
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Space and time greatly influence the arrangement of the microbiota in the human gut. On the 
“biogeography” point of view, microbiota composition changes along the length of the whole GIT 
and across the mucosal barrier, from the epithelial surface through the mucus layer to the lumen. 
Despite its low pH, the stomach possesses a low density rich microbiota, containing up to a few 
hundreds members. Components of gastric microbiota belong primarily to the Firmicutes, 
Actinobacteria, Bacteroides, Proteobacteria and Fusobacteria phyla, with less abundant members 
from TM7 phylum, Deferribacteres, Deinococcus/Thermus and others (O’May et al., 2005; Bik et 
al., 2006; Andersson et al., 2008). Further downstream, the small intestine presents an associated 
microbiota similar to that of the stomach (Hayashi et al., 2005). Along the length of the GIT, 
moving from the stomach towards distally intestinal regions, a shift in community structure has 
been reported: facultative anaerobes are replaced by obligate anaerobes (Wang et al., 2003; 
Hayashi et al., 2005). The lower GIT contains the highest density of microorganisms, with an 
estimated concentration of 1011-1012 bacterial cells per g of gut content, one of the densest 
community known (Whitman et al., 1998). The colon microbiota is predominated by two bacterial 
phyla, Bacteroides and Firmicutes, which represent together up to 90% of the total microbiota in 
the distal gut; Actinobacteria and to a lesser extent Proteobacteria and Fusobacteria have been 
detected as subdominant phyla (Fig. 2). Despite this small amount of divisions, hundreds of 
species and thousands of strains inhabit the distal gut, leading to a significant variability among 
individuals (Bäckhed et al., 2005; Eckburg et al., 2005; Ley et al., 2006a, 2006b, 2008; Dethlefsen 
et al., 2008; Turnbaugh et al., 2009; Qin et al., 2010). 
Microbiota composition differs across the transversal axis of the gut, from the epithelium to the 
lumen. Factors such as host defence molecules in the mucus layer or the oxygen gradient through 
this layer have a significant impact on the amount and the composition of the microbiota from the 
epithelium to the lumen (Van den Abbeele et al., 2011). For the same reason, the microbiota 
associated with the intestinal mucosa has a different composition from the faecal microbiota of 
the same individual (Momozawa et al., 2011). 
The microbial community reveals a high inter-individual variability due to host genetics, age, diet, 
microbial phylogeny, environment and health status. These factors have an important impact on 
the composition and variability of the microbiota, and every individual has its own unique 
microbiota, characterized by a specific combination of species and strains, like a fingerprint 
(Zoetendal et al., 1998, 2001; Bäckhed et al., 2005; Ley et al., 2008; Benson et al., 2010). Despite 
inter-individual composition variation, microbial function in healthy individual is maintained, 
suggesting the existence of a core microbiome in terms of functional genes (Tap et al., 2009; 
Turnbaugh et al., 2009; Qin et al., 2010). 
Bacteria are the major components of the gut microbiota, but other microorganisms inhabit this 
ecosystem. The two predominant Archaea found in the gut microbiota are Methanobrevibacter 
smithii and Methanosphaera stadtmanae (Scanlan et al., 2008b; Dridi et al., 2009). Among the 
eukaryotic members of the intestinal microbiota, culture-dependent approaches have detected 
Candida and Saccharomyces spp., but yeasts become less represented with culture-independent 
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analyses, that have revealed the predominance of species belonging to the Blastocystis genus (Ott 
et al., 2008; Scanlan and Marchesi, 2008). The viral component of the human gut microbiota has 
received limited attention, and recent studies have disclosed interesting insights, pointing out the 
enormous amount of estimated viruses present and their great diversity (Breitbart et al., 2003, 
2008; Zhang et al., 2006; Reyes et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Composition and luminal concentrations of dominant bacterial phyla along the human gastrointestinal tract 
(O’Hara and Shanahan, 2006; Marchesi, 2011). 
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Colonization and ageing 
Microbial colonization of the gut starts immediately after birth. Newborns acquire their microbial 
community coming in contact with bacteria from environmental and maternal origin (Palmer et 
al., 2007; O’Toole and Claesson, 2010). The initial lower gut community includes enterococci, 
streptococci, staphylococci, Bacteroides members, bifidobacteria, clostridia (Mackie et al., 1999; 
Favier et al., 2002; Park et al., 2005a; Palmer et al., 2007). It is thought that the first aerobes and 
facultative anaerobes that colonize the gut reduce the redox potential of the newborns intestine, 
creating favourable environmental conditions for the later colonization, growth and establishment 
of obligate anaerobes (Stark and Lee, 1982). Many factors influence the early colonization process: 
composition of the maternal microbiota, vaginal or caesarean delivery, full or preterm gestation, 
breast or formula feeding, environmental exposure and clinical intervention, like antibiotics (Favier 
et al., 2003; Schwiertz et al., 2003; Palmer et al., 2007; Biasucci et al., 2010; Dominguez-Bello et 
al., 2010; Vaishampayan et al., 2010; Morowitz et al., 2011). 
From the second year of life, the composition of gut microbiota acquires a more definite and 
stable profile, converging to a generalized adult distal gut community (Palmer et al., 2007). During 
adulthood, a relative stability characterizes the gut microbiota, which displays limited 
compositional fluctuations over extended periods; factors that can impact the microbiota 
composition are antibiotic treatments, some pathological conditions (for instance inflammatory 
bowel diseases or obesity), changes in diet and lifestyle (Frank et al., 2007; Dethlefsen et al., 2008; 
Spor et al., 2011). 
The ageing process involves changes in the composition and diversity of the gut microbiota, such 
as reduction of the Bifidobacterium presence (Woodmansey, 2007). Recently, the gut microbiota 
of elderly and centenarians has been studied with novel molecular techniques in order to shed 
some light on the changes that take place during the last part of life (Rajilid-Stojanovid et al., 
2009; Biagi et al., 2010; Claesson et al., 2011). 
The remarkable temporal stability of the adult gut microbiota could be explained by the resilience 
characteristic of this community: the microbial components of an individual microbiota have 
coevolved in that peculiar environment, occupying specific niches within the community and 
maintaining composition and function of the microbial association. This relationship established 
among all the “authoctonous” members of the microbiota allows the microbial community to 
recover to a similar composition as before the disturbance within a timeframe of few weeks (Van 
den Abbeele et al., 2011). Another linked aspect is the colonization resistance: once the gut 
microbiota has been established, its members occupy all the available niches in the gut, precluding 
exogenous microorganisms to colonize the intestine (Guarner and Malagelada, 2003; Sansonetti 
and Medzhitov, 2009). 
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Analysis of the microbiota 
The composition of the human intestinal microbiota has been studied until recently by using 
traditional culturing techniques, such as anaerobic cultures (Moore and Holdeman, 1974). These 
methods provide only a partial vision of the biodiversity of the human gut microbiota because just 
a minor fraction (20-40%) of this community can be cultured (Langendijk et al., 1995; Suau et al., 
1999; Hayashi et al., 2003; Eckburg et al., 2005). Moreover, culture-based methods are laborious, 
time-consuming and more inclined to statistical and methodological errors. The development of 
culture-independent methods based on molecular techniques allowed faster and more detailed 
analysis of the composition of this complex microbial community (Furrie, 2006). 
The most commonly employed strategies for uncovering the composition of complex microbial 
ecosystems utilize the 16S ribosomal RNA (16S rRNA) gene sequence. This gene consists of 
approximately 1500 nucleotides and presents regions conserved among all the bacteria, 
interspersed with 9 hyper-variable regions (V1 to V9), in which the sequence can be genus or 
species specific (Tannock, 1999). 
One molecular method commonly used for the analysis of microorganisms in complex 
environmental samples is the FISH technique, Fluorescence In Situ Hybridization. This strategy 
relies on fluorescent oligonucleotide probes designed on 16S rRNA gene sequences specific for 
bacterial species or genus, allowing bacteria visualization and quantification through microscopy or 
flow cytometry (Zoetendal et al., 2004). 
A PCR based method widely used to characterize the composition of complex bacterial 
communities is the quantitative real time-PCR. Genus or species specific primers designed on the 
16S rRNA gene sequence are used to allow the quantification of different bacterial populations 
present in the ecosystem (Zoetendal et al., 2004). 
Fingerprinting techniques allow semi-quantitative analysis of microbial communities by separating 
fragments of the 16S rRNA gene and detecting variations in the sequence among members of 
communities. The most important fingerprinting techniques are Denaturing/Temperature 
Gradient Gel Electrophoresis (D/TGGE), Single Strand Conformational Polymorphism (SSCP) and 
Terminal-Restriction Fragment Length Polymorphism (T-RFLP). 
Microarray technology has been developed to study bacterial diversity in several complex 
ecosystems, among which the intestinal microbiota (Vaughan et al., 2000; Zoetendal et al., 2004). 
Diversity DNA microarrays are usually based on the sequence of the 16S rRNA gene and allow the 
identification of bacteria in complex microbial communities. The huge amount of different specific 
probes present on the microarrays can give more precise information on the composition of the 
microbiota (Palmer et al., 2006, 2007; Paliy et al., 2009; Rajilid-Stojanovid et al., 2009). 
In recent times, next generation sequencing technologies have been applied for the deep analysis 
of the microbiota (Mardis, 2008; Shendure and Ji, 2008). Pyrosequencing is one of the main 
method: the massive sequencing of vast numbers of 16S rRNA genes from the complex gut 
Introduction 
12 
microbiota can further characterize in depth the intestinal ecosystem (Ronaghi et al., 1998; 
Margulies et al., 2005; Andersson et al. 2008; Dethlefsen et al., 2008; Claesson et al., 2009). 
The last frontier of microbial ecology is represented by metagenomic analysis techniques (Gill et 
al., 2006). These culture-independent methods are based on the analysis of the total genomic DNA 
present in a microbial community (metagenome) by sequencing or functional analysis. Together 
with other meta-“omic” approaches, such as metatranscriptomics, metaproteomics and 
metabonomics, these techniques provide further insights on the activity and functionality of the 
gut microbiota (Zoetendal et al., 2008). 
Microbiota activities and interactions with the host 
Through millennia, the host and the microbiota microorganisms have evolved an intricate network 
of reciprocal beneficial relationships, leading to the establishment of a balanced mutualistic 
symbiosis. It is thought that microorganisms that constitute the intestinal microbiota have been 
selected by the host because they have to face many specific host factors, such as physical 
conditions along the GIT (pH, temperature, retention time), diet types and the variety of defense 
systems present in this habitat (innate and adaptive immune system). The host environment has 
shaped the community structure of the microbiota, selecting for those microbial communities 
adapted to that habitat; and microorganisms have evolved specific functions useful for the host 
that the host hasn’t evolved by itself: this has led to the establishment of a functional stable and 
coevolved cooperation (Ley et al., 2006a, 2008; O’Hara and Shanahan, 2006; Blaser and Kirschner, 
2007; Muegge et al., 2011; Spor et al., 2011; Van den Abbeele et al., 2011). 
Microorganisms of the human gut microbiota provide the host with many metabolic activities that 
the host does not possess by itself, contributing to its nutrition. They possess a large metabolic 
degradation capacity of host indigestible substrates, such as complex plant-derived 
polysaccharides; they can degrade host mucin and influence bile salts and cholesterol metabolism, 
with an important impact on host energy harvest. Short chain fatty acids (SCFAs) are the end-
products of several microbial fermentations in the gastrointestinal ecosystem with important roles 
in energy and health-promoting effects to the host. Some essential vitamins, amino acids and 
several bioactive compounds are synthesized by microorganisms residing in the colon, that can 
also favour calcium, magnesium and iron uptake (Tannock, 1997; Hooper et al., 2001, 2002; 
Guarner and Malagelada, 2003; Macfarlane and Macfarlane, 2003; Flint et al., 2008; Cani and 
Delzenne, 2011; Kau et al., 2011). 
The intestinal microbiota plays also an important role as a barrier against invaders of the GIT. 
Competition for adhesion sites and production of antimicrobial peptides and SCFAs protect the gut 
mucosa from pathogen or opportunistic microorganisms (Liévin-Le Moal and Servin, 2006; 
Sansonetti and Medzhitov, 2009; Fukuda et al., 2011; Ashida et al., 2012). 
Moreover, the enormous microbial amount of the gut microbiota plays an essential role in the 
training and modulation of the gastrointestinal immune system. The direct or indirect interaction 
Introduction 
13 
between gut microorganisms and the epithelium is crucial for an appropriate shaping of the host 
innate and adaptive immune system, since the beginning of life. Innate and adaptive immune 
system actively monitors bacterial interactions with the intestinal mucosa interface, activating 
responses to limit bacterial contact with the mucosal surface. On the other hand, the resident gut 
microbiota has evolved traits in order to be ignored, or at least tolerated, by the gut immune 
system and stably inhabits that environment. Immunological host response and symbiont 
microorganisms modulation allow thus the establishment of an homeostatic balance, 
characterized by host tolerance towards gut microbiota members (Duerkop et al., 2009; Round 
and Mazmanian, 2009; Sansonetti and Medzhitov, 2009; Garrett et al., 2010; Hooper and 
Macpherson, 2010; Van den Abbeele et al., 2011) (Fig. 3). 
Gut microbiota and disease 
Individual microbial composition feels the effects of pathological conditions, antibiotic treatments, 
stress, diet changes and intestinal physiological alteration (Macfarlane and Cummings, 2002). The 
unnatural shift in the community composition of a “healthy” microbiota leads to an altered 
microbial colonization, named dysbiosis, with negative effects on the host health, such as a higher 
susceptibility to enteropathogens infections. Dysbiosis can also affect the immune system: recent 
studies have revealed altered immune responses in subjects with an unbalanced gut microbial 
composition (Round and Mazmanian, 2009; Lee and Mazmanian, 2010). 
In recent years, several studies have highlighted connections between intestinal microbiota 
composition and some pathologies, not only gastrointestinal but also systemic diseases: irritable 
bowel syndrome (IBS), inflammatory bowel disease (IBD), colorectal cancer (CRC), allergies, 
obesity, insulin resistance, cardiovascular disease (Seksik et al., 2003; Noverr and Huffnagle, 2005; 
Scanlan et al., 2006, 2008a; Frank et al., 2007; Kassinen et al., 2007; O’Mahony et al., 2009; Cani 
and Delzenne, 2011; Sobhani et al., 2011; Wang et al., 2011b). It’s important to note, however, 
that it is really difficult to determine if the detected microbial variations are one of the causes or a 
consequence of the disease (Zoetendal et al., 2006). 
IBD, with the two main forms Crohn’s disease and ulcerative colitis, and IBS are chronically 
relapsing gut diseases with a high incidence especially in developed countries. Shared 
characteristics are alterations in immune responses, altered microbiota composition, impaired 
intestinal barrier functions. Numerous studies have been carried out to unravel the intricate 
interconnections of gut microbial composition and inflammation and the underlying molecular 
mechanisms, and a recent review has focused on the possible role of bacterial proteases in the 
pathogenesis of these gastrointestinal disorders (Steck et al., 2011). 
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Fig. 3. Host immune system and microorganisms at the intestinal epithelial surface. A constant signalling between 
microorganisms and the host takes place at the epithelial surface of the intestinal mucosa. Intestinal epithelial cells 
(IECs) and dendritic cells (DCs) extending beyond the epithelium are essential for the initial recognition of 
microorganisms. Innate immunity pattern recognition receptors (PRRs) detect microorganisms-associated molecular 
patterns (MAMPs), allowing the host to distinguish between a microbial friend or foe and to initiate expression of 
anti-microbial peptides (AMPs). An important feature to distinguish between a microbial friend or foe is the strategic 
localization of PRRs and essential co-receptors: polarized (1–2), intracytosolic (3) or on specialized cells (4). 
Microorganisms can cross the epithelial barrier through IECs, DCs, villus M-cells and M-cells of the follicle-associated 
epithelium overlying the gut-associated lymphoid tissue of the Peyer’s patches. After or during this transport, antigens 
are engulfed in antigen presenting cells (APCs), that can be DCs, macrophages or B-cells. DCs travel from the 
epithelium through the lamina propria towards mesenteric lymphoid nodes, where they activate cells of the adaptive 
immune system. They are the only cells that can immediately bind with naïve T-cells, and through cytokine release, 
influence their maturation to Th1, Th2, Th17 or Treg. Th2 cells interact with B-cells to become plasma cells that 
secrete IgA antibodies and coat luminal microorganisms in order to prevent them from breaching the epithelium. 
Alternatively, DCs can also locally activate adaptive immune cells in the gut associated lymphoid tissue of the Peyer’s 
patches (Van den Abbeele et al., 2011). 
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Several clinical trials have demonstrated the impact of probiotics consumption on the altered gut 
microbial compositions characteristic of gastrointestinal disorders, suggesting a way to prevent 
and treat intestinal disorders (Chermesh and Eliakim, 2006; Jonkers and Stockbrügger, 2007; 
Imaoka et al., 2008). Probiotics have been defined as “live microorganisms which when 
administered in adequate amounts confer a health benefit on the host” (FAO/WHO, 2006). 
General characteristics of probiotic bacteria are effectiveness, safety and the capacity to go 
through the gastric barrier without their impairment from the action of acids, bile or proteolytic 
enzymes. Mechanisms by which probiotics may exert benefits to the host include modulation of 
the host immune system and pathogen prevention by binding site competition as well as 
antimicrobial compounds production (Fooks and Gibson, 2002; Vanderpool et al., 2008). The gut 
microbiota can be modulated also by the use of “prebiotics”, usually oligosaccharides that act as 
specific substrate for probiotic bacteria (such as members of Bifidobacterium and Lactobacillus 
genera) favouring their growth; generally, prebiotic substrates are not degraded by the host 
(Hamilton-Miller, 2004; Ouwehand et al., 2005; Hord, 2008). 
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Bifidobacterium 
 
Bifidobacterium is an important genus of the human intestinal microbiota. The bifidobacteria 
amount in the human gut seems to be dependent on various factors, for instance age and diet. 
Bifidobacteria are among the first colonizers of the GIT of newborns and represent the dominant 
genus of healthy breast-fed infants. During the first year of life, the intestinal microbiota 
undergoes several changes and bifidobacteria become less abundant, reaching an estimate 3% of 
the gut microbiota composition in the adults (Favier et al., 2002; Penders et al., 2006; Zoetendal et 
al., 2006; Kurokawa et al., 2007; Turroni et al., 2008, 2009; Ventura et al., 2009a; Roger et al., 2010). 
Bifidobacteria are Gram-positive, non-motile, non-spore-forming, non-gas-producing anaerobic 
bacteria (Scardovi, 1986; Ventura et al., 2004b; Klijn et al., 2005). Their morphology is variable and 
usually referred as bifid or irregular V- or Y-shaped rods, similar to branches (Fig. 4). The reason of 
this peculiar irregular shape is not yet clear, but different studies have pointed out that the 
absence of some nutrients in growth media can affect the shape (Glick et al., 1960; Kojima et al., 
1968; Kojima et al., 1970; Husain et al., 1972). 
 
 
 
 
 
 
 
 
Bifidobacteria were first isolated from the faeces of breast-fed infants by Henri Tissier in 1899, 
during his PhD project, and named Bacillus bifidus (Tissier, 1900). In 1924 Orla-Jensen proposed 
the novel genus Bifidobacterium (Orla-Jensen, 1924), but it has been recognized as an 
independent genus only in 1973 (Poupard et al., 1973; Bergey et al., 1974; Biavati et al., 2000). 
Two different approaches have been developed to isolate, detect and identify bifidobacteria: 
traditional culturing methods and molecular analysis. Culturing methods rely on the use of 
selective media. Selectivity can be achieved by means of antibiotics, such as neomycin, polymyxin 
B, nalidixic acid, mupirocin, or other inhibitory agents, like lithium chloride and propionate. 
Fig. 4. Scanning electron micrographs of B. longum NCC2705 cells. Bacteria have been grown in MRS medium under 
anaerobic conditions. During the exponential phase typical rod shapes are observed (A), while bifid or branched 
shaped forms are recognized in transition (B) and stationary (C) phases (Klijn et al., 2005). 
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Several molecular methods are culture-free and allow in situ analysis, avoiding the limitations of 
culturing (Mohania et al., 2008; Lee and O’Sullivan, 2010; Ashraf and Shah, 2011). 
Bifidobacteria are present in several ecological niches: different animal intestines (humans, mice, 
rabbit, cow, chicken, insects), oral cavity, sewage, food (Ventura et al., 2007b). The presence of 
bifidobacteria in the last two habitats is liable to be a consequence of contamination from the 
intestinal environment. Some bifidobacterial species are broadly distributed in the intestine of a 
wide variety of animals, whereas other species show a high ecological adaptation to a specific 
animal gut (Lamendella et al., 2008). 
Taxonomy 
The genus Bifidobacterium is a member of the Bifidobacteriaceae family and Bifidobacteriales 
order and belongs to the Actinobacteria phylum (Dworkin et al., 2006). Members of this phylum 
show a great variety of morphologies and physiological and metabolic characteristics, in addition 
to the extreme variety of their ecological niche: they range from plant to soil to GIT. 
Actinobacteria is one of the largest phyla in the Bacteria domain, characterized by Gram-positive 
microorganisms with high G+C DNA content, ranging between 51% to 70% (Dworkin et al., 2006; 
Ventura et al., 2007b). Two families belong to this order, Bifidobacteriales and Incertae. Based on 
the most recent “Taxomonic Outline of Bacteria and Archea” (TOBA 7.7), Bifidobacteriaceae family 
can be divided into five genera: Bifidobacterium, Aeriscardovia, Gardnerella, Parascardovia, 
Scardovia (Garrity et al., 2007). 
At present 39 species belong to the genus Bifidobacterium, isolated from the intestine of humans, 
mammals and insects, and also from raw milk, dental caries and sewage. 
Comparative analysis of the 16S rRNA gene sequences and the sequence analysis of other 
housekeeping genes (recA, tufA, atpD, groEL, dnaK, grpE, clpP, hrcA) allowed great advances in 
bifidobacterial taxonomy (Kullen et al., 1997; Jian et al., 2001; Ventura et al., 2004b, 2005b; Zomer 
et al., 2009). However, phylogenetic analysis based on a single molecular marker could not 
adequately reconstruct evolutionary relationships among bacteria, because of horizontal gene 
transfer phenomena, variable mutation or recombination rates (Ventura et al., 2007a). For this 
reason, analysis based on a set of combined alignments of conserved orthologous genes 
(supertrees - Bininda-Emonds, 2004) can produce a more robust evolutionary representation of 
bacterial phylogeny (Brown, 2001). The application of this approach allowed the clustering of the 
bifidobacterial species into six different phylogenetic groups: B. adolescentis, B. asteroides, B. boum, 
B. longum, B. pullorum, B. pseudolongum (Ventura et al., 2006a) (Fig. 5). Recently, the availability 
of several bifidobacterial genome sequences allows the application of a whole-genome 
phylogenomic approach, that will offer more insights into the classification of the Bifidobacterium 
genus (Lee and O’Sullivan, 2010). 
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The complete genome of 21 bifidobacterial strains has been sequenced to date and made publicly 
available in the GenBank database (Table 1). The genome size of bifidobacteria ranges from about 
2.0 to 2.8 Mb, with a G+C content between 54 and 67% (Lee and O’Sullivan, 2010). 
 
Table 1 - Sequenced Bifidobacterium genomes 
Species Genome 
size (bp) 
% 
GC 
genes proteins rRNA 
operons 
Source Accession 
number 
Institution References 
B. adolescentis 
ATCC15703 
 
2,089,645 59.2 1,702 1,632 5 Human GIT NC_008618.1 Gifu University, 
Japan 
Published in 
database 
only (2006) 
B. animalis subsp. 
lactis AD011 
1,933,695 60.5 1,603 1,527 2 Infant 
faeces 
NC_011835.1 Korea Research 
Institute of 
Bioscience and 
Biotechnology, 
Republic of Korea 
Kim et al., 
2009 
B. animalis subsp. 
lactis BB-12 
1,942,198 60.5 1,706 1,642 4 Fermented 
milk 
CP001853.1 Chr Hansen A/S, 
Denmark 
Garrigues et 
al., 2010 
Fig. 5. Phylogenetic tree of members of the Bifidobacterium genus as based on a comparative sequence analysis of 
1500 nucleotides of their 16S rRNA gene. The different phylogenetic clusters are highlighted (Turroni et al., 2011). 
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B. animalis subsp. 
lactis BI04 
1,938,709 60.5 1,631 1,567 4 Adult faeces NC_012814.1 Danisco/Penn 
State University, 
USA 
Barrangou 
et al., 2009 
B. animalis subsp. 
lactis BLC1 
1,943,990 60.5 1,622 1,549 4 Functional 
foods 
CP003039.1 Alimentary 
Pharmabiotic 
Centre, National 
University of 
Ireland, Ireland. 
Bottacini et 
al., 2011 
B. animalis subsp. 
lactis CNCM I-
2494 
1,943,113 60.5 1,724 1,660 4 Fermented 
dairy 
product 
CP002915.1 Danone 
Research, France 
Chervaux et 
al., 2011 
B. animalis subsp. 
lactis DSM10140 
1,938,483 60.5 1,629 1,566 4 French 
yogurt 
NC_012815.1 Danisco/Penn 
State University, 
USA 
Barrangou 
et al., 2009 
B. animalis subsp. 
lactis V9 
1,944,050 60.5 1,636 1,572 4 Healthy 
child faeces 
CP001892.1 Inner Mongolia 
Agricultural 
University, China 
Sun et al., 
2010 
B. bifidum 
PRL2010 
2,214,656 62.7 1,791 1,706 3 Human GIT NC_014638.1 University of 
Parma, Italy 
Turroni et 
al., 2010a 
B. bifidum S17 2,186,882 62.8 1,845 1,783 3 Breast-fed 
infant 
faeces 
NC_014616.1 University of 
Ulm, Germany 
Zhurina et 
al., 2011 
B. breve ACS-071-
V-Sch8b 
2,327,492 58.7 2,011 1,826 3 Human 
vagina 
CP002743.1 The J. Craig 
Venter Institute, 
USA 
GenBank 
direct 
submission 
(2011) 
B. breve UCC2003 2,422,684 58.7 1,985 1,854 2 Infant 
nursing 
stool 
CP000303.1 Alimentary 
Pharmabiotic 
Centre, National 
University of 
Ireland, Ireland 
O’Connell 
Motherway 
et al., 2011 
B. dentium Bd1 2,636,367 58.5 2,197 2,129 4 Dental 
caries 
NC_013714.1 University of 
Parma, Italy 
University 
College of Cork, 
Ireland 
Ventura et 
al., 2009c 
B. longum subsp. 
infantis 
ATCC15697 
2,832,748 59.9 2,588 2,416 4 Infant GIT NC_011593.1 University of 
California Davis, 
USA 
Sela et al., 
2008 
B. longum subsp. 
infantis 157F 
2,400,312 60.1 2,062 1,991 4 Infant 
faeces 
NC_015052.1 University of 
Tokyo, Japan 
Fukuda et 
al., 2011 
B. longum subsp. 
longum BBMN68 
 
2,265,943 59.9 1,878 1,806 3 Healthy 
centenarian 
faeces 
NC_014656.1 China 
Agricultural 
University, China 
Hao et al., 
2011 
B. longum subsp. 
longum DJO10A 
2,375,792 60.1 2,061 1,989 4 Human GIT NC_010816.1 University of 
Minnesota, USA 
Lee et al., 
2008 
B. longum subsp. 
longum JCM 1217 
2,385,164 60.3 2,009 1,924 4 Human GIT NC_015067.1 University of 
Tokyo, Japan 
Fukuda et 
al., 2011 
B. longum subsp. 
longum JDM301 
2,477,838 59.8 2,035 1,958 3 Human 
faeces 
NC_014169.1 Shanghai Jiao 
Tong University 
School of 
Medicine, China 
Wei et al., 
2010 
B. longum subsp. 
longum KACC 
91563 
2,385,301 59.8 2,036 1,971 3 Neonates 
faeces 
CP002794.1 National Institute 
of Animal 
Science, Republic 
of Korea 
Ham et al., 
2011 
B. longum subsp. 
longum NCC2705 
2,256,640 60.1 1,798 1,727 4 Human GIT NC_004307.2 Nestle Research 
Centre, 
Switzerland 
Schell et al., 
2002 
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The number of rRNA operons among Bifidobacterium species varies from 2 to 5, with a variability 
both among species and strains (Table 1). This variability might represent diverse ecological 
strategies adopted by different strains (Klappenbach et al., 2000). 
Physiology 
Human bifidobacterial strains grow at an optimal temperature of 36-38°C, but animal strains grow 
at a higher temperature, approximately 41-43°C. The extreme temperatures are reached by B. 
thermacidophilum, which has been reported to growth at temperatures as high as 49.5°C, and B. 
psychraerophilum, that can grow at 8°C (Gavini et al., 1991; Dong et al., 2000; Simpson et al., 
2004). Similarly to other organisms, bifidobacteria possess specific molecular mechanisms to cope 
with heat stress. They possess several molecular chaperones belonging to HSP60 (GroEL/GroES 
complex), HSP70 (DnaK, GrpE, DnaJ), HSP100 (ClpBCX) and small heat shock proteins (sHSPs) 
families to face heat stress, as well as the more general SOS response has been demonstrated to 
be involved (Ventura et al., 2006b, 2007c; Zomer et al., 2009). 
Bifidobacteria are generally described as strict anaerobes, although some of them can tolerate 
limited amounts of oxygen. The sensitivity to oxygen is variable, with the fermented-milk adapted 
B. animalis subsp. lactis the most aerotolerant (de Vries and Stouthamer, 1969; Scardovi, 1986; 
Shimamura et al., 1992; Meile et al., 1997; Simpson et al., 2005; Kawasaki et al., 2006). The 
capability to tolerate and survive in the presence of oxygen depends on the activity of some 
enzymes capable to detoxify and remove reactive oxygen species (ROS). Genomic and functional 
analysis of bifidobacteria revealed the presence of specific enzymes involved in these activities, in 
particular NADH oxidase, peroxyredoxin family alkyl hydroperoxide reductase gene analogues, 
thioredoxin reductase gene analogues and oxidative damage repair-related genes (Shimamura et 
al., 1992; Shin and Park, 1997; Talwalkar and Kailasapathy, 2003; Lee and O’Sullivan, 2010). A 
recent study has provided more insights on the mechanisms of oxygen tolerance in B. animalis 
subsp. lactis. Ruiz et al. (2012a) have reported that oxygen induces an overproduction of several 
glycolytic proteins and enzymes involved in redox reactions, the higher expression of specific 
oxidases and a higher membrane F1F0-type ATPase activity, all of these counteracting oxygen 
induced damages and maintaining the correct redox status of the cells. 
The optimum pH for growth of several bifidobacterial strains is between 6.5 and 7, but they can 
survive at lower pH, suggesting the presence of efficient acid tolerance mechanisms (Waddington 
et al., 2010). The F1F0-type ATPase system is involved in acid tolerance by pumping protons out of 
the cell. This system is encoded by the atp operon in bifidobacteria and it is supposed to be 
essential for their response to acid stress (Matsumoto et al., 2004; Ventura et al., 2004a). Recently, 
an alternative mechanism for acid tolerance has been revealed in B. dentium: it possesses the 
glutamate-dependent acid resistance system 2, which encodes a glutamate decarboxylase and a 
glutamate/gamma-aminobutyrate antiporter (Ventura et al., 2009c). 
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The capability to adapt and tolerate bile salts and acidic stress is a characteristic shared by several 
members of the Bifidobacterium genus, although high variability has been detected among strains 
(Sánchez et al., 2007a; Waddington et al., 2010). Adaptation and tolerance to physiological 
concentrations of bile salts (typically below 5 mM) is an essential factor for bacterial survival and 
colonization of the human GIT (Ridlon et al., 2006; Sánchez et al., 2007b). Bile salts are detergent-
like compounds secreted into the intestine during digestion for the emulsification and absorption 
of fats, but they exert also a strong antimicrobial activity (Bernstein et al., 1999b). The ability to 
tolerate these compounds gives bifidobacteria a selective advantage in the gut ecosystem. Bile 
salts resistance in bifidobacteria has been extensively studied, and these efforts have led to the 
identification in two Bifidobacterium species of a putative multidrug resistance (MDR) system, 
named betA (bile efflux transporter), whose expression is induced by bile (Gueimonde et al., 
2009). It’s worth noting that bile salts have a profound effect on the global protein expression in 
bifidobacteria (Sánchez et al., 2007b; Ruiz et al., 2009). 
Metabolism 
The genome analysis of bifidobacteria has improved the comprehension of the biosynthetic and 
metabolic capabilities of these microorganisms, starting from the bioinformatics analysis of the first 
bifidobacterial genome completely sequenced (Schell et al., 2002). These investigations have 
confirmed previous findings on the nutritional demands and biosynthetic features of Bifidobacterium 
(Hassinen et al., 1951; Matteuzzi et al., 1978; Deguchi et al., 1985), and added more information on 
the metabolic potential of this genus (Schell et al., 2002). 
Bifidobacterial genomes harbour genes for the synthesis of at least 19 amino acids from ammonia 
and also from different intermediates (Lee and O’Sullivan, 2010). They can produce a variety of B 
vitamins: thiamine (B1), nicotinic acid (B3) and folic acid (B9), while some strain differences have 
been reported for the biosynthesis of riboflavin (B2) and pyridoxine (B6), as well as for cobalamin 
(B12); bifidobacteria have an absolute requirement for pantothenate (B5) and biotin (B7) 
(Hassinen et al., 1951; Gyllenberg and Carlberg, 1958; Tamura, 1983; Deguchi et al., 1985). 
Bifidobacterial genomes encode all the genes required for the biosynthesis of purine and 
pyrimidine nucleotides (Lee and O’Sullivan, 2010). 
Bifidobacteria can use a wide variety of different carbohydrates as carbon source, and these 
metabolic activities may vary considerably among bifidobacterial strains (Pokusaeva et al., 2011). 
Hexose such as glucose and fructose are metabolized for energy production via the “bifid shunt”, a 
metabolic pathway involving the key enzyme fructose-6-phosphate phosphoketolase (F6PPK) 
(Scardovi and Trovatelli, 1965; de Vries et al., 1967; de Vries and Stouthamer, 1967, 1968; 
Scardovi, 1986; Bezkorovainy and Miller-Catchpole, 1989). Bifidobacterial genomes contain genes 
for the utilization of a broad spectrum of substrates, such as glucose, fructose, galactose, N-
acetylglucosamine, N-acetylgalactosamine, arabinose, xylose, ribose, sucrose, lactose, cellobiose, 
melibiose, gentobiose, maltose, isomaltose, raffinose and mannose (de Vries and Stouthamer, 
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1968; Pokusaeva et al., 2011). It has been reported the preference of bifidobacteria for utilizing di- 
and oligosaccharides: this could represent an evolutionary adaptation to an environment poor in 
monosaccharides but rich in complex sugars (Amaretti et al., 2006; Vernazza et al., 2006). 
Carbohydrate transportation occurs via permeases belonging to four classes: ATP-binding cassette 
(ABC)-type transport systems, a glucose-specific phosphotransferase transport system (PTS), MFS 
(major facilitator superfamily) systems, and the glycoside-pentoside-hexuronide (GPH) cation 
symporter family (Parche et al., 2007) (Fig. 6). All these systems present different level of sugar 
specificity. Bifidobacterial genomes possess a large array of genes for the utilization of complex 
carbohydrates. Host-indigestible complex polysaccharides are highly available nutrients in the 
lower gut and the capability to digest these molecules provides bifidobacteria with an ecological 
advantage in that specific niche (Hooper et al., 2002; Schell et al., 2002; Klijn et al., 2005; Parche et 
al., 2007; Turroni et al., 2008). Among bifidobacterial strains a great variability in carbohydrate 
and alcohol utilization has been reported. Several glycosyl hydrolases are still uncharacterized, but 
physiological data show that bifidobacteria can metabolize a wide spectrum of substrates: 
galactooligosaccharides (GOS), xylooligosaccharides (XOS), pectin, fructooligosaccharides (FOS), 
plant oligosaccharides and mucin (Kaplan and Hutkins, 2000; Van Laere et al., 2000; Slováková et 
al., 2002; Palframan et al., 2003; Ruas-Madiedo et al., 2008; Turroni et al., 2010a; Pokusaeva et al., 
2011). Glycosyl hydrolases have also been found extracellularly, probably for digestion of plant cell 
wall material and extracellular polysaccharides to smaller sugars (Schell et al., 2002; Pokusaeva 
et al., 2011). 
Recently, the capability of one bifidobacterial species to metabolize human intestinal mucus has 
been demonstrated, providing some insights on the protein expression and metabolic changes of 
this microorganism in response to different environmental conditions (Ruiz et al., 2011). 
Genes coding for proteins involved in complex polysaccharide utilization are organized in clusters, 
and their expression may be regulated by LacI-type repressors, suggesting a substrate-dependent 
repression (Rodionov et al., 2001; Schell et al., 2002; Rodionov, 2007; Lee et al., 2008; Sela et al., 
2008; Nentwich et al., 2009). This negative regulation of gene expression could facilitate a rapid 
response to fluctuation in nutrient availability and variety. Some bifidobacterial strains have the 
capability to degrade several host-derived glycans, among which syalic acid containing 
carbohydrates present in mucin, glycosphingolipids and human milk (Human Milk 
Oligosaccharides, HMOs), highlighting the strong symbiotic relationship between the host and this 
microbial group (Hoskins et al., 1985; Corfield et al., 1992; Wang et al., 2001). Polysaccharides 
metabolism specialization is strongly linked with the host type. B. longum subsp. longum 
possesses a large arsenal of enzymes specialized to degrade plant-derived dietary fibers, such as 
xylan, arabinan and arabinofuran, highly present in the intestine of an adult human host. On the 
contrary, B. longum subsp. infantis has genes predicted to be involved in HMOs degradation and 
this is in accordance to the presence of this subspecies mainly in breast-fed infant gut. In addition 
to specific carbohydrate degradation, B. lonugm subsp. infantis also contains a complete urease 
gene cluster that enables it to utilize urea present in human milk for its nitrogen needs, differently 
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from the other species that lack this cluster (Lee and O’Sullivan, 2010). It could be speculated that 
the genome of these two microorganisms encodes peculiar metabolic features that have been 
tailored to the nutrient availability of that specific gut environment. 
An interesting metabolite produced by a bifidobacterial strain is lantibiotic, encoded by a 
characteristic operon (Lee et al., 2008). Lantibiotics are a broad-spectrum class of bacteriocins, 
small antimicrobial peptides which inhibit the same or closely related species, giving that 
microorganism a competitive advantage in the ecosystem (Klaenhammer, 1993; Chen and Hoover, 
2003). Bioinformatics analysis of the available genomes has shown the presence of homologues 
remnants of the lantibiotic operon in different species, hints of a diffuse production in 
bifidobacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Overview of predicted carbohydrate uptake and metabolism systems in bifidobacteria. The fructose-6-
phosphate phosphoketolase (F6PPK) pathway, partial tricarboxylic acid (TCA) cycle, and UDP-glucose/galactose 
system (UDP-Gal/Glc) are indicated with different background colors (light yellow for F6PPK, light purple for the 
partial TCA cycle, and sky blue for the UDP-Glc/Gal system). Blue, ATP-binding cassette (ABC)-type transport systems; 
green, phosphotransferase transport system (PTS); grey, major facilitator superfamily (MFS); dark purple, major 
intrinsic protein (MIP) family; orange, glycoside-pentoside-hexuronide (GPH) cation symporter family. Genes encoding 
predicted metabolic enzymes from B. longum subsp. longum DJO10A are indicated (Lee and O’Sullivan, 2010). 
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Interaction with the host 
The molecular basis of the interaction between members of the Bifidobacterium genus and the 
host GIT remains mostly unclear. Bioinformatics analysis of bifidobacterial genomes has revealed a 
wealth of features linked to the metabolic adaptation of bifidobacteria to the gut environment. 
But it has also uncovered many aspects involved in the relationship with the host. 
Bifidobacteria are predicted to encode cell wall associated structures that may play an important 
role in the establishment and maintaining of the interaction with the host. The bioinformatics 
analysis of the first sequenced bifidobacterial genome (B. longum subsp. longum NCC2705) 
allowed the identification of more than 200 extracellular proteins, including 59 surface-associated 
lipoproteins and 26 solute-binding proteins of ABC transport systems (Schell et al., 2002). 
Comparative functional genome analyses have disclosed components of the bifidobacterial 
protein export systems: they contain Sec-dependent pathways, type I and II signal peptidases and 
components of signal recognition particle (SPR)-dependent pathways (Lee and O’Sullivan, 2010). 
Several surface associated proteins are covalently linked to the peptidoglycan layer by sortase 
transpeptidases. These enzymes recognize the LPXTG motif, a signature that target the protein to 
the cell wall (Navarre and Schneewind, 1999). The majority of LPXTG-proteins encoded by 
bifidobacterial genomes are unknown, but they are potential cell surface proteins that can be 
involved in cell or mucus attachment (Lee and O’Sullivan, 2010). Indeed, recent studies have 
revealed that cell surface components play an important role in the adhesion of bifidobacteria. 
Structures present on the cell wall of bifidobacteria have been demonstrated to mediate adhesion 
to intestinal epithelial cells and this ability is strain dependent and influenced by environmental 
conditions, such as pH, sugar availability and bile salts (Riedel et al., 2006; Guglielmetti et al., 
2009). Recent genomic analyses have revealed the presence of homologues of tad genes in 
bifidobacteria. tad (tight adherence) loci are involved in pilus construction and supposed to be 
important for adhesion to cell surface and mucus (Kachlany et al., 2001; Lee and O’Sullivan, 2010). 
The capability of bifidobacteria to construct pili may play important roles in their attachment to 
mucus and intestinal epithelial cells, as recently reported for the strain B. breve UCC2003: the 
identified tad locus results essential for efficient host colonization of the murine intestine 
(O’Connell Motherway et al., 2011). 
Different kinds of secreted proteins have been found in Bifidobacterium (Sánchez et al., 2008). The 
majority of secreted proteins are enzymes involved in different pathways, such as cell wall 
biosynthesis or carbohydrate degradation. Other secreted proteins may have a possible role in the 
interaction with the host. Recently, a serine protease inhibitor (serpin) has been characterized in 
different strains of Bifidobacterium (Ivanov et al., 2006; Turroni et al., 2010b). This molecule is 
able to inhibit several host proteases, among which neutrophil elastase that is released during the 
inflammatory response; its inhibition by bifidobacterial serpin could in part explain some of the 
immunomodulatory properties of this microorganism (Burg and Pillinger, 2001; Reeves et al., 
2002). The expression of serpins could also be viewed as an ecological advantage in the highly 
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proteolytic gut ecosystem, where the protection against exogenous proteolysis may have an 
important impact on the interaction of these microorganisms with the host. 
An interesting study has revealed another bifidobacterial component that can have a role in the 
immunomodulation: the B. animalis subsp. lactis pentapeptide CHWPR has been shown to 
influence the expression of genes involved in inflammation and oncogenesis, with a deep impact 
on the GIT physiology (Mitsuma et al., 2008). 
Another important actor that may have a role in GIT-bifidobacteria interaction is 
exopolysaccharide (EPS). Bifidobacteria contain clusters carrying genes predicted to be involved in 
EPS biosynthesis and extracellular polysaccharides from several strains have been characterized 
(Abbad Andaloussi et al., 1995; Ruas-Madiedo et al., 2007; Audy et al., 2010; Lee and O’Sullivan, 
2010). Bifidobacterial EPS can have a great variety of roles: adhesion to host cells, self-protection 
against toxic compounds such as bile salts, fermentable carbohydrate source for other gut 
microorganisms, counteraction of bacterial toxin cytotoxic effects on eukaryotic cells (Pérez et al., 
1998; Ruas-Madiedo et al., 2006, 2009, 2010; Salazar et al., 2008). 
Colonization of the GIT with different microbial species determines a diverse host response. An 
interesting study has investigated the consequences of co-colonization of mice with two 
components of the human gut microbiota, Bacteroides thetaiotaomicron and Bifidobacterium 
longum subsp. longum. It has been evidenced a differential immune host response towards the 
two bacteria, suggesting that host responses may affect bifidobacteria survival and have an impact 
on the composition of the gut microbiota. (Sonnenburg et al., 2006). 
Mobile genetic elements, prophages, restriction-modification systems, plasmids 
Transposable elements are mobile genetic units that shift from one position to another by a 
process of transposition; they can be grouped in two classes: insertion sequences (IS) and 
transposons. Eight IS families have been found in bifidobacterial genomes. B. longum subsp. 
infantis contains the greatest number and variability of IS elements, displaying all the eight 
families, while B. dentium possess the smallest set of these elements (Lee and O’Sullivan, 2010). IS 
elements are often involved in genome rearrangement or deletion events, supporting the role of 
these elements in genome plasticity and rapid genome adaptation to novel environments (Darling 
et al., 2008; Lee et al., 2008; Bickhart et al., 2009; Ooka et al., 2009). Only one transposon has 
been identified among bifidobacteria, transposon Tn5432, present in several strains of B. 
thermophilum (van Hoek et al., 2008). 
Prophage-like elements have been reported in the genome of different Bifidobacterium species 
(Ventura et al., 2009b). They share nucleotide and organizational homology with double-stranded 
DNA bacteriophages infecting high G+C Gram-positive bacteria, suggesting a common phage 
evolution within the ecosystem. A recent comparative analysis of these elements has highlighted 
that bifidobacteria are under an intense selective pressure from (pro)phages, with a deep impact 
on bifidobacterial population composition in the gut (Ventura et al., 2009b). An interesting 
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characteristic of these prophage-like elements is their integration site: they commonly integrate 
into a tRNAmet gene, and this integration site is well conserved among bifidobacteria (Ventura et 
al., 2005a, 2009b). Genomic analysis allowed the detection of CRISPR structures in several 
bifidobacteria (CRISPRs: clustered regularly interspaced short palindrome repeats) (Lee and 
O’Sullivan, 2010). CRISPRs have been demonstrated to be involved in acquiring resistance against 
infecting bacteriophages, protecting the microorganism from the infection (Barrangou et al., 2007; 
Deveau et al., 2008). The presence of these structures in bifidobacteria can be due to the need 
of protection from bacteriophages present in the complex intestinal environment  (Ventura et 
al., 2009b). 
Genes for restriction-modification systems coding for methyltransferases and restriction enzymes 
have been found in bifidobacterial genomes (Schell et al., 2002; Lee et al., 2008; O’Connell 
Motherway et al., 2009; Yasui et al., 2009). These systems have an essential role in protection of 
methylated host DNA against invasion of unmethylated foreign DNA (Price and Bickle, 1986). 
These protection systems represent the major obstacle that inhibits the introduction of foreign 
DNA into bifidobacteria; recently, some studies have demonstrated the possibility to overcome 
this problem by the methylation of the shuttle vector and the removal of restriction sites 
(O’Connell Motherway et al., 2009; Yasui et al., 2009; Kim et al., 2010). 
Plasmids are not frequently found among members of the genus Bifidobacterium, and 
approximately 20% of the isolated bifidobacterial strains contains detectable plasmids (Sgorbati et 
al., 1982). The majority of the currently sequenced bifidobacterial plasmids have been isolated 
from B. longum strains, but they are present also in other species: B. pseudolongum, B. indicum, B. 
asteroides, B. breve, B. bifidum, B. catenulatum and B. pseudocatenulatum (Sgorbati et al., 1986a, 
1986b; Iwata and Morishita, 1989; Gibbs et al., 2006; Alvarez-Martín et al., 2007; Shkoporov et al., 
2008). These plasmids vary in size from 1.8 kb to 10.2 kb and the majority of them replicate via a 
rolling circle mechanism, whereas the others have theta replication features (Corneau et al., 2004; 
Lee and O’Sullivan, 2006, 2010; Alvarez-Martín et al., 2007; Moon et al., 2009). On the basis of a 
comparative analysis of the bifidobacterial plasmid replication proteins, these plasmids can be 
clustered into five different groups (Corneau et al., 2004; Guglielmetti et al., 2007). The G+C 
content of the sequenced bifidobacterial plasmids is quite different from that of the host 
chromosome, suggesting a recent and non-bifidobacterial origin of these extrachromosomal 
elements (Lee and O’Sullivan, 2010). All of the sequenced plasmids of Bifidobacterium are cryptic, 
but one study has reported a possible function for an unsequenced plasmid: its presence in a B. 
bifidum strain is associated with the production of bifidocin B (Yildirim et al., 1999). The presence 
of native bifidobacterial plasmids have provided the basis for the construction of cloning and 
expression vector systems. The main problems encountered in the bifidobacterial genetic 
engineering are the low transformation efficiencies, segregational instability and limited host-
range of these plasmids (Argnani et al., 1996; Rossi et al., 1998; Fu et al., 2005; Lee and O’Sullivan, 
2006; Alvarez-Martín et al., 2007). Transformation efficiencies have been improved by methylating 
plasmids, in order to overcome bifidobacterial restriction systems (O’Connell Motherway et al., 
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2009; Yasui et al., 2009). These vectors have been successfully used in promoter-screening assays, 
gene expression and protein secretion (Moon et al., 2005; Park et al., 2005b, 2008; Klijn et al., 
2006; Rhim et al., 2006; Cronin et al., 2008). Recent studies have revealed an interesting medical 
application of these engineered bifidobacterial plasmids. Anaerobic bacteria have been 
demonstrated to localize in hypoxic regions, such as tumour areas (Nakamura et al., 2002; Vassaux 
et al., 2006), allowing an accurate targeting of these regions. Researchers have demonstrated the 
possibility to target bifidobacteria carrying the gene of interest, for example cytosine deaminase, 
precisely in the tumour region (Yazawa et al., 2000, 2001; Li et al., 2003; Cronin et al., 2010). This 
opens novel scenarios for the development of the bifidobacterial genetic engineering. 
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Plasminogen/Plasmin System 
 
The plasminogen/plasmin system is a proteolytic system that has a crucial role in several 
extracellular proteolytic processes present in mammals. It is involved in fibrinolysis, homeostasis 
and degradation of the extracellular matrix (ECM) and basement membrane, cellular migration, 
wound healing, tissue remodelling and inflammatory processes (Marsh, 1981; Dano et al., 1985; 
Saksela and Rifkin, 1988) (Fig. 7). 
 
 
 
 
 
 
 
 
 
Key actors: plasminogen and plasmin 
The key protein is plasminogen (Plg), the proenzyme form of the serine-protease plasmin. Plg is a 
single chain glycoprotein with a molecular mass of approximately 92 kDa; the proenzyme 
circulates in human plasma at concentrations around 200 μg/ml (ca. 2 µM; Miyashita et al., 1988), 
but it is also present in interstitial fluids and milk (Myöhänen and Vaheri, 2004; Wang et al., 2006). 
Plg is mainly synthesized by hepatocytes, but other tissue sources have been identified, including 
the intestine (Zhang et al., 2002). Human Plg is synthesized as a 810 amino acids (aa) protein; the 
cleavage of the 19 aa signal peptide leads to the mature protein (791 aa) with an N-terminal 
glutamic acid residue (Glu-Plg) (Fig. 8). Glu-Plg possesses a phosphorylation site [Ser578 (Wang et 
al., 1997)] and two glycosylation sites [Thr346, Asn289 (Hayes and Castellino, 1979a, 1979b, 1979c)], 
but two Plg glycoforms can be distinguished: type I, glycosylated at both sites, and type II, with 
only O-glycosylation. Besides Glu-Plg, other Plg isoforms are present originating from enzymatic 
hydrolysis of specific peptide bonds: Lys-Plg [84 kDa, 713-714 aa (Mori et al., 1995)] and Val-Plg or 
mini-Plg [38 kDa, 344 aa (Folkman, 1995)]. Plasmin formation from these truncated forms is faster 
respect to Glu-Plg. 
Fig. 7. The mammalian plasminogen 
system. The proenzyme plasminogen 
(Plg) is converted to the active 
protease plasmin by tissue-type Plg 
activator (tPA) or urokinase (uPA). 
Plasmin degrades fibrin and various 
ECM components, such as laminin 
and fibronectin, and also activates 
procollagenases to active collagen-
degrading enzymes. Dashed arrows 
indicate inhibition of the enzymes: 
Plg activator inhibitors (PAIs) inhibit 
Plg activation, and α2-antiplasmin is 
the main inhibitor of plasmin 
(Lähteenmäki et al., 2001). 
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The conversion of Plg into the active enzyme plasmin involves the proteolytic cleavage of the 
Arg561-Val562 peptide bond, resulting in an N-terminal heavy chain and a C-terminal light chain, linked 
by two disulphide bonds (Cys548-Cys666; Cys558-Cys566). The heavy chain possesses the N-terminal 
activation peptide (residues 1-77, approx. 8kDa), followed by 5 consecutive kringle domains (K1-K5); 
the light chain harbours the serine-protease domain (25 kDa) containing the catalytic triad His603-
Asp646-Ser741 (Vassalli et al., 1991; Ponting et al., 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kringle domains are structures composed of around 80 amino acidic residues (65 kDa), folded in a 
triple loop stabilized by 3 disulphide bridges (Sottrup-Jensen et al., 1978). These domains mediate 
inter-molecular interactions, regulating the activity of proteins containing these domains. Many 
molecules possess kringle-like structures: prothrombin, Plg activators tissue-type Plg activator 
(tPA) and urokinase (uPA), angiostatin *it has the first four kringles of Plg (O’Reilly et al., 1994)], 
apolipoprotein A (it contains more than 40 kringles), hepatocyte growth factor (HGF) and HGF-like 
proteins, defensins, coagulation factor XII (Ponting et al., 1992; Bork et al., 1996). Several studies 
Fig. 8. Structure of human plasminogen. Plasminogen is the zymogen form of plasmin, a fibrinolytic serine protease. It 
consists of an N-terminal activation peptide (PAN), five conserved kringle domains (K1–K5), as well as the protease 
domain. The triangle indicates where plasminogen activators (urokinase [uPA] and tissue-type plasminogen activator 
[tPA]), cleave plasminogen to yield the active serine protease plasmin (Soff, 2000). 
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show that kringles interact with ligands by means of lysine binding sites [LBS (Ponting et al., 
1992)]. Regading Plg/plasmin, kringles 1, 4 and 5 exhibit the highest affinity to lysine containing 
ligands, whereas kringle 2 possesses the weakest affinity (Marti et al., 1997). 
The main target of plasmin proteolytic activity is fibrin, a protein derived from fibrinogen that 
constitutes clot structure. Besides this molecule, plasmin recognizes many substrates, among 
which there are vitronectin, fibronectn and laminin, the most important components of basement 
membrane and ECM (Plow et al., 1995). Plasmin can also activate other proteolytic enzymes, such 
as matrix metalloproteinases and macrophage latent elastases, that are responsible of the 
degradation of collagen, elastin and proteoglycans (Murphy et al., 1999). 
Regulating the plasminogen/plasmin system: activators, inhibitors, receptors 
The Plg/plasmin proteolytic system is tightly regulated in human tissues because Plg is highly 
abundant in the human organism and plasmin has a wide substrate spectrum. 
Plasmin activation is mediated by Plasminogen Activators (PAs). PAs physiologically present in 
mammals are tPA and uPA (Castellino and Powell, 1981): both are secreted serin-proteases 
activated by proteolytic cleavage. tPA is mostly synthesized by vascular endothelial cells and 
contains a finger domain that binds fibrin (homologous to the domain present in type-1 
fibronectin), a growth factor like domain (GFD), two kringle domains and the catalytic domain; this 
activator possesses high affinity to Plg only in the presence of fibrin, allowing plasmin formation 
directly on the clot. uPA has a structure similar to tPA: it possesses GDF domain, one kringle and 
the protease domain. Urokinase acts in different situations and cellular localizations: it binds to a 
specific receptor present on the cellular membrane (uPA receptor, uPAR) and this binding 
enhances uPA activity and protects it from PA inhibitors and plasmin. Because of these different 
binding properties, these two activators act in different processes: uPA is mainly involved in Plg 
activation during eukaryotic cell migration processes, whereas tPA has a primary role in fibrinolysis 
(Lijnen and Collen, 1995; Plow et al., 1999). 
Besides activators, several specific inhibitors, belonging to the serpin group, regulate the 
Plg/plasmin system. These molecules form a stable complex in the active site, blocking the catalytic 
activity of the enzyme. The main plasmin inhibitor is α2-antiplasmin (α2-AP): it binds kringle 
domains and blocks the active site, inhibiting efficiently soluble plasmin. Another important 
inhibitor highly present in human plasma is α2-macroglobulin (α2-M), which is less active respect to 
α2-AP (Miyashita et al., 1988). PA inhibitors (PAI1-3) negatively regulate plasmin activity in an indirect 
way, blocking PAs activity (Saksela and Rifkin, 1988; Rijken, 1995). 
Other actors involved in the regulation of the Plg/plasmin system are Plg receptors: these 
molecules are characterized by low Plg affinity, high density and ubiquitous distribution. Indeed, 
these receptors are displayed on the surface of several mammals cells and recognize Plg kringle 
domains (Hajjar, 1991; Miles et al., 1991; Redlitz and Plow, 1995). Plg receptors can be proteins 
with C-terminal lysine residues (α-enolase) or lysine-rich proteins (anfoterin), and even non 
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proteic receptors (gangliosides and glycosaminoglycans); the molecular identity of these receptors 
is specific to the cell type (Plow et al., 1995; Miles et al., 2005). Plg receptors exert a key control on 
plasmin activity, localizing proteolytic activity on the cell surface, enhancing Plg activation and 
plasmin activity and protecting cell-bound plasmin from inactivation. Plg binding to the receptor 
alters its conformation, facilitating its activation by PAs and protecting the active protease from 
α2-AP inhibitor (Wiman et al., 1979; Mangel et al., 1990). Modulation of Plg receptors is a further 
aspect of plasmin activity regulation: fluctuation in receptor presence on the cell surface may act 
as a control mechanism of many cellular Plg/plasmin-dependent responses (Herren et al., 2003). 
Plasminogen in the gut 
Gut epithelium constitutes an efficient selective barrier between lumen and the underlying 
tissues. The epithelial cells form a tight monolayer since junctional complexes allow adhesion 
between cells and between cells and basement membrane. However, enterocytes are 
continuously replaced by a rapid cell turnover that starts from stem cells located at the crypts 
basis: adhesion sites must be disrupted and reorganized in a controlled manner and this process 
involves the Plg/plasmin system (Gibson et al., 1998). The uPA-uPAR system allows the cell surface 
localization of the proteolytic activity of plasmin, thus enabling intercellular junctions disruption by 
diminishing cell-cell and cell-basement membrane adhesion and favouring the turnover process. 
Components of the Plg/plasmin system have been individuated in different compartments of the 
gut. Zhang et al. (2002) have shown that Plg and tPA genes are expressed at low level in the gut; 
colon epithelial cells secrete uPA and express uPAR (Gibson et al., 1991). uPA is highly expressed 
on the epithelial surface of the colon and the upper part of villi in the small intestine, in 
differentiated cells involved in absorption processes. These cells are weakly bound to the 
basement membrane and subjected to a continuous turnover; after apoptosis the cells are 
dispersed in the intestinal lumen or phagocytized by subepithelial macrophages. There are 
evidences that this system has an important role in the cell turnover of the epithelium present in 
other districts in addition to gut, such as skin and cornea (Lazarus and Jensen, 1991; Morimoto 
et al., 1993). 
Plg/plasmin system is involved not only in physiological but also in pathological processes. Plg 
dependent extracellular proteolysis plays a crucial role in tumor cell invasiveness. Controlled 
degradation of components of basement membrane and ECM allows tumor cells to invade 
contiguous tissues and generate metastases. This process is tightly regulated by cytokines and 
growth factors present in the surrounding environment and requires the overexpression of 
proteolytic systems components, one of which is the Plg/plasmin system (Berger, 2002; Saucy et 
al., 2011). Tumor cells display plasmin and uPA receptors on the plasma membrane, focusing the 
proteolytic activity on their surface; moreover, they produce PAI-1 and PAI-2 in order to prevent 
excessive ECM degradation and facilitating adhesion/detachment processes and migration 
through this matrix (Tang and Wei, 2008). Besides cancer, inflammatory processes deeply affect 
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the host Plg/plasmin system equilibrium. In particular, pro-inflammatory cytokines elicit the up-
regulation of Plg activator uPA, shifting the Plg/plasmin system balance towards active plasmin in 
inflamed tissues. The increased availability of active plasmin enhances the release of 
proinflammatory mediators and the activation of pro-forms of matrix metalloproteases (MMPs), 
thus amplifying the inflammatory reaction (Mondino and Blasi, 2004; Okumura et al., 2008). 
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Microorganisms and Human Plasminogen Interaction 
 
A great variety of eukaryotic and prokaryotic organisms interact with components of the 
Plg/plasmin system. Most of these organisms are pathogens, taking advantage of the proteolytic 
activity of this system in order to facilitate invasion and establishment in the host. Table 2 shows a 
list of these organisms, both pathogens and commensals. 
 
Table 2 - Plg interaction with prokaryotic and eukaryotic organisms 
 Organisms References 
Bacteria Aeromonas hydrophila Sha et al., 2009 
 Bacillus anthracis Agarwal et al., 2008; Matta et al., 2010 
 Bacteroides fragilis Sijbrandi et al., 2005, 2008; Ferreira Ede et al., 2009 
 Bifidobacterium animalis subsp. lactis; B. 
longum; B. bifidum; B. breve 
Candela et al., 2007, 2009 
 
Borrelia burgdorferi; B. coriaceae; B. garinii; 
B. parkeri; B. anserina; B. turicatae; B. 
hermsii; B. crocidurae 
Fuchs et al., 1994; Klempner et al., 1996; Hu et al., 1997; 
Nordstrand et al., 2001; Floden et al., 2011 
 Branhamella catarrhalis Ullberg et al., 1990 
 Escherichia coli Kukkonen et al., 1998; Lähteenmäki et al., 2001 
 Francisella tularensis Clinton et al., 2010 
 Fusobacterium nucleatum subsp. nucleatum; 
subsp. vincentii; subsp. polymorphum 
Darenfed et al., 1999 
 Haemophilus influenzae Ullberg et al., 1990; Barthel et al., 2011 
 Helicobacter pylori Dubreuil et al., 2002; Jönsson et al., 2004 
 Lactobacillus crispatus; L. johnsonii Antikainen et al., 2007a, 2007b; Hurmalainen et al., 2007 
 Legionella pneumophila Vranckx et al., 2007 
 
Leptospira interrogans; L. borgpetersenii; L. 
kirshneri; L. santarosai; L. biflexa 
Vieira et al., 2009, 2010; Oliveira et al., 2011 
 Listeria monocytogenes Schaumburg et al., 2004 
 Mycobacterium tuberculosis Monroy et al., 2000; Xolalpa et al., 2007 
 Mycoplasma fermentans; M. gallisepticum Yavlovich et al., 2001, 2007; Chen et al., 2011 
 Neisseria meningitidis; N. gonorrhoeae Ullberg et al., 1992; Knaust et al., 2007 
 Peptostreptococcus micros Grenier and Bouclin, 2006 
 Porphyromonas gingivalis Grenier, 1996 
 Proteus mirabilis Ullberg et al., 1990; D’Alessandro et al., 2011 
 Pseudomonas aeruginosa Ullberg et al., 1990; da Silva et al., 2004; Kunert et al., 2007 
 Salmonella enterica Kukkonen et al., 1998; Lähteenmäki et al., 2001; 
Kukkonen and Korhonen, 2004 
 Staphylococcus aureus Lähteenmäki et al., 2001; Mölkänen et al., 2002 
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group A, C and G streptococci; Streptococcus 
suis; S. mutans; S. pneumoniae; S. agalactiae; 
S. anginosus, S. oralis; S. mitis; S. salivarius; S. 
canis 
Pancholi and Fischetti, 1998; Lähteenmäki et al., 2001; 
Jobin et al., 2004; Urdaneta et al., 2004; Bergmann and 
Hammerschmidt, 2007; Magalhães et al., 2007; Kinnby et 
al., 2008; Itzek et al., 2010; Fulde et al., 2011 
 Treponema denticola Fenno et al., 2000 
 Yersinia pestis Sodeinde et al., 1992; Lathem et al., 2007 
Yeasts/moulds Aspergillus fumigatus Behnsen et al., 2008; Zaas et al., 2008  
 Candida albicans Crowe et al., 2003; Jong et al., 2003; Poltermann et al., 
2007; Luo et al., 2009 
 Cryptococcus neoformans Stie et al., 2009 
 Paracoccidioies brasiliensis Barbosa et al., 2006; Nogueira et al., 2010 
 Pneumocystis jiroveci (carinii) Fox and Smulian, 2001 
Protozoa Leishmania mexicana Calcagno et al., 2002; Vanegas et al., 2007 
 Plasmodium falciparum; P. berghei Ghosh et al., 2011 
 Trichomonas vaginalis Mundodi et al., 2008 
 Trypanosoma cruzi Almeida et al., 2004; Rojas et al., 2008 
Worms Clonorchis sinensis Wang et al., 2011a 
 Dirofilaria immitis González-Miguel et al., 2012 
 Echinostoma caproni Marcilla et al., 2007 
 Fasciola hepatica Bernal et al., 2004 
 Onchocerca volvulus Jolodar et al., 2003 
 Schistosoma bovis Ramajo-Hernández et al., 2007; de la Torre-Escudero 
et al., 2010 
 
Bacterial pathogens and the plasminogen/plasmin system 
Several pathogenic bacteria have developed different strategies in order to make use of the high 
Plg concentration in body fluids and the broad spectrum of plasmin substrates during the host 
colonization process (Sun et al., 2004; Bergmann et al., 2005; Lähteenmäki et al., 2005; Bergmann 
and Hammerschmidt, 2007) (Fig. 9). Few bacterial species directly activate Plg by producing PAs, 
but a considerably higher amount of pathogens have been found to bind Plg on their surface via 
Plg surface receptors, favouring plasmin conversion by host PAs. In this way, microorganisms 
acquire a broad spectrum surface associated proteolytic activity: this characteristic favours 
migration through tissue physical barriers and responds to the microorganism nutritional demands 
during the invasion and colonization processes. Indeed, in vitro studies have shown that plasmin 
immobilized on different pathogens (e.g. Yersinia pestis, Borrelia burgdorferi, Streptococcus 
pneumoniae, Haemophilus influenzae, Salmonella enterica) degrades mammals ECM, allowing 
them to penetrate through basement membrane and epithelial cell monolayers, a process 
described as “bacterial metastasis” (Lähteenmäki et al., 2005). Nevertheless, direct involvement of 
Plg activation in pathogenesis in vivo has been reported only for some of these microorganisms 
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(Yersinia pestis, Borrelia burgdorferi and species belonging to group A streptococci, or GAS) 
(Lähteenmäki et al., 2005; Bergmann and Hammerschmidt, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bacterial plasminogen activators 
Bacterial proteins that function as PAs can be divided in two groups: enzymes that resemble 
mammalian PAs in functions, such as Pla in Yersinia pestis or Salmonella enterica PgtE, and 
proteins that are not enzyme themselves but form 1:1 complexes with Plg and plasmin, as 
streptokinase (SK) in Streptococcus (A, C and G groups) and staphylokinase (SAK) in Staphylococcus 
aureus (Lähteenmäki et al., 2001). 
Fig. 9. Overview of the mammalian plasminogen (Plg) system and its control and how pathogenic bacteria engage the 
system. tPA: tissue-type plasminogen activator; uPA: urokinase; PAI-1: plasminogen activator inhibitor 1; uPAR: uPA 
receptor; ECM: extracellular matrix; Pro-MMPs: precursors of matrix metalloproteases; MMPs: matrix 
metalloproteases; MФ: macrophages (Lähteenmäki et al., 2005). 
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The surface protease Pla of the plague bacterium Y. pestis is a highly efficient Plg activator. Pla 
cleaves Plg at the same peptide bond as the host PAs tPA and uPA; it also acts as adhesin, with 
affinity for ECM and basement membrane laminin. Studies with mice infected with Pla-knock out 
Y. pestis strains have shown the importance of this protein in the pathogen migration from the 
primary intradermal infection site into blood circulation. Pla belongs to the family of omptins, a 
class of surface adhesins/proteases found in the enterobacterial outer membrane; these proteins 
share a common β-barrel fold (Sodeinde et al., 1992; Lathem et al., 2007). Salmonella enterica 
PgtE omptin activates Plg in vitro, but the role of Plg activation in salmonellosis pathogenesis 
remains unclear (Kukkonen and Korhonen, 2004). Another omptin with a Plg activation function is 
Lpa, found on the outer membrane of the pathogen Legionella pneumophila (Vranckx et al., 2007). 
The periodontal pathogen Porphyromonas gingivalis possesses an 80-kDa trypsin-like protease 
that activates Plg and inactivates plasmin inhibitors α2-AP and α2-M, leading to uncontrolled 
plasmin activation (Grenier, 1996). 
SK and SAK proteins are secreted bacterial PAs that form a 1:1 complex with Plg, leading to 
changes in conformation that promote Plg activation to plasmin. There are some differences in Plg 
activation mediated by these two proteins. SK acts directly as a PA: the formation of the SK-Plg 
complex induces a conformational change in Plg structure, leading to its conversion to plasmin. 
Differently from SK, SAK-Plg complex is enzymatically inactive and requires conversion of Plg to 
plasmin; only the SAK-plasmin complex acts as a PA and activates preferably fibrin-bound Plg 
(Lähteenmäki et al., 2001). SK has been largely studied in several GAS species; Sun et al. (2004) 
have underlined the importance of plasmin in the pathogensis of Streptococcus infections. In fact, 
without plasmin activity, local microvascular occlusion caused by fibrin clots formation represents 
a host defence mechanism against GAS. SK activated plasmin mediates fibrin degradation and 
allows invasive microorganisms to cross this barrier, favouring bacterial dissemination. 
Bacterial plasminogen receptors and “moonlighting proteins” 
Bacterial Plg receptors (PlgR) are surface structures used by bacteria to immobilize Plg and favour 
its conversion to plasmin by PAs. This system allows microorganisms to acquire a strong 
proteolytic activity localized on their external surface, cell wall or outer membrane. The main 
PlgRs in Gram-negative bacteria are fimbriae and flagella, filamentous appendages present on the 
surface of these organisms (Lähteenmäki et al., 2001). In addition, some Gram-negative 
microorganisms harbour on their outer membrane proteins that bind host Plg. Two Plg binding 
proteins have been identified in the spirochete Borrelia burgdorferi, the etiological agent of Lyme 
disease: the outer surface protein A (OspA) and a 70 kDa surface protein that shows homology to 
the periplasmic ABC transpoter proteins of other bacterial pathogens (Fuchs et al., 1994; Hu et al., 
1997). No endogenous PAs have been found, but bacterial bound Plg is activated to plasmin by 
human uPA, promoting ECM components degradation and bacterial migration through endothelial 
monolayers (Coleman and Benach, 1999). It has been demonstrated that B. burgdorferi cells and 
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purified OspA stimulate pro-uPA production in human monocytes, besides the expression increase 
and release of uPAR from monocytes (Coleman et al., 2001; Coleman and Benach, 2003). Recent 
studies have demonstrated the presence of two Plg receptors on the surface of the pathogenic 
bacteria Helicobacter pylori: PgbA and PgbB, characterized by a high lysine content (Jönsson et al., 
2004). The Gram-negative bacterium Bacteroides fragilis, a common member of the human 
microbiota but also an opportunistic pathogen, can bind Plg molecules on its surface. This binding 
depends on the presence of specific proteins in the outer membrane, such as Pbp (putative Plg 
binding protein). B. fragilis is not capable to activate Plg to plasmin, and the role of Pbp could be 
only sequestering Plg and keeping it locally on the bacterial surface in an inactive form (Sijbrandi 
et al., 2005, 2008). 
In Gram-positive bacteria, Plg binding proteins have been identified on their cell wall. PlgR activity 
has been detected on several pathogens, and most of these molecules have other important 
functions, such as adhesion, movement, enzymatic activity, nutrient uptake, or interaction with 
immune system. Moreover, a single bacterial species can express different PlgR kinds 
(Lähteenmäki et al., 2001). 
GAS express different surface Plg binding proteins; one with the highest affinity is the Plasminogen 
binding group A streptococcal M-protein, PAM. M-proteins are antiphagocytic fibrillar, helical 
surface proteins containing numerous repeated regions (Berge and Sjobring, 1993). Plg interaction 
is mediated by two 13-aa repeated sequences (a1 and a2) containing a central lysine residue, 
localized to the N-terminal portion on the exposed surface of PAM. The substitution of the lysine 
residue with alanine residue in the a1 sequence has been demonstrated to decrease Plg binding of 
80% (Ringdahl and Sjobring, 2000). Recently, other surface proteins that bind Plg with high affinity 
have been identified in Streptococcus: PAM-related protein (Prp), belonging to the M-protein 
family (Sanderson-Smith et al., 2007), and choline-binding protein E (CBPE), member of the 
surface exposed choline-binding protein family (Attali et al., 2008b). 
Recently, some cytoplasmic proteins have been identified as bacterial PlgRs. These proteins have 
essential roles in bacterial metabolism and growth and are usually localized in the cytoplasm, but 
they have been found to be exposed on the bacterial cell surface, even if they lack any exporting 
and anchoring signal. These molecules have been described as “moonlighting proteins” because of 
their ability to have more than one job or, in a scientific language, to harbour more than one 
biological function, and this multitasking characteristic is embedded within a single polypeptide 
chain (Jeffery, 1999, 2009). The secretion and anchoring mechanisms of these moonlighting 
proteins are still unclear. Moonlighting proteins perform multiple independent and often 
unrelated activities without partitioning these functions into different domains. In a recent review, 
it is stated that the term “moonlighting” can describe two different phenomena. The first is the 
presence of a second, third, etc. “biochemical” site(s) on the protein enabling additional biological 
activities; but these new functions may be exerted only when the moonlighting protein is in a 
location different from the one normally occupied. Thus, beside a biochemical moonlighting there 
is also a “geographical” moonlighting, and both may be required to the exhibition of a true 
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moonlighting activity (Henderson and Martin, 2011). The presence of moonlighting functions in 
several proteins is not typical of bacteria, but it is a widespread phenomenon present in all the 
kingdoms of life (Huberts and van der Klei, 2010). Focusing on bacteria, many of the principal 
moonlighting proteins can be gathered in two main groups: metabolic enzymes, among which 
components of the glycolytic pathway are the most represented, and housekeeping proteins, 
specifically molecular chaperones such as heat shock proteins (HSPs). 
Some glycolytic enzymes have been found interacting in a specific manner with Plg in different 
microorganisms; among these proteins, glyceraldehyde-3 phosphate dehydrogenase (GAPDH) and 
α-enolase have been the most investigated. 
GAPDH has been the first PlgR identified on GAS capable of binding Glu-Plg. Site-specific 
mutagenesis studies have demonstrated the importance of the C-terminal lysine residue in the 
interaction between GAPDH and Plg: in fact, leucine substitution of this residue leads to a Plg 
binding reduction. Nonetheless, cells bearing a mutation in this protein show a Plg binding similar 
to non mutant cells, indicating the existence of other surface PlgRs on these microorganisms 
(Winram and Lottenberg, 1998). GAPDH has been found in the cell wall protein fraction of Listeria 
monocytogenes and could represent another virulence factor of this pathogenic bacterium 
(Schaumburg et al., 2004). Plg binding of this enzyme has also been found for different Escherichia 
coli pathogenic strains (Egea et al., 2007). 
α-enolase is an essential enzyme in glycolysis: it catalyzes the conversion of 2-phospho-D-glycerate 
(2-PGE) to phosphoenolpyruvate (PEP). In eukaryotic organisms the active enzyme forms a dimer, 
while in bacteria it is found as an octamer (Brown et al., 1998; Ehinger et al., 2004). α-enolase cell 
surface localization is very common in several prokaryotic and eukaryotic organisms (Pancholi, 
2001). This enzyme is the main PlgR present on the surface of several Streptococcus species. Two 
lysine residues localized on the C-terminal of Streptococcus pneumoniae α-enolase (binding site 1, 
BS1) are important in the interaction with Plg/plasmin (Bergmann et al., 2001), but removal of 
these two amino acids by carbossipeptidase B treatment, or their substitution with two leucine 
residues, partly decreases Plg binding. A second Plg binding site (BS2) has been therefore 
identified on the α-enolase of S. pneumoniae (amino acidic sequence: 248FYDKERKVY256) 
(Bergmann et al., 2003) and the crystallographic structure resolution of this protein has shown its 
localization on a surface exposed loop (Ehinger et al., 2004). α-enolase surface localization and its 
Plg binding activity have been demonstrated for several prokaryotic and eukaryotic organisms, 
both commensals and pathogens (Table 3). 
 
 
 
 
Introduction 
39 
Table 3 - α-enolase - Plg interaction 
 Organisms References 
Bacteria Aeromonas hydrophila Sha et al., 2009 
 Bacillus anthracis Agarwal et al., 2008 
 Bifidobacterium animalis subsp. lactis, B. 
longum; B. bifidum; B. breve 
Candela et al., 2007, 2009 
 Borrelia burgdorferi Floden et al., 2011; Nogueira et al., 2012; Toledo et al., 2012 
 Lactobacillus crispatus; L. johnsonii Antikainen et al., 2007b 
 Listeria monocytogenes Schaumburg et al., 2004 
 Mycoplasma fermentans; M. gallisepticum Yavlovich et al., 2007; Chen et al., 2011 
 Neisseria meningitidis Knaust et al., 2007 
 Staphylococcus aureus Mölkänen et al., 2002 
 group A streptococci; Streptococcus 
pneumoniae; S. mutans; S. suis; S. oralis; S. 
mitis; S. salivarius 
Pancholi and Fischetti, 1998; Bergmann et al., 2001; Ge et 
al., 2004; Jones and Holt, 2007; Esgleas et al., 2008; Itzek 
et al., 2010 
Yeasts Candida albicans Jong et al., 2003 
 Paracoccidioies brasiliensis Nogueira et al., 2010 
 Pneumocystis jiroveci (carinii) Fox and Smulian, 2001 
Protozoa Leishmania mexicana Vanegas et al., 2007 
 Plasmodium falciparum; P. berghei Ghosh et al., 2011 
 Trichomonas vaginalis Mundodi et al., 2008 
Worms Clonorchis sinensis Wang et al., 2011a 
 Echinostoma caproni Marcilla et al., 2007 
 Fasciola hepatica Bernal et al., 2004 
 Onchocerca volvulus Jolodar et al., 2003 
 Schistosoma bovis Ramajo-Hernández et al., 2007; de la Torre-Escudero et 
al., 2010 
 
Plg binding and adhesion to ECM proteins have been usually regarded as virulence factors, 
involved in bacterial invasion and colonization processes. However, a study of Antikainen et al. 
(2007b) has pointed out that α-enolase molecules localized both on the cell wall of different 
commensal species of Lactobacillus (L. crispatus ST1, L. johnsonii F133) and on the surface of 
pathogenic bacteria Streptococcus pneumoniae TIGR4, S. pyogenes IH32030 and Staphylococcus 
aureus 8325-4 possess an equivalent Plg binding and ECM proteins adhesion activity. But, 
differently from Lactobacillus, Streptococcus and Staphylococcus express their own Plg activators: 
the interaction with Plg/plasmin system might therefore represent an ecologic strategy common 
among bacteria that inhabit different niches of the same ecosystem, leading to a different 
interaction outcome (commensalism or pathogenesis). 
Another important moonlighting protein belonging to the HSP group is the molecular chaperone 
DnaK, a member of the HSP70 family. Molecular chaperones form complexes whose components 
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are highly conserved and present both in eukaryotes and prokaryotes. These protein complexes 
are involved in protein folding processes: folding and assembling of newly synthesized proteins, 
refolding of unfolded or aggregated proteins, cellular protein transport. Several molecular 
chaperone complexes have been identified; one of the most important is the HSP70 complex, 
homologue to the DnaK complex present in bacteria. This chaperone system allows protein folding 
through ATP-dependent binding and release cycles of hydrophobic segments of an unfolded 
polypeptide chain. DnaK is one component of this complex and shows a highly conserved 
structure: an N-terminal ATPase domain and a C-terminal substrate binding domain (Hartl, 1996; 
Bukau and Horwich, 1998; Mayer and Bukau, 2005). DnaK has been found on the surface of three 
pathogenic species (Listeria monocytogenes, Neisseria meningitidis, Mycobacterium tuberculosis) 
and its interaction with Plg/plasmin system has been demonstrated (Schaumburg et al., 2004; 
Knaust et al., 2007; Xolalpa et al., 2007). 
Interaction of Bifidobacterium with human plasminogen 
The molecular mechanisms implicated in the interaction between Bifidobacterium and the host 
gut remain largely unclear, but recently some studies have pointed out that these microorganisms 
can interact with the human Plg. Indeed, these studies have shown that PlgRs are present on the 
surface of human GIT symbiont bacteria, such as members of Bifidobacterium genus. Candela et al. 
(2007) have demonstrated that four strains of three different species of Bifidobacterium (B. animalis 
subsp. lactis, B. longum and B. bifidum) possess a dose-dependent Plg binding activity. A 
proteomic analysis of the cell wall protein fraction of B. animalis subsp. lactis BI07, a probiotic 
strain used in the pharmaceutical preparation VSL#3, allowed the identification of five putative Plg 
binding proteins: DnaK, glutamine synthetase, α-enolase, bile salt hydrolase and phosphoglycerate 
mutase. All these proteins, except glutamine synthetase, have a C-terminal lysine residue, 
probably involved in Plg interaction. Like other Gram-positive bacteria, some of these B. 
animalis subsp. lactis BI07 PlgRs are moonlighting proteins. A deep analysis of the extracellular 
proteome of the probiotic strain B. animalis subsp. lactis BB-12 allowed the identification of four 
proteins (choloylglycine hydrolase, glutamine synthetase, enolase, DnaK) with high homology to 
the PlgRs exposed on the cell wall of B. animalis subsp. lactis BI07. It could be speculated that 
these proteins interact with Plg, considering the high homology level between these molecules 
and the fact that another strain of the B. animalis subsp. lactis taxon binds Plg. The possible role 
of these molecules in Plg binding highlights the importance of the Plg/plasmin system in the 
bacteria-host interaction and colonization (Gilad et al., 2011). 
As reported above, α-enolase plays an important role in Plg binding in numerous microorganisms. 
The Plg binding activity of B. animalis subsp. lactis BI07 α-enolase has been deeply characterized, 
allowing the identification of two binding sites: a C-terminal lysine residue (BS1) and an 
internal binding site (BS2). Like Streptococcus pneumoniae α-enolase, Plg binding mainly 
depends on the internal binding site (Candela et al., 2009). 
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Enzymatic activity assays have shown that Plg bound on the B. animalis subsp. lactis BI07 outer 
surface is activated to plasmin by host PAs: in this way, the microorganism acquires a surface-
associated proteolytic activity useful for ECM components degradation (Candela et al., 2008b). It is 
worth noting that B. animalis subsp. lactis BI07 does not express endogenous PAs and it does not 
possess any surface proteolytic activity in the absence of Plg. 
 
In the human GIT, pathogen and symbiont bacteria compete each other to colonize the same 
ecological niche. As reported by Ochman and Moran (2001), the biological process of host 
colonization is very similar for pathogens and symbionts, independently from the final outcome. It 
might be hypothesized that these microorganisms share some molecular mechanisms useful to 
establish and maintain their relationship with the host: the interaction with the host Plg/plasmin 
system can be one of these strategies. The result of the interaction (pathogenesis or 
commensalism) shall therefore be determined by other microbial characteristics, such as 
pathogenicity islands. In addition, an important aspect to consider is the effect of the 
microenvironment on the biology of the microorganisms. Different environmental conditions 
affect protein expression and the global response of the microorganism to that specific situation, 
shaping the outcome of the interaction with the host. As an example, in the GIT the presence of 
bile salts can have an important impact on the interaction between bacteria and the host. Recent 
studies have highlighted the capability of different Bifidobacterium species to adapt to bile salts, 
leading to a large-scale change in protein expression profile (Sánchez et al., 2007b; Ruiz et al., 
2009). This change could affect the mode of colonization of Bifidobacterium, with consequences 
for the microorganism-host interaction. 
The host colonization and the establishment of a microorganism in a particular niche are extremely 
intricate processes, involving the host genetics, the microorganism genetics and its capability to 
respond and adapt to the different environmental conditions. The final outcome derives from the 
combination of all these factors, and both pathogens and commensals face the same difficulties: it 
could be supposed that they often follow the same path and use similar instruments to find their 
way and survive in that specific ecosystem. 
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mong the components of the human gastrointestinal microbiota, the genus Bifidobacterium 
represents one of the main health promoting groups, affecting several host physiological 
features (Lee and O’Sullivan, 2010; Cronin et al., 2011). Despite the presence of bifidobacteria in 
the human gut has been related to numerous health-promoting activities, there is a lack of 
information about the molecular mechanisms at the basis of the interaction between these 
probiotic microorganisms and the host. Proteins present on the microorganism surface may play 
an important role in the interaction with the host since they can intervene with host molecules 
and components present in the host environment. Recently, the interaction of bifidobacterial 
surface proteins and a host protein present in the gastrointestinal environment, plasminogen 
(Plg), has been reported (Candela et al., 2007). Plg is the monomeric proenzyme of plasmin, a 
trypsin-like serine protease with a broad substrate specificity. 
The studies presented here aim to shed some light on the dynamics of interaction between 
Bifidobacterium and the human Plg/plasmin system, looking on this host system as a valuable tool 
used by the microorganism for the interaction with the host, following the track of similar studies 
carried out on pathogens. The studies reported in this thesis start from the molecular analysis of 
the specific Plg binding of one bifidobacterial receptor, going on with the study of the biological 
significance of this interaction, examining the impact of environmental variables on the Plg binding 
to bifidobacterial cells and the role of Plg/plasmin system in the interplay between bacteria and 
host cells. 
Bifidobacteria possess different Plg receptors on their cell surface, and one of these, α-enolase, a 
Plg receptor widely shared among bacteria, has been characterized (Candela et al., 2007, 2009). 
DnaK represents another important Plg receptor, conserved among bifidobacteria. Here, the 
molecular and biochemical characterization of the bifidobacterial surface Plg receptor DnaK has 
been undertaken, with particular attention on the structure of this protein and its binding to 
human Plg. 
The second aspect taken into consideration has been the environment and its variables. Factors 
present in the gut environment can have an important influence on the interactions that take place 
in the gut ecosystem. Bile salts are among the major challenging factors because of their 
bacterial toxicity (Begley et al., 2005). In recent times, the adaptation of bifidobacterial species to 
bile salts has been evaluated, revealing many changes in the cell wall proteome (Ruiz et al., 2009), 
that can likely affect the modality of interaction with the host. Considering the impact of bile salts 
adaptation on the Bifidobacterium extracellular proteome, the effect of bile salts on the Plg 
binding activity of Bifidobacterium has been evaluated. 
The role of Plg/plasmin system in the biology of interaction between Bifidobacterium and human 
intestinal epithelial cells is another important aspect studied to elucidate the importance of this 
host system in the cross-talk between this probiotic microorganism and the host. To this aim, 
Bifidobacterium Plg-mediated early interaction with human enterocytes has been investigated, 
using HT29 cell line as model system for the human intestinal epithelium, being a mucus-
A 
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producing cell line derived from human colorectal adenocarcinoma (Fogh and Trempe, 1975; 
Rousset, 1986). 
Gut environmental conditions can affect the host Plg/plasmin system equilibrium; in particular, 
inflammatory processes involve an up-regulation of the Plg activators expression, leading to a 
clear increase of plasmin availability in inflamed tissues (Mondino and Blasi, 2004; Killeen et al., 
2009). Taking into account changes associated with gut inflammatory processes, the impact of 
inflammation on the Bifidobacterium-Plg-host enterocytes early interaction has been evaluated, 
mimicking this condition stimulating HT29 cells with the pro-inflammatory cytokine TNF-α, an 
important mediator of gut inflammation (Ma et al., 2004; Yan et al., 2008). 
Components of the Plg/plasmin system are present in the gastrointestinal environment (Zhang et 
al., 2002), but until now the relevance of the interaction between Bifidobacterium and this system 
in a physiological ecosystem has not yet been elucidated. To this purpose, the capability of 
bifidobacteria to recruit components of the Plg/plasmin system present at physiological 
concentrations has been evaluated in a physiological human intestinal ecosystem, represented by 
crude faecal extracts. These extracts has been chosen as a model of the human gastrointestinal 
environment because they represent the only possibility for a non-invasive sampling of the human 
gastrointestinal tract content and reflect the entire content of the full length of the colon-rectum 
(Ang et al., 2010). 
The comprehension of the molecular mechanisms underlying the cross-talk between 
bifidobacteria and the human host and the modulation of this interaction under different 
environmental conditions can be important to better understand the probiotic properties of this 
bacterial group. 
The research project presented here led to the publication of three research articles: “DnaK from 
Bifidobacterium animalis subsp. lactis is a surface-exposed human plasminogen receptor 
upregulated in response to bile salts” (Candela et al., 2010, Microbiology, 156:1609-1618); 
“Relevance of Bifidobacterium animalis subsp. lactis plasminogen binding activity in the human 
gastrointestinal microenvironment” (Candela et al., 2011, Applied and Environmental 
Microbiology, 77:7072-7076); “Tumor Necrosis Factor Alpha modulates the dynamics of the 
plasminogen-mediated early interaction between Bifidobacterium animalis subsp. lactis and 
human enterocytes” (Centanni et al., 2012, Applied and Environmental Microbiology, 78:2465-2469). 
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Introduction 
 
Due to its intrinsic proteolytic potential, host Plg/plasmin system represents a valuable tool used 
by several microorganisms to interact with the host. Plg molecule possesses an N-terminal pre-
activation peptide, five consecutive kringle domains and a serine-protease domain (Ponting et al., 
1992). The capability to intervene with this system is a host-colonization tactic present both in 
pathogens and commensals of the human GIT, as Lactobacillus and Bifidobacterium (Parkkinen 
and Korhonen, 1989; Schaumburg et al., 2004; Lähteenmäki et al., 2005; Sijbrandi et al., 2005; 
Bergmann and Hammerschmidt, 2007; Hurmalainen et al., 2007; Candela et al., 2008b). The 
recruitment of host Plg on the microorganism cell surface, and its following conversion to the 
active enzyme plasmin, allows the microorganism to acquire a surface-associated and host-derived 
proteolytic activity, functional to the migration across tissue barriers and to the nutritional 
demands during the colonization process (Lähteenmäki et al., 2005). 
Binding of host Plg on the microorganism depends on the presence of Plg binding proteins on the 
microorganism outer surface. Lysine residues present on these receptors mediate the interaction 
with Plg molecules, specifically with Plg kringle domains; these lysine residues have been located 
in the C-terminal portion of the proteins or/and in lysine enriched internal Plg binding motive(s) 
(Bergmann and Hammerschmidt, 2007). One of the most investigated Plg receptor, found in 
bacteria but also in yeasts, protozoa and worms, is α-enolase (Fox and Smulian, 2001; Jolodar et 
al., 2003; Jong et al., 2003; Bernal et al., 2004; Marcilla et al., 2007; Nogueira et al., 2010; Avilán et 
al., 2011; Wang et al., 2011a). α-enolase is a glycolytic cytoplasmic enzyme that has also been 
found on the cell surface of several prokaryotic and eukaryotic organisms (Pancholi, 2001); in this 
different localization it displays an additional function different from the one exerted in the 
cytoplasm, a “moonlighting” function (Jeffery, 1999). Several studies have been performed to 
elucidate molecular and biochemical characteristics of the α-enolase-human Plg interaction in 
numerous streptococcal species. In Streptococcus pneumoniae surface α-enolase binds human Plg 
with high affinity and presents two Plg binding sites, a C-terminal binding site constituted by two 
lysine residues, and an internal binding site, with the amino acid sequence 248FYDKERKVY256 
(Bergmann et al., 2001, 2003). This internal binding site is the major determinant of host Plg 
binding because of its localization on the outer surface of the octameric molecule, as revealed by 
the crystallographic resolution of the protein structure (Ehinger et al., 2004). A recent molecular 
and biochemical study has underlined the importance for Plg binding of lysine residues present in 
a similar internal binding site also in GAS α-enolase, probably acting in concert with C-terminal 
lysine residues (Cork et al., 2009). Recently, α-enolase has been found as a Plg receptor also in 
commensal bacteria. Antikainen and co-workers showed that α-enolase molecules localized both 
on the cell surface of different commensal Lactobacillus species and on the surface of 
Streptococcus pneumoniae, S. pyogenes and Staphylococcus aureus possess an equivalent Plg 
binding activity (Antikainen et al., 2007b). 
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Different bifidobacterial species have shown Plg binding activity. It has been demonstrated that 
Bifidobacterium longum, B. bifidum, B. breve and B. animalis subsp. lactis possess Plg receptors on 
their cell wall (Candela et al., 2007, 2009). B. animalis subsp. lactis, initially isolated from 
fermented milk (Meile et al., 1997; Lee and O’Sullivan, 2010), is usually present in the gut of 
healthy infants and adults (Wall et al., 2008; Turroni et al., 2009) and is one of the most common 
probiotic bifidobacterial species utilized in commercial dairy products and pharmaceutical 
preparations in Europe and North America, combining health-promoting activities with 
technological properties (Barrangou et al., 2009). One widely used B. animalis subsp. lactis strain, 
BI07, has been chosen as a bifidobacterial model and the proteomic analysis of its cell wall fraction 
allowed the identification of five putative human Plg receptors: DnaK, glutamine synthetase, α-
enolase, bile salt hydrolase (BSH) and phosphoglycerate mutase (Candela et al., 2007). The 
complete inhibition of Plg binding to B. animalis subsp. lactis BI07 cells in the presence of the 
lysine analogue ε-aminocaproic acid (EACA) suggested that lysine residues present on these 
surface Plg receptors are involved in Plg binding, a common trait of Plg receptors. Analogously to 
other Gram-positive bacteria (Lähteenmäki et al., 2001), the Plg binding proteins found on the 
surface of B. animalis subsp.lactis BI07 are “moonlighting” proteins, highly conserved cytoplasmic 
proteins that, displayed on the bacterial cell surface, acquire a different secondary function. The 
analysis of the cell wall fractions of other bifidobacterial strains in order to screen common 
conserved putative surface Plg receptors allowed the identification of two major Plg binding 
proteins: α-enolase and DnaK (Candela et al., 2009). 
B. animalis subsp. lactis BI07 α-enolase is localized both in the cytoplasm and in the cell wall, and 
its Plg binding capability has been demonstrated. It shows a high affinity for human Plg, with an 
equilibrium dissociation constant in the nanomolar range. The construction of a homology 
model of bifidobacterial α-enolase allowed the identification of two putative Plg binding sites: a 
C-terminal binding site, constituted by a unique lysine residue, and an internal binding site, 
homologous to the internal binding site of pneumococcal α-enolase, with amino acid sequence 
248FYNKETGKY256. Mutagenesis and biochemical analysis demonstrated that the internal binding 
site is essential for human Plg binding, while the C-terminal lysine is only marginally involved in 
this interaction (Candela et al., 2009). 
DnaK represents another Plg receptors conserved among bifidobacteria, but it has been also 
detected on the surface of pathogenic bacteria, such as Listeria monocytogenes, Neisseria 
meningitidis and Mycobacterium tuberculosis, where it shows a human Plg binding activity 
(Schaumburg et al., 2004; Knaust et al., 2007; Xolalpa et al., 2007). Here the Plg binding function of 
B. animalis subsp. lactis BI07 DnaK has been investigated from the molecular and biochemical 
point of view, with an attempt to identify the determinants of this interaction. 
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Materials and methods 
 
Bacterial strains, media and growth conditions 
Bifidobacterium animalis subsp. lactis BI07, isolated from dairy products, was cultured in de Man-
Rogosa-Sharpe (MRS) medium (Difco) supplemented with 0.05% (wt/vol) L-cysteine at 37°C in 
anaerobiosis. The anaerobic condition was obtained in a jar by using Anaerocult A (Merck). 
Bifidobacterial cells were grown for 18 h until they reached the stationary phase. Escherichia coli 
OneShot TOP10, BL21Star(DE3) and XL10-Gold strains were cultured in Luria-Bertani (LB) 
medium at 37°C with shaking. MagicMedia (Invitrogen) was used for recombinant protein  
expression. 50 µg/ml kanamycin were added as selective agent when appropriate.  
Extraction of bifidobacterial cytoplasmic and cell wall proteins 
Cytoplasmic proteins were extracted as reported by Candela et al. (2009). In brief, after washing in 
50 mM Tris-HCl (pH 7.6), stationary phase B. animalis subsp. lactis BI07 cells were resuspended in 
500 µl of TE buffer (50 mM Tris-HCl [pH 7.6], 5 mM EDTA) and 50 µl of Complete Protease 
Inhibitors Solution (Roche) were added. The suspension was sonicated to disrupt bacterial cells 
and centrifuged for 10 min at 14000 rpm at 4°C to precipitate debris. The supernatant was 
collected and centrifuged for 2 h at 45000 rpm at 4°C by using a Beckman Ultracentrifuge L7-55. 
The supernatant, containing cytoplasmic proteins, was stored at -20°C. 
Cell wall proteins were extracted as reported by Hardie and Williams (1998). Stationary phase 
cells of B. animalis subsp. lactis BI07 were collected, washed in 50 mM Tris-HCl (pH 7.6) and 
resuspended in 2 ml of protoplast buffer (50 mM Tris-HCl [pH 7.6], 1 M sucrose, 1.4 mM 
phenylmethylsulfonyl fluoride, 15 mg/ml lysozyme). After an incubation for 90 min at 37°C, the 
suspension was centrifuged for 3 min at 4000 rpm at 4°C and the supernatant, containing the cell 
wall proteins, was collected and stored at -20°C. In order to remove sucrose excess, cell wall 
proteins were precipitated with 15% trichloroacetic acid (TCA), centrifuged for 10 min at 13000 
rpm at 4°C, and resuspended in acetone. After 5 min incubation on ice, proteins were centrifuged 
for 10 min at 13000 rpm at 4°C and acetone was completely removed. 
Electron microscopy and immunoblot analysis 
Pre-embedding immunogold experiments were performed in order to visualize DnaK on the cell 
surface of B. animalis subsp. lactis BI07 cells, using whole bifidobacterial cells. Stationary phase 
cells were washed with PBS and adjusted to the concentration of 1 × 109 CFU/ml. Bacterial cells 
were resuspended in 100 µl of rabbit polyclonal anti-meningococcal DnaK antiserum (Knaust et al., 
2007) diluted 1:100 in PBS-1% bovine serum albumin (BSA) and incubated for 1 h at 25°C under 
constant agitation. Bacteria were washed twice with 1 ml PBS-1%BSA and resuspended in 25 µl of 
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10 nm gold particles conjugated anti-rabbit IgG (AuroProbe, GE Healthcare) diluted 1:5 in PBS-1% 
BSA, incubating for 30 min at 25°C under agitation. Bacteria cells were collected, washed twice in 
PBS-1% BSA and fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer for 4 h at 4°C. 
Transmission electron microscopy (TEM) processing was carried out as reported by Candela et al. 
(2007). Glutaraldehyde-fixed bacteria were washed with 0.15 M cacodylate buffer and postfixed 
for 1 h at 4°C with 1% OsO4. After washing, bacteria were dehydrated in a graded alcohol series 
and embedded in araldite (Fluka, Sigma-Aldrich). Ultrathin sections, obtained with a Reichert 
OMu3 ultramicrotome, were counterstained with uranyl acetate and lead citrate and examined 
with a Philips 400T transmission electron microscope. Electronic microscopic experiments were 
repeated four times. 
Western blotting analysis was performed for both cytoplasmic and cell wall proteins of B. animalis 
subsp. lactis BI07. After mixing samples with loading buffer (0.5 M Tris-HCl [pH 6.8], 4% (wt/vol) 
SDS, 20% glycerol, 0.1% bromophenol blue, 5% β-mercaptoethanol) and boiling for 5 min, 10 µg of 
proteins were resolved by SDS-PAGE in 12% polyacrylamide gel using a SE 250 mini vertical 
electrophoresis unit (GE Healthcare) for 2.5 h at 160 V. Proteins were blotted onto a nitrocellulose 
membrane (BioRad) using the Minitrans-Blot Electrophoretic Cell (BioRad) at 100 V, 90 mA, at 4°C 
overnight. After protein transfer, the membrane was blocked in a solution of 4% skim milk (Fluka, 
Sigma-Aldrich) in TBS-T (20 mM Tris-HCl [pH 7.6], 0.5 M NaCl, 0.15% Tween 20) for 1 h at 25°C and 
subsequently incubated with cross reactive anti-meningococcal DnaK antiserum (Knaust et al., 
2007) for 1 h at 25°C under constant agitation. The membrane was then washed three times in 
TBS-T and incubated with the horseradish peroxidase conjugated anti-rabbit IgG (GE Healthcare) 
at 25°C for 1 h. After three TBS-T washings, the membrane was incubated with ECL Plus (GE 
Healthcare) and the chemiluminescent signal detected by using a PhosphorImager Storm system 
(GE Healthcare). 
Construction of a B. animalis subsp. lactis BI07 genomic library and screening for the 
dnaK gene 
The restriction enzyme Mbo I was employed to partially digest 300 µg of B. animalis subsp. lactis 
BI07 chromosomal DNA. DNA fragments of about 20 kb were isolated by ultracentrifugation at 
26000 rpm for 24 h at 18°C in a sucrose gradient 10%-40%, purified by precipitation with ethanol 
and ligated to BamH I digested Lambda EMBL3 vectors (Stratagene). Lambda EMBL3/BamH I 
Gigapack III Gold Cloning kit (Stratagene) was used to package recombinant lambda phages and 
the library was amplified and titered following the kit instructions. In order to screen for the dnaK 
gene in the library, a specific probe was obtained amplifying the B. longum NCC2705 
chromosomal DNA with the primers set L-DnaK (5’-TTGGCACGTGCAGTTG-3’) and R-DnaK (5’-
TCACTTGTTGTCCTTGTCG-3’), designed on the basis of the genome sequence of B. longum 
NCC2705. The dnaK gene targeting DNA probe was labelled with digoxygenin by using the DIG-
DNA Labelling and Detection Kit (Roche). For dnaK gene detection, phage library was plated on 
120 mm NZY agar plates using E. coli XL1-Blue MRA P2 as host strain. Plates were blotted onto 
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nylon membranes (Hybond N+, GE Healthcare). Neutralization, denaturation, crosslinking, 
membranes hybridization with the DIG-labelled DNA probe and detection were carried out as 
described in the DIG-DNA Labelling and Detection kit manual (Roche). Plaques corresponding to 
the positive signals in the original plates were cut out and resuspended in SM buffer to isolate the 
recombinant phage population. Phage DNA was extracted with the Qiagen Lambda mini kit 
(Qiagen), positive clones were sequenced and the B. animalis subsp. lactis BI07 dnaK gene 
sequence was obtained. 
Cloning, expression and purification of B. animalis subsp. lactis BI07 His6-DnaK 
Genomic DNA was extracted from 1 ml of a B. animalis subsp. lactis BI07 overnight culture by 
using DNeasy Blood and Tissue kit (Qiagen) following the kit manual instructions. The genomic 
DNA was used as template in a PCR reaction for the amplification of the dnaK gene using the 
primer set DnaK-TOPO-L (5’ -CACCATGGGACGCGCAGTTGGT- 3’) and DnaK-TOPO-R (5’-
TTACTTGTTGTCCTTGTCGTCGTC- 3’), designed on the basis of the sequence of the phage clone 
containing bifidobacterial dnaK gene. The CACC sequence at the 5’ terminus of DnaK-TOPO-L 
primer is essential for the PCR product directional cloning in the expression vector pET200/D-
TOPO (Invitrogen). Amplification reaction was carried out in a Biometra Thermal Cycler II 
thermocycler (Biometra), using Platinum Pfx DNA polymerase (Invitrogen). The PCR reaction was 
conducted in a final volume of 50 µl, containing 0.3 µl 50 µM primer DnaK-TOPO-L, 0.3 µl 50 µM 
primer DnaK-TOPO-R, 6 µl 2.5 mM dNTPs, 1 µl 50 mM MgSO4, 10 µl 10X Pfx Amplification buffer, 
10 µl 10X PCRx Enhancer Solution, 0.4 µl Platinum Pfx DNA polymerase, 5 µl B. animalis subsp. 
lactis BI07 genomic DNA 8 ng/µl, 17 µl H2O. The amplification reaction was carried out in a 
thermocycler with a first denaturation step at 94°C for 5 min, followed by 30 cycles of 
denaturation at 94°C for 30 s, annealing at 62°C for 30 s, elongation at 68°C for 1 min 30 s, with a 
final elongation step at 68°C for 10 min. Amplification product (1866 nt) was visualized on 1% 
agarose gel electrophoresis, using λDNA/EcoRI+HindIII (MBI Fermentas) as molecular weight 
marker, then purified with QIAquick Gel Extraction Kit (Qiagen) and quantified with Qubit 
fluorometer (Invitrogen) and the sequence was controlled using a PRISM377 sequencer (ABI-
Perkin Elmer). The PCR product was cloned in the expression vector pET200/D-TOPO (Invitrogen) 
to obtain the construct pDKwt using the Champion pET Directional TOPO Expression Kit 
(Invitrogen). E. coli OneShot TOP10 and E. coli BL21Star(DE3) (Invitrogen) were utilized for B. 
animalis subsp. lactis BI07 dnaK gene cloning and expression, respectively. The His6-tagged fusion 
DnaK was purified by affinity chromatography under native conditions on Ni-nitrilotriacetic acid 
resin according to the ProBond™ Purification System manual (Invitrogen). The purified 
bifidobacterial DnaK protein was dialyzed at 4°C using Spectra/Por membranes 6000-8000 Da 
(Spectrum Laboratories Inc) and 20 mM Tris-HCl, 120 mM NaCl as dialysis buffer. His6-tagged 
recombinant protein His6-DnaK expression was verified by immunoblot analysis with polyclonal 
anti-meningococcla DnaK antiserum (Knaust et al., 2007) and anti HisTag antibody (Sigma). 
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Site-directed mutagenesis for construction of DnaKΔLys621 
As several Plg binding proteins, B. animalis subsp. lactis BI07 DnaK possesses a C-terminal lysine 
residue potentially involved in Plg binding. To investigate the contribution of this specific residue 
in Plg interaction a DnaK mutant protein was constructed. To this aim, plasmid holding the mutant 
dnaK gene deleted of the nucleotides encoding the C-terminal lysine residue (pDKbs1) was 
created by using QuikChange Multi Site Directed Mutagenesis kit (Stratagene). To replace 
the C-terminal lysine residue with a stop codon the primer DnaKmutBS1 (5’-
GACGACGACAAGGACAACTAATAAAAGGGCGAGCTC-3’) was designed. The reaction mix was 
constituted by 1.8 µl (100 ng) 50 µM 1:10 DnaKmutBS1 primer, 1 µl dNTP mix, 2.5 µl 10X reaction 
buffer, 1 µl QuikChange Multi enzyme blend, 1 µl pDKwt template, H2O to 25 µl. Mutagenesis 
reaction was carried out in a thermocycler with an initial denaturation step at 95°C for 1 min, 
followed by 30 cycles of 95°C for 1 min, 55°C for 1 min and 65°C for 15 min 10 s. The DNA template 
was removed by DpnI treatment at 37°C for 2 h. The reaction was used to transform E. coli XL10-
Gold strain and several clones were sequenced to isolate the mutant. The mutant protein His6- 
DnaKΔLys621 was expressed and purified as described previously for the wild type recombinant 
DnaK protein. 
In silico modelling of B. animalis subsp. lactis BI07 DnaK 
A homology model of B. animalis subsp. lactis BI07 DnaK was constructed in order to characterize 
possible internal putative Plg binding site(s), as frequently found for other bacterial Plg binding 
proteins. The homology model was calculated as reported by Zambelli et al. (2009). The amino 
acidic sequence of B. animalis subsp. lactis BI07 DnaK (Appendix 1) was used to search for possible 
structural templates by using the bioinformatic tool BLAST (Altschul et al., 1990, 1997). Four DnaK 
and three Hsc70 structures with a high identity score were recovered, including full-length 
proteins and isolated domains (Table 4). 
In order to identify a conserved motif, other nine DnaK sequences reported to possess a Plg 
binding activity were also included in the considered dataset. Multiple sequence alignment was 
carried out by using ClustalW (Thompson et al., 1994). Secondary structure prediction for all 
sequences was performed using the program JPred (Cuff et al., 1998) and the alignment was 
manually optimized basing on the secondary structure information. Fifty model structures were 
calculated with the program MODELLER 9v6 (Martí-Renom et al., 2000) using the structural 
templates indicated above. The best model was selected on the basis of the lowest value of the 
MODELLER objective function. Structure validation was performed with PROCHECK software 
(Laskowski et al., 1993). The last 35 residues of the protein were not modelled due to the absence 
of structural data covering such region. The program UCSF Chimera (Pettersen et al., 2004) was 
used for protein visualization. The analysis of protein-protein interaction sites was carried out by 
using a combination of the predictions obtained from the following tools: SPPIDER predictor 
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(Porollo and Meller, 2007), ProMate (Neuvirth et al., 2004), cons-PPISP (Zhou and Shan, 2001), 
PPI-Pred (Bradford and Westhead, 2005), PINUP (Liang et al., 2006). 
Table 4 - DnaK structural templates 
ID Chain Source Description 
Plg 
binding 
activity 
Identity 
(%) 
Length 
(aa) 
Resolution 
(Å) 
/ / 
Bifidobacterium animalis 
subsp. lactis BI07 
DnaK yes / 621 / 
ABF57997 / Bifidobacterium bifidum DnaK yes 92 623 / 
YP_910410 / Bifidobacterium adolescentis Chaperone DnaK (Hsp70) / 93 626 / 
ZP_00121343 / 
Bifidobacterium longum 
NCC2705 
Molecular chaperone yes 92 626 / 
ABF57996 / Bifidobacterium breve DnaK yes 89 626 / 
NP_283534 / Neisseria meningitidis Z2491 Molecular chaperone DnaK yes 55 642 / 
NP_273598 / Neisseria meningitidis MC58 Molecular chaperone DnaK yes 55 642 / 
NP_214864 / 
Mycobacterium tuberculosis 
H37Rv 
Molecular chaperone DnaK yes 68 625 / 
YP_014090 / 
Listeria monocytogenes str. 
4b F2365 
Chaperone protein DnaK yes 60 613 / 
NP_464998 / 
Listeria monocytogenes 
EGD-e 
Molecular chaperone DnaK yes 59 613 / 
1YUW A Bos taurus 
Hsc70 (E213A/D214A 
mutant) 
/ 50 554 2.60 
1DKG D Bos taurus DnaK (ATPase domain) / 54 383 2.80 
1HPM A Bos taurus Hsc70 (ATPase fragment) / 46 386 1.70 
2E8A A Homo sapiens Hsc70 (ATPase fragment) / 46 391 1.77 
1DKZ A Escherichia coli 
DnaK (substrate binding 
domain) 
/ 55 219 2.00 
1BPR A Escherichia coli 
DnaK (substrate binding 
domain) 
/ 60 191 NMR 
1Q5L A Escherichia coli 
DnaK (peptide binding 
domain) 
/ 69 125 NMR 
 
Plasminogen binding analysis by solid phase binding assay 
Plg binding activity of recombinant bifidobacterial DnaK or mutant DnaKΔLys621 was evaluated by 
means of a solid phase Plg binding assay, performed as previously described by Sanderson-Smith 
et al. (2006, 2007). Human Plg (Sigma-Aldrich) was biotinylated by using EZ-Link Micro Sulfo-NHS-
SS Biotinylation Kit (Pierce). Ninety-six-well microtiter plates (OptiPlate-96, Perkin Elmer) were 
coated with 150 nM recombinant DnaK or DnaKΔLys621 (50 µl in 0.1 M NaHCO3) and incubated 
overnight at 4°C. After a washing step with PBS, plates were blocked with 200 µl of in PBS-2% 
bovine serum albumin (BSA) for 1 h at 37°C. Plates were washed three times and increasing 
concentration of biotinylated human Plg in PBS (2, 6, 18, 36, 55, 110, 166, 250 nM) were added to 
the plates, in the presence or absence of 50-fold molar excess of unlabelled Plg, incubating the 
plates for 2 h at 25°C. After three washings in PBS, 50 µl ExtrAvidin HRP conjugated (Sigma-Aldrich) 
diluted 1:5000 in PBS-1% BSA were added to each well and incubated for 2 h at 25°C. Plates were 
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washed four times with PBS and 0.05% Tween 20 and 100 µl of Chemiluminescent Peroxidase 
Substrate for ELISA (Sigma-Aldrich) were added to each well, reading luminescence by using 
Victor3V 1420 Multilabel Counter scanner (Perkin Elmer) and the software Wallac 1420 
WorkStation. Wells coated with BSA were used as negative control for Plg binding. For both the 
recombinant proteins, Plg binding assays were performed three times and for a given Plg 
concentration each measure was repeated in triplicate. The experiments were repeated in the 
presence of 0.5 M of the lysine analogue ε-aminocaproic acid (EACA) (Sigma-Aldrich) in order to 
evaluate the involvement of lysine residues in the DnaK-Plg binding. Data were normalized against 
the highest and lowest luminescence values, and non-linear regression analysis was performed 
with Graph Pad Prism software, version 5.0 (Graph Pad software). One- and two-site binding 
analysis were carried out for equilibrium dissociation constant (KD) calculation and the best-fit 
curve was selected. 
Impact of DnaK and enolase on B. animalis subsp. lactis BI07 cells plasminogen binding 
activity 
The role of DnaK and enolase in the interaction between human Plg and whole B. animalis subsp. 
lactis BI07 cells was evaluated in a Plg binding assay with bifidobacterial cells pretreated with cross 
reactive anti-meningococcal DnaK antiserum (Knaust et al., 2007) or anti-pneumococcal enolase 
antiserum (Bergmann et al., 2003). Stationary phase B. animalis subsp. lactis BI07 cells were 
resuspended in PBS at a concentration of 1 x 109 CFU/ml and incubated for 1 h at 25°C under 
agitation with anti-meningococcal DnaK antiserum diluted 1:250 or anti-pneumococcal enolase 
antiserum diluted 1:100 in PBS-1% BSA. Bacterial cells were washed with PBS-1% BSA, 
resuspended in PBS and incubated with 100 µg of human Plg (Sigma-Aldrich) for 30 min at 37°C 
under agitation. After three washings with PBS to remove unbound Plg, bacterial cells were 
resuspended in 20 µl NH4Cl 2% for MALDI-TOF analysis of Plg binding. One µl of bacterial 
suspension was spotted, airdryed and then overlaid with 1.0 µl of matrix solution (12.5 mg/ml 
ferulic acid in a mixture of formic acid/acetonitrile/water 17:33:50). The resulting droplet was left 
to crystallize by airdrying and then analyzed in a Voyager DE Pro MALDI-TOF mass spectrometer 
(Applied Biosystems) operating in linear positive ion mode in the range of 20000-100000 Da and 
equipped with a pulsed N2 laser at 337 nm. Default operating conditions were as follow: 
accelerating voltage 25000 V, grid voltage 22500 V, extraction delay time 750 ns. All acquisitions 
were generated automatically on the instrument software (VoyagerTM, Biospectrometry 
Workstation) using a random search pattern mode and based on overaging 1600 shots from 20 
non-overlapping positions (80 shots/position). A standard bovine serum albumin (BSA) solution 
(67 kDa) was used for data external calibration. Two-hundred ng of human Plg (Sigma-Aldrich) 
were used as analytical standard. 
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Fig. 10. (right) Immunoblot analysis (right panel) 
using anti-DnaK polyclonal antiserum of 
cytoplasmic (A) and cell wall (B) protein fractions 
of B. animalis subsp. lactis BI07 resolved by SDS-
PAGE (left panel). 
500 nm
Results 
 
Surface localization of B. animalis subsp. lactis BI07 DnaK protein 
The immunoblot analysis using a cross reactive anti-meningococcal DnaK antiserum (anti-DnaK) 
(Knaust et al., 2007) demonstrated the presence of the DnaK protein both in the cytoplasm and in 
the cell wall fraction of B. animalis subsp. lactis BI07 (Fig. 10). 
 
 
 
 
 
The visualization of the DnaK 
protein on the bifidobacterial cell 
surface was performed by using 
immunoelectron microscopy. B. 
animalis subsp. lactis BI07 cells 
were incubated with the anti-
DnaK antiserum under pre-
embedding conditions and 
subsequently with the 
secondary antibody conjugated 
with 10 nm gold particles. 
Ultrathin sections analysis at a 
magnification of X 22000 
demonstrated the presence of 
DnaK directly on the bacterial 
cell wall region, as indicated by 
the black dots pointed by 
arrows (Fig. 11). Secondary 
antibody unspecific binding was 
not detected (data not shown). 
A B 
Fig. 11. (below) Immunoelectron microscopic 
localization of DnaK on the cell surface of B. 
animalis subsp. lactis BI07. DnaK was detected on 
the bacterial surface by anti-DnaK antiserum and 
secondary antibody coupled to 10 nm gold 
particles in pre-embedding experiments. An 
ultrathin section shows DnaK (black dots, 
arrowed) localized directly in the cell-wall region. 
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Analysis of B. animalis subsp. lactis BI07 dnaK gene 
A phage library of the B. animalis subsp. lactis BI07 genome was constructed and, using a 
digoxigenin-labelled DNA probe designed on the B. longum NCC2705 dnaK gene, it was screened 
for the B. animalis subsp. lactis BI07 dnaK gene. The nucleotide sequence of B. animalis subsp. 
lactis BI07 dnaK gene (GenBank acc. no.: AB514431, Appendix 1) showed an identity of 87% with 
the dnaK gene of B. longum NCC2705 (GenBank acc. no.: AE014295) and 100% with the one of 
B. animalis subsp. lactis DSM10140 (GenBank acc. no.: CP001606). 
Analysis of B. animalis subsp. lactis BI07 DnaK - human plasminogen binding 
With the purpose to analyze the specific human Plg binding activity of the B. animalis subsp. lactis 
BI07 DnaK protein, a recombinant His6-tagged DnaK protein was expressed, purified and used in a 
solid phase Plg binding assay, as reported by Sanderson-Smith and co-workers (Sanderson-Smith 
et al., 2007). A dose-dependent binding between biotinylated human Plg and immobilized 
recombinant DnaK was demonstrated and a saturation binding was achieved in the presence of a 
Plg concentration of 150 nM (Fig. 12A). In the presence of 50-fold molar excess of unlabelled Plg 
non-specific binding was determined. The subtraction of non-specific binding from the total 
binding obtained at each concentration of biotinylated human Plg allowed the calculation of Plg 
specific binding to DnaK. BSA-coated wells were used as negative control. The best-fit non linear 
regression analysis permitted the calculation of an equilibrium dissociation constant (KD) for the 
interaction with Plg of about 11 nM. The essential role of DnaK lysine residues in the interaction 
with Plg was proved in an solid phase Plg binding assay in the presence of 0.5 M EACA as lysine 
competitor, that completely inhibited Plg binding. The C-terminal lysine residues have been 
indicated as main Plg binding sites for numerous Plg receptors (Lähteenmäki et al., 2001; 
Bergmann and Hammerschmidt, 2007). To assess the involvement of the C-terminal lysine residue 
of B. animalis subsp. lactis BI07 DnaK in Plg binding, the codon encoding the C-terminal lysine 
residue at position 621 was deleted. The recombinant His6-tagged DnaK
ΔLys621 was expressed, 
purified, immobilized and its Plg binding activity was assessed in a saturation binding analysis, 
performing a solid phase Plg binding assay (Fig. 12B). B. animalis subsp. lactis BI07 DnaKΔLys621 
displayed a dose-dependent and saturable Plg binding activity, with a KD value of about 20 nM, 
reflecting an affinity only slightly lower with respect to wild type DnaK protein. 
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In silico modelling of B. animalis subsp. lactis BI07 DnaK and prediction of putative 
plasminogen binding site(s) 
In order to determine the presence of putative Plg binding site(s) in the B. animalis subsp. lactis 
BI07 DnaK, a protein homology model was constructed. As template, the coordinates of seven 
homologous proteins (or protein domains) of known structure were used; Fig. 13 shows the 
multiple alignment of the amino acid sequence of B. animalis subsp. lactis BI07 DnaK with other 
nine bacterial DnaK proteins interacting with Plg and the sequence of seven template structures. 
The Ramachandran plot analysis of the calculated structure model of B. animalis subsp. lactis BI07 
DnaK revealed that 95% residues reside in the most favoured and in the allowed regions, 
indicating an high quality model. The global architecture of the structure model (Fig. 14) resembles 
the structural organization of HSP70 family proteins, with a Nucleotide Binding Domain (NBD) from 
residue 1 to 366, followed by a flexible linker characterized by the conserved motif DVLL[IL]DVTP 
(residues 367-375) and a C-terminal Substrate Binding Domain (SBD), spanning residues 376 to 
586.The NBD and the SBD domains interact by two α-helices and a β-strand formed by residues 124-
138, 487-501 and 189-195, respectively. B. animalis subsp. lactis BI07 DnaK model structure shows 
A 
B 
Fig. 12. Saturation binding 
analysis of biotinylated 
plasminogen to immobilized 
recombinant B. animalis subsp. 
lactis BI07 His-tagged DnaK (A) 
and DnaK
ΔLys621
, here indicated 
as DnaK-BS1 (B). The black dots 
represent the specific binding. 
Specific Plg binding was 
calculated at each concentration 
of biotinylated Plg by 
subtracting non-specific binding 
obtained in the presence of 50-
fold molar excess of unlabelled 
Plg from total binding. One-site 
hyperbolic binding function was 
fitted to the data and the KD 
determined. The experiment 
was repeated in the presence of 
the lysine analogue EACA 0.5 M 
(grey triangles). 
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a high lysine content, with 45 lysine residues accounting for 7.7% of total residues, and most of 
them (41) are found uniformly distributed on the surface of the protein model structure (Fig. 15). 
The C-terminal region of SBD domain, from residue 503 to 586, folded as helices presents an 
elongated topology, where 12 exposed lysine residues are placed very closed to each other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13. Multiple sequence alignment of the DnaK sequences of B. animalis subsp. lactis BI07 (01), B. bifidum ID: 
ABF57997 (02), B. adolescentis ID: YP_910410 (03), B. longum ID: ZP_00121343 (04), B. breve ID: ABF57996 (05), N. 
meningitidis ID: NP_283534 (06), N. meningitidis ID: NP_273598 (07), L. monocytogenes ID: YP_014090 (09), L. 
monocytogenes ID: NP_464998 (10), Bos taurus ID: 1YUW (11), Bos taurus ID: 1DKG (12), Bos taurus ID: 1HPM (13), 
Homo sapiens ID: 2E84 (14), E. coli ID: 1DKZ (15), E. coli ID: 1BPR (16), E. coli ID: 1Q5L (17). The secondary structure 
indication (α-helix, yellow; β-strand, cyan) are derived from JPred prediction for B. animalis subsp. lactis BI07 DnaK 
and from the PDB structure for all the remaining sequences. 
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Fig. 14. Ribbon diagram of the model structure of B. animalis subsp. lactis BI07 DnaK coloured from blue in the 
proximity of the N-terminus to red at the C-terminus. Lysine residues are reported as “sticks and balls” and atoms are 
coloured according to atom type (carbon, grey; nitrogen, blue; oxygen, red; hydrogen, white). 
Fig. 15. Solvent excluded surface of the model structure of B. animalis subsp. lactis BI07 DnaK reported in the same 
orientation as in Fig. 14. Lysine residues are coloured according to the predicted interaction attitude (low, orange; 
medium, yellow; strong, green). 
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This DnaK structural model has been utilized to locate putative protein-protein interaction sites 
using several predictor tools, such as SPPIDER, ProMate, cons-PPISP, PPI-Pred, PINUP. As a result 
of this investigation, the best score lysine residues evidenced are Lys-233 and Lys-366, both 
located in the NBD domain and in regions predicted to be favourable to protein-protein 
interaction (Fig. 16). Additionally, both Lys-233 and Lys-366 are present in protruding edges of the 
protein surface, close to another lysine residue, Lys-231 and Lys-362, respectively, similar to the 
enolase Plg binding site. On the contrary, a low probability of protein-protein interaction is 
associated with the lysine-rich C-terminal region of SBD domain. Lys-618 and Lys-621 where not 
included in the present protein model structure because of the absence of structural data for this 
region in the template structure, and with this model it is not possible to predict the Plg binding 
capability of these two residues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16. Protein-protein interaction attitude prediction calculated normalizing the results from SPPIDER, ProMate, 
cons-PPISP, PPI-Pred, and PINUP servers. 
Chapter I 
63 
35000 50000 65000 80000 95000 110000
Mass (m/z)
0
5
0
10
20
30
40
50
60
70
80
90
100
%
 I
n
te
n
s
it
y
82113.77
41447.74
BI07+Plg+anti-DNAK
BI07+Plg+anti-Enolase
BI07+Plg
BI07
[M+H]+
[M+2H]2+
%
 I
n
te
n
s
it
y
Role of surface enolase and DnaK in B. animalis subsp. lactis BI07 plasminogen binding 
The role of surface DnaK and enolase as Plg receptors on B. animalis subsp. lactis BI07 cells was 
experimentally evaluated by analyzing the impact of anti-DnaK or anti-enolase antibodies 
treatment on the bifidobacterial Plg binding capability. MALDI-TOF-MS analysis was used to 
compare Plg binding activity of bifidobacterial cells untreated or pretreated with anti-DnaK or anti-
pneumococcal enolase antisera (anti-Eno) (Candela et al., 2009). As shown in Fig. 17, the anti-Eno 
treatment decreased the Plg binding activity of B. animalis subsp. lactis BI07 of about 30%, while 
the treatment with anti-DnaK antiserum greatly impaired this interaction, reducing B. animalis 
subsp. lactis BI07 binding activity of about 80%. No reduction in Plg binding was measured when 
using anti-rabbit IgG as a blocking antibody. Data obtained from this assay imply that enolase but 
mainly DnaK are important for the capture of Plg on the surface of B. animalis subsp. lactis BI07. 
 
 
 
 
 
  
Fig. 17. MALDI-TOF analysis of Plg binding to B. animalis subsp. lactis BI07 cells untreated (BI07+Plg), and pre-treated 
with anti-DnaK (BI07+Plg+anti-DnaK) or anti-Eno (BI07+Plg+anti-Enolase). As negative control,  B. animalis subsp. lactis 
BI07 cells not incubated with Plg (BI07) are shown. Plg [M+H]
+
 signal at 81 kDa, [M+2H]
2+
 at 40 kDa. 
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Discussion 
 
This work has demonstrated the importance of surface DnaK in the interaction between B. animalis 
subsp. lactis BI07 and human Plg. A highly conserved 67 kDa cytoplasmic protein, DnaK belongs to 
the heat shock protein 70 family (HSP70), chaperone proteins with important roles in protein 
folding and transport (Bukau and Horwich, 1998). 
B. animalis subsp. lactis BI07 DnaK has been characterized in order to achieve a comprehensive 
view of this protein in the context of the interaction with human Plg. Immunoelectron microscopy 
allowed the visualization of DnaK protein on the cell wall of B. animalis subsp. lactis BI07. Despite 
its surface localization, DnaK lacks any of the predicted protein sorting and bacterial cell wall 
anchoring signals, similarly to the surface located B. animalis subsp. lactis BI07 enolase, as 
reported by Candela and co-workers (Candela et al., 2009). The secretion and surface localization 
of these cytoplasmic proteins, known as moonlighting proteins for their ability to carry out a 
second different function, are still unknown. Some hints come from a recent finding for 
Streptococcus pneumoniae: Claverys and Havarstein (2007) reported bacterial scavenging of 
intracellular proteins released through allolysis as a possible mechanism for surface localization of 
cytoplasmic proteins. DnaK protein has been found in the surface associated proteome of several 
bacteria, the pathogens Neisseria meningitidis, Lysteria monocytogenes and Mycobacterium 
tuberculosis (Schaumburg et al., 2004; Knaust et al., 2007; Xolalpa et al., 2007) and the human gut 
microbiota probiotic member Lactobacillus salivarius (Kelly et al., 2005), but the role of DnaK has 
Plg receptor has been reported only for N. meningitidis, L. monocytogenes and M. tuberculosis. 
The affinity of the interaction between human Plg and B. animalis subsp. lactis BI07 DnaK has been 
investigated through a saturation binding analysis using a purified recombinant His6-tagged DnaK 
protein. It has been found that B. animalis subsp. lactis BI07 DnaK possesses a high affinity for 
human Plg, with a KD of about 11 nM, a value higher respect to that reported for B. animalis subsp. 
lactis BI07 enolase (KD = 42.8 nM), but close to the affinity values for human Plg of enolases from 
Streptococcus pyogenes, S. pneumoniae and S. suis (1-4 nM, 0.55 nM and 14 nM, respectively) 
(Pancholi and Fischetti, 1998; Bergmann et al., 2003; Esgleas et al., 2008). Similarly to other Plg 
receptors, lysine residues were essential for DnaK-Plg interaction, as indicated by the complete 
inhibition of Plg binding in the presence of the lysine analogue EACA. The best fit non linear 
regression analysis of data recovered in the saturation binding assay indicated that B. animalis 
subsp. lactis BI07 DnaK possesses exclusively one binding site for human Plg. Generally, the C-
terminal lysine residue has been pointed out as the major binding site for Plg interaction for 
numerous proteins, but the deletion of this residue (Lys-621) in B. animalis subsp. lactis BI07 DnaK 
only slightly affected the interaction with Plg, with a KD of about 20 nM. In silico analysis were 
performed to construct an homology model of the B. animalis subsp. lactis BI07 DnaK protein in 
order to try to uncover putative internal Plg binding sites or motifs. From the analysis of the DnaK 
homology model, two internal lysine-rich motifs (Lys-321-Lys-233 and Lys-362-Lys-366) have been 
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found that have high probability of interaction with Plg. According to this prediction, these lysine 
residues could represent possible candidates for bifidobacterial DnaK internal Plg binding site(s). 
These data are in agreement with findings described for N. meningitidis DnaK by Knaust et al. 
(2007), that reported the main role of internal Plg binding motifs rather than C-terminal lysine 
residues for DnaK-Plg binding. Internal Plg binding sites have been identified in several bacterial 
Plg receptors: enolases from S. pneumoniae, Aeromonas hydrophila and B. animalis subsp. lactis, 
and PAM, a Plg binding group A streptococcal M-type surface protein (Bergmann et al., 2005; 
Candela et al., 2009; Sha et al., 2009). The homology search within the B. animalis subsp. lactis 
BI07 DnaK aminoacid sequence did not show a significant similarity with internal Plg binding 
sites of enolases from B. animalis subsp. lactis BI07 and S. pneumoniae (Bergmann et al., 2003; 
Candela et al., 2009). 
After the molecular characterization of DnaK, the importance of the specific surface DnaK and α-
enolase proteins on the bacterial Plg binding capability has been investigated. Blocking the surface 
DnaK with cross reactive DnaK-specific antiserum greatly impaired the human Plg binding activity 
of B. animalis subsp. lactis BI07 cells, with a Plg binding reduction of about 80%. The same 
treatment with anti-Eno antiserum to block surface enolase decreased Plg binding to B. animalis 
subsp. lactis BI07 cells only of the 30%. This difference could be partially explained by the higher 
Plg affinity of DnaK compared to enolase, but another important aspect to bear in mind that can 
have an important impact in receptor blocking is the different efficacy of the antisera in blocking 
the respective antigens. It’s worth noting that several other variables may impact the contribution 
of a single receptor to Plg capture on the bacterial cell surface, such as Plg receptor availability on 
the bacterial cell surface and the binding epitope number (Knaust et al., 2007). 
DnaK importance as a Plg receptor for B. animalis subsp. lactis BI07 has been demonstrated 
throughout this chapter. Further studies of this bifidobacterial receptor can be carried out in order 
to better characterize the mechanism of Plg binding, both in B. animalis subsp. lactis BI07 and in 
other bifidobacterial strains. 
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BILE SALTS EFFECTS ON BIFIDOBACTERIUM ANIMALIS SUBSP. 
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Introduction 
 
The gut environment represents a highly challenging place for commensal microorganisms. 
Several biological barriers threaten bacterial survival: pH variations, different oxygen levels, 
nutrient limitations, elevated osmolarity (Chowdhuri et al., 1996). Besides this, bacteria have to 
face numerous toxic compounds of intestinal origin, among which bile components are the most 
important. Major constituents of bile are bile salts, detergent-like compounds synthesized from 
cholesterol by hepatocytes and stored in the gallbladder as amino acid conjugates, usually glycine- 
or taurine-conjugates. Bile is secreted into the intestine during digestion, playing a major role in 
the emulsification, solubilisation and absorption of fats. Besides this physiological role, bile 
possesses strong antimicrobial properties (Begley et al., 2005). The main antibacterial 
characteristic affects bacterial membrane integrity: due to their amphipathic nature, bile salts 
cause membrane damages disrupting the lipid bilayer structure. In addition, they induce protein 
misfolding and oxidative damage to DNA (Bernstein et al., 1999a, 1999b; Leverrier et al., 2003). 
The capability to adapt and tolerate bile salts, present usually at concentrations below 5 mM 
(Hofmann, 1999), is an essential feature of intestinal microorganisms for the colonization of the 
human gastrointestinal tract (Begley et al., 2005; Ridlon et al., 2006). Bile-modifying enzymes and 
bile transporters have been described in intestinal bacteria (Piddock, 2006; Kim and Lee, 2008), 
but the mechanisms used by these bacteria to cope with bile stress are still poorly understood. 
Recent studies have begun to reveal some molecular mechanisms of the adaptation and tolerance 
to bile salts of Bifidobacterium. Changes in the expression profile after bile salts exposure of two 
Bifidobacterium species, B. longum and B. animalis subsp. lactis, have been investigated recently 
(Sánchez et al., 2005, 2007b). It has been reported that bifidobacterial responses to bile stress 
involve the up-regulation of general stress response chaperones and oxidative stress target 
proteins, expression changes of several proteins and enzymes involved in carbohydrate 
metabolism leading to changes in the manner of energy production, up-regulation of proteins 
involved in transcription, translation and metabolism of amino acids and nucleotides. Besides 
these wide-range responses that impact on general metabolic pathways, recent studies have 
elucidated some specific molecular mechanisms directly involved in bile resistance/tolerance. It 
has been shown that B. longum NCC2705 possesses a bile efflux transporter whose expression is 
induced by bile at concentrations similar to those present in the colon (Gueimonde et al., 2009). 
More recently, six bile-induced putative transport systems have been described in another 
bifidobacterial species, B. breve UCC2003 (Ruiz et al., 2012b), each one with different substrate 
specificities and induction profiles leading to a complementary activity among them. 
Counteracting bile toxicity by direct bile transport outside the cell, these systems could play a 
significant role in bifidobacteria resistance and tolerance to bile, underlining the importance of 
these transport systems for bifidobacterial survival in and colonization of the gut environment. 
Most of the bacterial factors involved in the colonization process and interaction with the host are 
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localized on the microorganism cell surface, and global expression profile changes due to 
adaptation responses can affect these extracellular components. Recently, the effect of bile on the 
B. longum cell wall proteome have been investigated with the attempt to evaluate a possible 
impact of bile on the interaction between Bifidobacterium and the host (Ruiz et al., 2009). Ruiz 
and co-workers have reported the up-regulation of several cell-wall proteins in response to bile 
and, among them, they have identified two surface Plg receptors, enolase and glutamine 
synthetase, suggesting that the adaptation of B. longum to bile environment can prompt the 
expression of bacterial factors useful for facilitating the colonization of the human gut. Here the 
effect of the adaptation to a bile environment on the Plg binding capability of B. animalis subsp. 
lactis BI07 has been assessed, with a particular interest on the Plg binding proteins present on the 
bifidobacterial cell surface. 
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Materials and methods 
 
Culturing of Bifidobacterium animalis subsp. lactis BI07 
In this study the strain Bifidobacterium animalis subsp. lactis BI07 was used, originally isolated 
from dairy products. Bacteria were cultured in de Man-Rogosa-Sharpe (MRS) medium (Difco) 
supplemented with 0.05% (wt/vol) L-cysteine at 37°C in an anaerobic atmosphere, obtained in a 
jar by using Anaerocult A (Merck). Bifidobacteria cells were grown for 18 h until they reached the 
stationary phase. When necessary, bile salts (oxgall, Difco) were added to a final concentration of 
1.2 or 3 g/l. Oxgall was used because of the difficulties in recovering human bile salts. Differently 
from human bile, oxgall possesses higher bile salt and phospholipid concentrations and lower 
phospholipid/bile salt molar ratios, while the ratio of glycine- to taurine-conjugated bile acids is 
similar (Hafkenscheid and Hectors, 1975; Coleman et al., 1979). For growth curve study, liquid 
cultures were performed in 100 ml MRS medium supplemented with 0.05% L-cysteine in the 
absence and in the presence of oxgall. The 100 ml liquid cultures were inoculated at 1% (vol/vol) 
with fresh overnight cultures, incubated in anaerobiosis and monitored spectrophotometrically 
at 600 nm. 
Extraction of bifidobacterial cell wall proteins 
Bifidobacterial cell wall protein fraction was extracted as reported by Hardie and Williams (1998). 
Stationary phase cells of B. animalis subsp. lactis BI07 were collected, washed in 50 mM Tris-HCl 
(pH 7.6) and resuspended in 2 ml of protoplast buffer (50 mM Tris-HCl [pH 7.6], 1 M sucrose, 1.4 
mM phenylmethylsulfonyl fluoride, 15 mg/ml lysozyme). The suspension was incubated at 37°C for 
90 min, then centrifuged for 3 min at 4000 rpm at 4°C and the supernatant, containing the cell 
wall proteins, was collected and stored at -20°C. Proteins were subsequently precipitated with 
15% trichloroacetic acid (TCA) and acetone in order to remove sucrose excess. 
Two-dimensional gel electrophoresis and comparative analysis of protein expression 
Proteomic analysis was carried out as reported by Candela et al. (2007). B. animalis subsp. lactis 
BI07 cell wall proteins were solubilised in IEF solution containing 7 M urea, 2 M thiourea, 4% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), and 0.005% (vol/vol) 2-
mercaptoethanol for two-dimensional polyacrylamide gel electrophoresis (2DE) analysis. The 
estimate of total protein concentration was carried out with PlusOne 2D Quant kit (GE 
Healthcare). Isoelectric focusing was performed using Immobiline DryStrips with a linear gradient 
between 4 and 7 (in 7 cm) on an IPGphor system (GE Healthcare). The rehydration of 40 µg of cell 
wall proteins was carried out for 12 h in 125 µl of buffer A (8 M urea, 2% [wt/vol] CHAPS, 2% 
[vol/vol] Ampholine pH 4.0 to 6.5 [GE Healthcare], 10 mM dithiothreitol, 0.8% bromophenol blue). 
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Proteins were focused for a total of 10 kV · h. Reduced and alkylated IPG strips (Görg et al., 1988) 
were loaded onto 12% acrylamide separating gels and proteins were resolved by SDS-PAGE at 160 
V for 2.5 h using a SE 250 mini vertical electrophoresis unit (GE Healthcare). Spots were visualized 
by silver staining. GS-800 imaging densitometer (Bio-Rad) was used for the digital acquisition of 
gels protein patterns. Spot detection, matching and the analysis of differentially expressed 
proteins were performed by PDQuest v. 8.0.1 software (Bio-Rad). For each conditions, two 
biological and three technical replicates were carried out to constitute one replicate group with 
averaged normalized intensities for each spot. 
Comparative analysis was performed between cell wall fractions from stationary-phase bacterial 
cells grown in MRS medium with and without 1.2 g/L oxgall. Differentially expressed proteins were 
considered proteins showing at least two-fold enhanced or decreased expression levels. The 
identification of plasminogen (Plg) binding proteins was carried out comparing the two 
dimensional gels with the reference map shown by Candela et al. (2007). 
MALDI-TOF-MS analysis of plasminogen binding to B. animalis subsp. lactis BI07 
A MALDI-TOF-MS based approach was used to evaluate Plg binding to B. animalis subsp. lactis 
BI07 cells, as reported by Candela and co-workers (Candela et al., 2008a). In brief, 1 × 109 CFU of 
stationary-phase B. animalis subsp. lactis BI07 cells grown in MRS medium in the presence or 
absence of 1.2 g/l bile salts (oxgall, Difco) were incubated with 0, 10, 20, 50, 100 and 200 µg of 
human Plg (Sigma-Aldrich). After three washings in PBS to remove unbound Plg, bifidobacterial 
cells were resuspended in 20 µl NH4Cl 2% for MALDI-TOF analysis in order to detect bacteria 
surface bound Plg. One µl of each bacterial suspension was spotted, airdryed and then overlaid 
with 1.0 µl of matrix solution (12.5 mg/ml ferulic acid in a mixture of formic 
acid/acetonitrile/water 17:33:50). The resulting droplet was left to crystallize by airdrying and 
then analyzed in a Voyager DE Pro MALDI-TOF mass spectrometer (Applied Biosystems) operating 
in linear positive ion mode in the range of 20000-100000 Da and equipped with a pulsed N2 laser 
at 337 nm. Default operating conditions were as follow: accelerating voltage 25000 V, grid voltage 
22500 V, extraction delay time 750 ns. All acquisitions were generated automatically on the 
instrument software (VoyagerTM, Biospectrometry Workstation) using a random search pattern 
mode and based on overaging 1600 shots from 20 non-overlapping positions (80 shots/position). A 
standard bovine serum albumin (BSA) solution (67 kDa) was used for data external calibration. 
Two-hundred ng of human Plg (Sigma-Aldrich) were used as analytical standard. Three biological 
and three technical replicates were performed for each Plg concentration. 
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Plasmin activity assay 
The assay was carried out as previously reported by Candela et al. (2008b), with minor 
modifications. After a washing step in PBS, 1 × 109 CFU/ml of stationary-phase B. animalis subsp. 
lactis BI07 cells grown in MRS with or without 1.2 g/l bile salts (oxgall, Difco) were incubated with 
20 µg/ml human Plg (Sigma-Aldrich) for 30 min at 37°C. Bacteria were washed twice in PBS and 
resuspended in 50 mM Tris-HCl (pH 7.5). One hundred µl of bacterial suspension were added per 
well in a 96-well microtitre plate (Perkin Elmer) and 0.06 KIU of urokinase (uPA, Calbiochem) were 
added to activate Plg. A volume of 30 µl of the plasmin chromogenic substrate D-Val-Leu-Lys 4-
nitroanilide dihydrochloride (0.54 mM; Sigma-Aldrich) was added to each well and absorbance at 
405 nm was measured immediately after the addition of the chromogenic substrate and every 7 
min during 1 h incubation at 37°C by using the Victor3V multilabel plate reader (Perkin Elmer). As 
negative control, B. animalis subsp. lactis BI07 cells not treated with Plg were used. Further 
control for the kinetic experiment were carried out with bifidobacteria incubated with Plg in the 
presence of 0.1 M of the lysine analogue ε-aminocaproic acid (EACA), and in the absence of uPA. 
Spontaneous hydrolysis of D-Val-Leu-Lys 4-nitroanilide dihydrochloride was checked with the 
chromogenic substrate alone and in the presence of uPA. For each condition, two experimental 
replicates and ten technical replicates were performed. 
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Results 
 
B. animalis subsp. lactis BI07 growth in the presence of bile salts 
The ability of B. animalis subsp. lactis BI07 to grow in the presence of bile salts was tested. 
B. animalis subsp. lactis BI07 was grown in batch cultures in the absence and in the presence of 
bile salts at concentrations of 1.2 and 3 g/l. As reported for B. longum NCIMB 8809 (Sánchez et al., 
2005), during the exponential phase bacterial growth rates were very similar for the three 
different conditions (Fig. 18). Differently, the CFU/ml reached at the stationary phase was lower in 
the presence of bile salts, being 1.2 × 109 in the absence of bile salts, 5 × 108 and 1 × 108 in the 
presence of 1.2 and 3 g/l of bile salts, respectively. 
 
 
 
 
 
 
 
 
 
 
Analysis of bifidobacterial cell wall protein expression profile in the presence and in the 
absence of bile salts 
The impact on the cell wall proteome of long-term exposure of B. animalis subsp. lactis BI07 to 
bile salts was investigated, with particular attention on the expression of surface Plg receptors. To 
this aim, a comparative proteomic approach was carried out. Cell wall proteomes of B. animalis 
subsp. lactis BI07 grown in media supplemented or not with 1.2 g/l bile salts were compared by 
using two-dimensional gel electrophoresis, followed by software analysis to evaluate expression 
profile changes (Fig. 19). Bile salts adaptation involved several physiological modifications that 
affect cell wall proteome, as indicated in Fig. 19; Plg binding proteins numbering follows the one 
Fig. 18. Growth curves of B. animalis subsp. lactis 
BI07 in MRS medium with 0 (black), 1.2 (dark 
grey) and 3 g/l bile salts (light grey). For all the 
experimental conditions growth curves were 
performed in three biological replicates and 
values represent the mean ± SD. 
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reported by Candela et al. (2007). Interestingly, after bile salts exposure, three Plg binding proteins 
were up-regulated: DnaK, enolase and phosphoglycerate mutase showed a 2.8-, 2.3- and 10-fold 
up-regulation, respectively. The exposure to bile salts induced a slight down-regulation of the 
putative Plg binding protein bile salt hydrolase (BSH), by about 1.7-fold, as well as for the as yet 
unidentified Plg binding proteins no. 2 and no. 8. 
 
 
 
 
 
 
 
 
 
 
B. animalis subsp. lactis BI07 - human plasminogen binding capability in the presence of 
bile salts 
Physiological changes resulting from the B. animalis subsp. lactis BI07 long-term exposure to bile 
salts can have an important impact on the capability of this microorganism to bind human Plg. In 
order to elucidate if bile salts adaptation affects Bifidobacterium Plg binding activity, stationary-
phase B. animalis subsp. lactis BI07 cells grown with or without 1.2 g/l of bile salts were incubated 
with increasing concentrations of human Plg and the bacterial-bound Plg was measured by MALDI-
TOF-MS analysis (Fig. 20). In both conditions B. animalis subsp. lactis BI07 displayed a dose-
dependent Plg binding activity, but the capability to recruit Plg on the cell surface was 10 times 
more high in bacteria grown in the presence of bile salts. 
Plasmin activity assay was carried out to compare the capacity of B. animalis subsp. lactis BI07 
grown in the absence or presence of 1.2 g/l of bile salts to acquire a surface-associated plasmin 
activity after incubation with human Plg and the addition of host PA. Stationary-phase cells were 
incubated with 20 μg/ml Plg and the cell-bound Plg was activated to plasmin by the addition of 
uPA. The evaluation of acquired bacterial surface-associated plasmin activity was carried out in 
kinetic experiments, measuring the hydrolysis of the plasmin-specific chromogenic substrate 
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Fig. 19. Cell-wall proteome of stationary-phase B. animalis subsp. lactis BI07 cells cultured with (B) and without (A) 
bile salts at 1.2 g/l. Cell-wall proteins up- and downregulated as a consequence of bile salts adaptation are marked 
with circles and squares, respectively. Plg-binding proteins are numbered: DnaK (1), unidentified (2), glutamine 
synthetase (3), enolase (4), BSH (5, 6), phosphoglycerate mutase (7), unidentified (8). 
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D-Val-Leu-Lys 4-nitroanilide dihydrochloride every 7 minutes over a period of 1 h (Fig. 21). The 
plasmin activity associated with microorganisms grown in the presence of bile salts was greater 
compared to bifidobacteria grown in standard conditions, as indicated by the increased rate of 
chromogenic substrate hydrolysis. The inhibition of plasmin formation on the B. animalis subsp. 
lactis BI07 cell surface by treatment with the lysine analogue EACA underlined the crucial role of 
lysine residues in Plg recruitment on bacterial cell surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 20. MALDI-TOF analysis of the 
plasminogen binding activity of stationary-
phase cells of B. animalis subsp. lactis BI07 
grown in the presence (OX) or in the 
absence (MRS) of 1.2 g bile salts/l. The 
bars represent the response, expressed as 
Plg amplitude/reference signal amplitude 
(RS amplitude), with the standard 
deviation, of B. animalis subsp. lactis BI07 
cells incubated with different 
concentrations of Plg (10, 20, 50, 100, 200 
µg/ml). Reference signal: 23 000 Da. 
Fig. 21. Plasmin activity of B. 
animalis subsp. lactis BI07 cells 
grown in the presence (OX) or in 
the absence (MRS) of 1.2 g bile 
salts/l. Plg-pretreated bacterial 
cells were incubated with uPA and 
then with the plasmin-specific 
chromogenic substrate D-Val-Leu-
Lys 4-nitroanilide dihydrochloride. 
The kinetics of plasmin formation 
was evaluated by measuring the 
increase in A405 at intervals of 7 
min during 1 h incubation. 
Bacterial cells untreated with Plg 
were used as negative control. 
Experiments were repeated by 
incubating the bacteria with Plg in 
the presence of 0.1 M EACA. 
Values represent the mean ± SEM 
of 20 measurements. 
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Discussion 
 
B. animalis subsp. lactis BI07 adaptation to bile salts induces a global physiological response 
affecting several cell pathways and compartments. Long term exposure of B. animalis subsp. lactis 
BI07 to bile salts has an important impact on the cells growth: even if the growth rate during the 
exponential phase is similar, the bacterial concentration reached at the stationary phase is less in 
the presence of increasing concentrations of bile salts, probably because bacterial metabolism is 
more focused on the specific responses needed to cope with the stressor present in the 
environment. A similar growth profile has been reported for another bifidobacterial strain, B. 
longum NCIMB 8809 (Sánchez et al., 2005), which has been grown in medium containing similar 
bile salts concentrations, described as “sublethal” because bacteria can still grow even if to a 
lesser amount. 
Physiological adaptation to bile salts leads to several changes in the bifidobacterial cell wall 
proteome, as previously reported for B. longum (Ruiz et al., 2009). Similarly to B. longum, B. animalis 
subsp. lactis BI07 exposure to a bile environment determines an up-regulation of three surface 
Plg binding proteins, DnaK, α-enolase and phosphoglycerate mutase. The up-regulation of DnaK 
has been reported as a common response to bile salts in several bifidobacterial species (Schmidt 
and Zink, 2000; Savijoki et al., 2005; Sánchez et al., 2007b). To investigate if the changes resulting 
from bile salts adaptation could have a role on the interaction between B. animalis subsp. lactis 
BI07 and human Plg, Plg binding activity and Plg-dependent plasmin activity of B. animalis subsp. 
lactis BI07 grown in the presence or absence of 1.2 g/l bile salts were compared. Bifidobacterial 
cells grown with bile salts were about 10 times more efficient in Plg binding respect to cells grown 
in standard medium and the addition of host uPA led to a significant higher rate of surface-
associated plasmin activity. As demonstrated in this work, bile salts enhance B. animalis subsp. 
lactis BI07 capability to interact with the host Plg system, illustrating the potential impact of one 
gut environment variable on the interaction process between Bifidobacterium and the host. The 
increase in Plg surface recruitment can be partially explained by the up-regulation of surface Plg 
receptors, but other mechanisms can contribute, such as different Plg receptor accessibility due to 
changes in the bifidobacterial cell-surface structure in response to bile adaptation (Ruiz et al., 
2007), that can influence bacterial affinity for human Plg (Stie et al., 2009). 
Bifidobacterium capability to interact with host Plg system has been regarded as one of the 
possible mechanisms that facilitate colonization of the human gut ecosystem (Candela et al., 
2008b). The increased ability of Bifidobacterium to interact with this system as a consequence of 
adaptation to a gut environmental factor may favour its colonization capacity in the 
gastrointestinal ecosystem. 
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Introduction 
 
The capacity of bifidobacteria to intervene with the host Plg/plasmin system has been considered 
as an important actor in the interaction between Bifidobacterium and human intestinal epithelial 
cells (Sánchez et al., 2008; Gilad et al., 2011). The modality of interaction with host Plg/plasmin 
system components is similar to the one characteristic of several enteropathogens, such as 
Salmonella enterica, Listeria monocytogenes and Escherichia coli (Parkkinen and Korhonen, 1989; 
Schaumburg et al., 2004; Lähteenmäki et al., 2005; Sijbrandi et al., 2005; Sun, 2005; Sebbane et 
al., 2006). The role of Plg system in bacterial pathogenicity has been widely elucidated and the 
capability of microorganisms to intervene with this host system has been regarded as a paradigm 
of pathogenicity (Parkkinen and Korhonen, 1989; Steinert et al., 2000; Schaumburg et al., 2004; 
Lähteenmäki et al., 2005; Sijbrandi et al., 2005; Sebbane et al., 2006; Bergmann and 
Hammerschmidt, 2007). Indeed, thank to the broad spectrum specificity of the enzymatic activity 
of plasmin, the acquisition of a Plg-dependent surface-bound proteolytic activity facilitates 
bacterial pathogens transmigration through tissue barriers and dissemination in the host tissues, a 
process named “bacterial metastasis” in analogy to the role of Plg in tumour cell invasion 
(Ertongur et al., 2004; Setyono-Han et al., 2005). Since several Bifidobacterium strains, such as the 
common human gut inhabitant B. animalis subsp. lactis (Turroni et al., 2009), possess a probiotic 
and harmless nature, the capacity of these microorganisms to interact with host Plg/plasmin 
system should have a different aim than bacterial invasion, but the significance of this interaction 
for bifidobacterial ecology is still poorly understood. 
The impact of the gut environmental status on the intestinal microbiota composition can be very 
deep. Inflammatory bowel disease (IBD) constitutes a group of disorders characterized by chronic 
and relapsing inflammation in the gastrointestinal tract frequent in Western countries (Loftus, 
2004). Gut microbiota of IBD patients is characterized by a considerable depletion of health-
promoting groups, as members of Clostridium leptum group, Clostridium cluster XIVa, 
Bacteroidetes and Bifidobacterium (Frank et al., 2007; Peterson et al., 2008; Sokol et al., 2008, 
2009). Several studies have demonstrated that intestinal inflammatory processes alter the 
microbial ecology of the human gut, but the molecular mechanisms involved remain almost 
unclear (Lupp et al., 2007; Rawls, 2007; Stecher et al., 2007; Walker et al., 2011). It has been 
reported that gut inflammatory processes affect the host Plg/plasmin system equilibrium; in 
particular, inflammation involves an NF-κB dependent up-regulation of Plg activator uPA, leading 
to a clear increase of active plasmin availability in inflamed tissues (Mondino and Blasi, 2004; 
Okumura et al., 2008; Killeen et al., 2009). If the host Plg/plasmin system may have a role in the 
interplay between Bifidobacterium and the human host, inflammation dependent fluctuations of 
the components of the Plg/plasmin system could modulate the dynamics of interaction with the 
host intestinal epithelium, with consequences on the bifidobacterial ecology in the gut ecosystem. 
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Here the role of human Plg in the early Bifidobacterium-enterocyte interaction process has been 
investigated, evaluating this Plg-mediated interaction in two different environmental conditions, 
in the absence and in the presence of inflammation. As a bifidobacterial model, B. animalis subsp. 
lactis BI07 has been chosen. The HT29 cell line has been selected as human enterocyte model. This 
cell line derives from human colonic adenocarcinoma and, under standard culture conditions, 
shows a polarized organization similar to that found in a normal intestinal epithelial tissue, with 
mucus-secreting cells allowing the formation of a mucus layer on the apical side of the cell 
monolayer (Fogh and Trempe, 1975; Rousset, 1986). To mimic inflammatory conditions, the pro-
inflammatory cytokine TNF-α has been used to stimulate HT29 cell monolayers. TNF-α has been 
selected because of the central role played by this cytokine in intestinal inflammation, as reported 
by several studies (Ma et al., 2004; Yan et al., 2008). 
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Materials and methods 
 
Bacteria, media and growth conditions 
Bifidobacterium animalis subsp. lactis BI07 was grown in de Man-Rogosa-Sharpe (MRS) medium 
(Difco) supplemented with 0.05% (wt/vol) L-cysteine at 37°C in anaerobic conditions, obtained in a 
jar by using Anaerocult A (Merck). Bifidobacterial cells were grown for 18 h until they reached the 
stationary phase. The enteropathogen Salmonella enterica serovar Typhimurium was cultured in 
brain-heart infusion (BHI) broth (Difco) in aerobiosis for 12 h at 30°C with shaking. 
Eukaryotic cell culture 
Human colonic epithelial HT29 cell line (German Collection of Microorganisms and Cell Cultures 
*DSMZ+, Germany) was cultured in Dulbecco’s modified Eagle’s minimal essential medium with 4.5 
g/l glucose (DMEM, PAA Laboratories) supplemented with 10% heat-inactivated foetal calf serum 
(FCS, PAA Laboratories), 1% L-glutamine (PAN Biotech GmbH) and 1% penicillin-streptomycin (100 
U/ml penicillin, 100 µg/ml streptomycin) (PAN Biotech GmbH). Cells were routinely propagated in 
60.1-cm2 petri dishes (TPP) at 37°C in 5% CO2 in a humidified atmosphere until they reached 90% 
confluence. For adhesion and intracellular invasion assays, 2.5 × 105 HT29 cells were seeded per 
well in 24-well tissue culture plates (TPP) and 12 mm-diameter glass coverslips, allowing them to 
grow to confluent monolayers. For transmigration assay, 1 × 105 HT29 cells were layered on 3 µm-
pore size transwell inserts (Falcon - Becton Dickinson) in 24-well tissue culture plates and grown to 
confluent and fully differentiated monolayers. The tightness of the cell layers was verified as 
described by Attali et al. (2008a). Briefly, 200 µl of complete medium were added in the upper 
compartment, followed by incubation at 37°C and 5% CO2 for 16 h. The absence of medium in the 
lower compartment was the proof of complete tightness of the cell layer. Twenty-four h before 
each assay (adhesion, invasion, transmigration), the cell medium was replaced with Interaction 
Medium (IM) (DMEM, 25 mM HEPES, 1 g/l glucose [Gibco], 1% FCS); to induce a pro-inflammatory 
response (O’Hara et al., 2006), 2 ng/ml human recombinant TNF-α (Thermo Scientific) were added 
when necessary. 
Antiserum development against B. animalis subsp. lactis BI07 
Polyclonal antibodies against B. animalis subsp. lactis BI07 were generated in Balb/C mice 
according to standard protocols. In brief, 1 × 108 heat-inactivated B. animalis subsp. lactis BI07 
cells were mixed with Freund’s incomplete adjuvant and the mixture was intraperitoneally 
injected in 12-week-old female Balb/C mice (Jackson Laboratories). After 10 days, the antigen 
injection was repeated and blood was recovered after control of antibody titer after 21 days. Serum 
samples from non-immunized mice were used as control. 
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Bacterial cells incubation with plasminogen, uPA, aprotinin and anti-human 
plasminogen antibodies 
For Plg pre-treatment, stationary phase B. animalis subsp. lactis BI07 cells were collected by 
centrifugation at 6000 rpm for 10 min, washed in IM and resuspended in IM at the concentration 
of 1 × 108 CFU/ml before the incubation with 100 µg/ml human plasminogen (Plg, Sigma-Aldrich) 
for 30 min at 37°C. Bacteria were washed with IM to remove unbound Plg. For uPA pre-incubation, 
Plg pre-treated bacterial cells were incubated with 1 µg/ml human urokinase (uPA, Sigma-Aldrich) 
for 30 min at 37°C, then washed with IM. Whenever required, 8 U/ml aprotinin (Sigma-Aldrich) 
were added to the cell monolayers 10 min before bacterial cell addition in order to inhibit plasmin 
activity (Bergmann et al., 2005; Attali et al., 2008a). To prevent the Plg-mediated adhesion to 
epithelial cells, Plg pre-treated B. animalis subsp. lactis BI07 cells were incubated with 5 µg/ml of 
polyclonal goat anti-human Plg IgG (Kordia) for 1 h at 37°C. As negative control, the incubation of 
Plg-untreated B. animalis subsp. lactis BI07 cells with polyclonal goat anti-human Plg IgG was 
carried out. 
Adhesion and intracellular invasion assays, immunofluorescence microscopy and 
quantitative PCR 
The adherence of B. animalis subsp. lactis BI07 to HT29 cell monolayers was determined by 
quantitative PCR (qPCR), as reported by Candela et al. (2005). In brief, confluent HT29 cell 
monolayers grown in 24-well tissue culture plates were incubated with 5 × 107 bifidobacterial CFU 
in IM for 1 h at 37°C and 5% CO2. Bacterial cells in the supernatants were collected by 
centrifugation at 6000 rpm for 10 min and resuspended in 400 µl of PBS for subsequent qPCR 
quantification. After three washings with PBS, 200 µl of trypsin 0.05%/EDTA 0.02% solution (PAN 
Biotech GmbH) were added to each well and incubated for 10 min at 37°C. Wells were rinsed with 
200 µl of PBS and bacteria adherent to HT29 cells were quantify by qPCR. Before quantification, 
aliquots of cell suspension were treated with 1 mg/ml trypsin inhibitor (Type I-S: from soybean, 
Sigma-Aldrich) in H2O for 10 min at 25°C. Quantitative PCR reactions were performed in a 
LightCycler instrument (Roche), with SYBR Green I as fluorophore and the Bifidobacterium genus-
specific primer set Bif164 (5’-CATCCGGCATTACCACCC-3’) and Bif662 (5’-CCACCGTTACACCGGGAA-3’) 
(Kok et al., 1996; Vitali et al., 2003). Amplification was carried out in a final volume of 20 µl 
containing 2 µl of cell suspension, following the instruction of the LightCycler FastStart DNA 
MasterPLUS SYBR Green I (Roche) kit manual. The experimental protocol consisted of a starting 
denaturation step at 95°C for 10 min, followed by amplification consisting of 40 cycles of 4 steps 
each at the temperature transition time of 20°C/s: denaturation at 95°C for 15 s, annealing at 60°C 
for 25 s, extension at 72°C for 30 s, and fluorescence acquisition at 90°C for 5 s, then by melting 
curve analysis: heating at 20°C/s to 95°C, cooling at 20°C/s to 60°C with 15 s hold and then heating 
0.2°C/s until 99°C. Serial dilutions of B. animalis subsp. lactis BI07 suspension in PBS, ranging from 
1 × 106 to 1 × 103 CFU/ml, were amplified and used as internal standards for quantification. To 
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assess whether Plg secreted by HT29 cells contributes to the B. animalis subsp. lactis BI07 
adhesion to enterocytes, the same adhesion assay was performed with HT29 cell monolayers pre-
incubated with 5 µg/ml of polyclonal goat anti-human Plg IgG for 1 h at 37°C in 5% CO2. For each 
experimental condition, six independent replica experiments were carried out. 
Immunofluorescent studies of bifidobacterial adherence and internalization were carried out as 
recently described (Bergmann et al., 2009), with some modifications. Confluent HT29 cell 
monolayers grown on 12 mm-diameter glass coverslips in 24-well tissue culture plates were 
incubated with 5 × 107 bifidobacterial CFU in IM per well for 1 h at 37°C and 5% CO2. Non-adherent 
bacteria were removed by rinsing the HT29 cell layers three times with PBS. After washings, cells 
were fixed on glass coverslips with 1% paraformaldehyde at 4°C overnight. The fixed samples were 
blocked with PBS-10% FCS and then incubated for 1 h with mouse anti-bifidobacterial antiserum 
diluted 1/100 in PBS-10% FCS, followed by 30 min of incubation with Alexa-Fluor 488-labelled goat 
anti-mouse IgG (green, dilution 1/200; MoBiTec) at 25°C at dark. After permeabilization of the cells 
with 0.1% Triton X-100 for 5 min, HT29 cells were stained with Alexa-Fluor 568-labelled phalloidin 
(red; Molecular Probes) diluted 1/200 in PBS-10% FCS and incubated for 45 min at 25°C at dark. To 
differentiate extracellular from intracellular bacteria, fixed samples were stained with mouse anti-
bifidobacterial antiserum in combination with a secondary Alexa-Fluor 488-labelled goat anti-
mouse IgG (green, dilution 1/200) at 25°C at dark. After several washings with PBS, samples were 
permeabilized with 0.1% Triton X-100 for 5 min and then incubated with mouse anti-
bifidobacterial antiserum, followed by 30 min of incubation at 25°C at dark with Alexa-Fluor 568-
labelled goat anti-mouse IgG (red, MoBiTec), diluted 1/300 in PBS-10% FCS. This procedure results 
in Alexa-Fluor 568-labelled intracellular bacteria (red) and Alexa-Fluor 488/568-labelled 
extracellular bacteria (green/yellow). Glass coverslips were mounted in ProLongGold (Invitrogen) 
and incubated overnight before observation (fluorescence microscope Axiophot, Zeiss). The Axio 
Vision Rel 4.7.2 software was used for image acquisition and ImageJ software to process images 
for contrast and brightness. Pictures of the same area were taken for each sample under both 
fluorescent light and phase contrast. HT29 cells and bacteria were counted in at least 8 
different microscopic views for each coverslip. For each experimental condition, three 
independent adhesion experiments were performed. After 1 h incubation in IM in 5% CO2 
atmosphere, B. animalis subsp. lactis BI07 survival was checked by plating bacterial suspension 
on MRS agar plates. 
Intracellular invasion assays of Salmonella enterica serovar Typhimurium were performed as 
described by Hess et al. (2002). Briefly, 1 × 108 CFU/ml S. Typhimurium suspension in IM were 
added to confluent HT29 cell monolayers grown in 24-well tissue culture plates and incubated for 
1 h at 37°C in 5% CO2. After five washing steps in PBS, 1 ml of IM containing 50 µg/ml gentamicin 
sulphate (Cambrex/BioWhittaker) was added each well and plates were incubated for 2.5 h at 
37°C in 5% CO2. HT29 cell monolayers were washed five times with PBS and lysed with 1% Triton 
X-100 for 5 min at 37°C. Intracellular bacteria were quantified by counting after culture on BHI 
agar plates. Invasion experiments were repeated six times. 
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Transmigration assay 
The assay was carried out following the protocols described in Hess et al. (2002) and Attali et al. 
(2008a). A volume of 200 µl of a bacterial suspension containing 1 × 108 CFU/ml B. animalis subsp. 
lactis BI07 or S. Typhimurium in IM was added to the upper compartment of a transwell insert 
with membrane pore size of 3 µm (Falcon - Becton Dickinson) and incubated for 1 h at 37°C in 5% 
CO2. The lower compartment contained 600 µl of IM. To quantify bacterial transmigration by 
colony counting, the basal chamber was sampled, serially diluted and plated on the appropriate 
agar medium. The assay was done twice for each experimental condition. 
Evaluation of plasminogen activation by HT29 cells 
This assay was carried out as described by Attali et al. (2008a) with slight modifications. In brief, 
HT29 cells were grown to confluent monolayers on 24-well tissue culture plates. Twenty-four h 
before the assay, the medium was replaced with DMEM 1 g/l glucose without phenol red 
(Sigma-Aldrich) supplemented with 1% FCS in the presence or absence of 2 ng/ml TNF-α. After 
medium removal, 200 µl of 100 µg/ml human Plg in PBS were added to each well and incubated 
for 1 h at 37°C. Positive and negative controls were carried out without cells using 200 µl of 100 
µg/ml human Plg in PBS in the presence or absence of 0.5 µg uPA, respectively. After Plg 
incubation, 100 µl of the plasmin chromogenic substrate D-Val-Leu-Lys 4-nitroanilide 
dihydrochloride (0.54 mM; Sigma-Aldrich) were added to each well and incubated for 30 min at 
37°C. Subsequently, 150 µl of the supernatant were transferred to transparent 96-well microtiter 
plates (Nunc) and absorbance at 405 nm was measured using the Victor3V multilabel plate reader 
(Perkin Elmer). The assays were performed two times independently, repeating each experimental 
condition four times. 
Statistical analysis 
Data were expressed as the mean ± s.e.m. . The statistical significance of between-group 
comparisons was determined with Mann-Whitney U test, and the probability value P < 0.001 was 
considered statistically significant. 
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Results 
 
Plasminogen role in the interaction between B. animalis subsp. lactis BI07 and HT29 cells 
At first, the contribution of endogenous Plg secreted by HT29 cells on the adhesion of B. animalis 
subsp. lactis BI07 to the enterocyte surface was evaluated. To this aim, the adhesion of B. animalis 
subsp. lactis BI07 cells to HT29 cell monolayers untreated or pre-treated with polyclonal anti-
human Plg IgG was compared by qPCR. In accordance to our data, the anti-human Plg antiserum 
pre-treatment resulted in a slight decrease of bifidobacterial adhesion to the enterocyte surface 
(-16%), although this decrease was not significant (P > 0.05). These data pointed out that the 
endogenously produced Plg of HT29 cells exerted only a marginal contribution to the B. animalis 
subsp. lactis BI07 adhesion to HT29 cells. The role of Plg in the B. animalis subsp. lactis BI07-
enterocyte interaction process was therefore evaluated by pre-incubating bifidobacterial cells with 
100 µg/ml human Plg, as reported by Attali et al. (2008a), and then bacterial adhesion to HT29 
cells was assessed with a conventional adhesion assay. In particular, B. animalis subsp. lactis BI07 
cells were pre-incubated with human Plg alone or Plg + uPA, and the interaction with the 
enterocyte cell line HT29 was compared with the one shown by untreated bifidobacterial cells. 
Adherence of bifidobacteria was quantify by qPCR (Table 5). B. animalis subsp. lactis BI07 
adhesion to HT29 cell monolayers was significantly enhanced by human Plg pre-incubation 
(+225%, P < 0.001); specifically, Plg pre-treatment increased bifidobacterial adhesion from 18.87 ± 
1.20 to 61.08 ± 2.85 bacteria/HT29 cell. Plg contribution to the bifidobacterial adhesion to HT29 
enterocyte cell surface was completely abolished when Plg pre-treated B. animalis subsp. lactis 
BI07 cells were incubated with polyclonal anti-human Plg IgG (Table 5). Interestingly, the addition 
of the Plg activator uPA lowered the adhesion of B. animalis subsp. lactis BI07 pre-treated with Plg 
to 28.87 ± 1.93 bacteria/HT29, a drop of 50% with respect to the value obtained without uPA 
(P < 0.001). In order to determine whether the acquisition of a cell surface plasmin activity was 
involved in the reduction of B. animalis subsp. lactis BI07 adhesion to HT29 cells, the assay was 
repeated in the presence of the plasmin inhibitor aprotinin (Table 5). Aprotinin addition 
determined the complete recovery of the Plg-dependent HT29 cell adhesion of B. animalis subsp. 
lactis BI07 cells pre-incubated with Plg + uPA. Aprotinin did not exert any impact on the B. animalis 
subsp. lactis BI07 adhesion to HT29 cell monolayers in the absence of Plg pre-treatment (Table 5). 
These data demonstrated that the uPA-dependent acquisition of bacterial cell surface plasmin 
activity was enough to reduce the contribution of human Plg to B. animalis subsp. lactis BI07 
adhesion to the HT29 cell surface. The visualization of bifidobacterial adherence to HT29 cell 
monolayers by immunofluorescence microscopy confirmed the increase in amount of attached 
bacteria after Plg pre-incubation and the impact of uPA and aprotinin on bifidobacterial 
adhesion (Fig. 22). 
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Table 5 - qPCR quantification of the plasminogen-mediated adhesion of B. animalis subsp. lactis 
BI07 to untreated and TNF-α pre-treated HT29 cells. 
 No. of bacteria / HT29 cell (mean ± SD) 
Experimental condition(s)
a
 No treatment + TNF-α 
BI07 18.87 ± 1.20 26.65 ± 2.02 
BI07 + Plg 61.08 ± 2.85 41.09 ± 2.74 
BI07 + Plg + anti-Plg 19.40 ± 1.24 - 
BI07 + Plg + uPA 28.87 ± 1.93 36.57 ± 2.27 
BI07 + Plg + uPA + Aprotinin 81.15 ± 3.58 79.81 ± 3.52 
BI07 + Plg + Aprotinin - 75.96 ± 5.67 
BI07 + Aprotinin 20.23 ± 2.21 23.55 ± 1.55 
a
: Untreated and TNF-α pre-treated (+ TNF-α) confluent HT29 cell monolayers were incubated with 5 x 10
7
 CFU of: 
untreated B. lactis BI07 cells (BI07); Plg pre-treated B. lactis BI07 cells (BI07 + Plg); Plg pre-treated B. lactis BI07 cells 
incubated with anti-Plg IgG (BI07 + Plg + anti-Plg); Plg and uPA pre-treated B. lactis BI07 cells (BI07 + Plg + uPA); Plg 
and uPA pre-treated B. lactis BI07 cells in the presence of aprotinin (BI07 + Plg + uPA + Aprotinin); Plg pre-treated B. 
lactis BI07 cells in the presence of aprotinin (BI07 + Plg + Aprotinin); B. lactis BI07 cells in the presence of aprotinin 
(BI07 + Aprotinin). 
 
 
Enterocyte internalization and transmigration of B. animalis subsp. lactis BI07 untreated, pre-
treated with Plg or with Plg and uPA was studied. HT29 cells internalization was evaluated by 
double immunofluorescence microscopy, enabling a differential staining of intracellular (red) and 
adherent (green/yellow) bacteria. Six independent interaction experiments were performed for 
each experimental condition. As shown in Fig. 23, microscopic analysis of the whole HT29 cell 
monolayer did not reveal any bifidobacterial internalization by the HT29 cell line in any of the 
tested conditions. As a control, the enterocyte internalization of the pathogen S. enterica serovar 
Typhimurium was investigated using a gentamicin protection assay (Hess et al., 2002). Accordingly 
to data reported by Hess and co-workers (Hess et al., 2002), after 1 h of incubation with 1 × 108 
CFU of S. enterica, a HT29 cell internalization value of 9.32 ± 1.58 × 104 CFU of this microorganism 
was determined. In accordance to the results obtained by qPCR, in double immunofluorescence 
microscopy experiments Plg pre-treatment increased the adhesion of B. animalis subsp. lactis BI07 
to HT29 cell monolayers (Fig. 23, +Plg). With the purpose of analyzing the transmigration of 
B. animalis subsp. lactis BI07 through HT29 cell monolayers, a transwell system-based 
transmigration assay was carried out. Bacterial cells were added to the upper compartment of the 
transwell inserts containing the HT29 cell monolayers and, after 1 h of co-incubation, bacterial 
transmigration was quantified by plating the medium from the lower compartment. Interestingly, 
neither untreated nor Plg pre-treated nor Plg and uPA pre-treated B. animalis subsp. lactis BI07 
cells displayed transmigration through HT29 cell monolayers (data not shown). As a control, the 
transmigration of 2 × 107 CFU of S. enterica serovar Typhimurium bacteria through HT29 cell 
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monolayers was evaluated. Accordingly to data reported by Hess et al. (2002), 7.84 ± 1.03 × 105 
bacteria penetrated from the apical to the basal compartment of HT29 cell monolayers. Taken 
together these data demonstrated that Plg recruited on the B. animalis subsp. lactis BI07 cell 
surface enhances bacterial adhesion to the enterocytes, whereas the activation of bacterial bound 
Plg to plasmin by host uPA results in a significant decrease of the Plg-mediated adhesion process. 
The acquisition of a cell surface plasmin activity does not result in B. animalis subsp. lactis BI07 
invasion of host intestinal epithelial cells or transmigration through enterocyte monolayers. 
TNF-α impact on the plasminogen-mediated interaction between B. animalis subsp. 
lactis BI07 and HT29 cells 
HT29 cell monolayers were stimulated with the pro-inflammatory cytokine TNF-α to mimic an 
inflammatory condition and the interaction between these layers and untreated, Plg or Plg + uPA 
pre-treated B. animalis subsp. lactis BI07 cells was studied by qPCR and immunofluorescence 
microscopy analysis, as previously described. In TNF-α incubated HT29 cell monolayers, only a 
minor increase of Plg pre-treated B. animalis subsp. lactis BI07 adhesion to enterocytes was 
detected. While untreated bifidobacterial cells showed an adhesion value of 26.65 ± 2.02 
bacteria/HT29 cell, Plg pre-treatment resulted in a bacterial adhesion value of 41.09 ± 2.74 
bacteria/HT29 cell (Table 5). Furthermore, after HT29 monolayers pre-incubation with TNF-α, 
comparable adhesion values were shown by Plg pre-treated and Plg + uPA pre-treated B. animalis 
subsp. lactis BI07 cells (Table 5). These data suggested that HT29 cell response to TNF-α 
stimulation significantly affects Plg-mediated contribution to B. animalis subsp. lactis BI07 
adhesion to enterocyte surface. Plg-dependent B. animalis subsp. lactis BI07 adherence to TNF-α 
incubated HT29 cell monolayers was efficiently recovered with the addition of aprotinin, both for 
Plg and Plg + uPA pre-treated bifidobacterial cells (Table 5). Similarly to data obtained in non-
inflamed conditions, aprotinin did not exert any effect on the B. animalis subsp. lactis BI07 
adhesion to TNF-α stimulated HT29 cells in the absence of pre-treatment with Plg. Quantitative 
PCR data of bifidobacterial adherence were confirmed by the immunofluorescence microscopy 
visualization of B. animalis subsp. lactis BI07 adhesion to HT29 cell monolayers (Fig. 24). After 
bifidobacterial adhesion in inflamed conditions, the analysis of bacterial internalization and 
transmigration was carried out. Similarly to the non inflamed status, bacterial internalization 
(Fig. 25) and transmigration (data not shown) were not found after the co-incubation of 
untreated, Plg or Plg + uPA pre-treated B. animalis subsp. lactis BI07 cells with TNF-α stimulated 
HT29 cell monolayers. 
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Fig. 22. Immunofluorescence microscopy visualization of B. animalis subsp. lactis BI07 adhesion to HT29 cells. 
Confluent HT29 cell monolayers were incubated with 5 x 10
7
 CFU of B. animalis subsp. lactis BI07 untreated (BI07), 
pre-treated with Plg (+Plg), pre-treated with Plg and uPA (+Plg+uPA) and with Plg and uPA in the presence of aprotinin 
(+Plg+uPA+aprotinin). Adherent bacterial cells were visualized (magnification: X 100) by staining with mouse anti-
bifidobacterial antiserum and Alexa-Fluor 488-conjugated anti-mouse antibody (green). HT29 cells were labelled with 
Alexa-Fluor 568-conjugated phalloidin (red). Assays were repeated three times, and a representative experiment is 
shown for each experimental condition. 
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Fig. 23. Intracellular invasion assay of B. animalis subsp. lactis BI07 into HT29 cells. HT29 cell monolayers grown to 
confluence were incubated with 5 x 10
7
 CFU of B. animalis subsp. lactis BI07 untreated (BI07), pre-treated with Plg 
(+Plg) and pre-treated with Plg and uPA (+Plg+uPA). Intracellular and adherent bacteria were differentiated by double 
immunofluorescence microscopy. Adherent B. animalis subsp. lactis BI07 bacteria were stained with mouse anti-
bifidobacterial antiserum followed by a secondary Alexa-Fluor 488-conjugated anti-mouse antibody (green). After 
HT29 cell permeabilization, internalized bacteria were stained with mouse anti-bifidobacterial antiserum and a 
secondary Alexa-Fluor 568-conjugated anti-mouse antibody (red). The corresponding phase contrast images are 
shown in the right panel (magnification: X 100). For each experimental condition, the assay was repeated three times. 
A representative experiment is shown. 
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In order to investigate whether stimulation with TNF-α cytokine favoured migration of Plg pre-
treated B. animalis subsp. lactis BI07 to the lumen compartment, quantification of bifidobacterial 
cells present in the supernatant of TNF-α incubated and non-incubated HT29 cell monolayers was 
performed. qPCR analysis allowed the detection of 1.91 ± 0.55 × 107 bifidobacterial cells in the 
supernatant of TNF-α stimulated HT29 cells, a value two times higher than the amount of 
bifidobacteria detected in the supernatant from untreated HT29 cell monolayers (9.22 ± 1.78 × 106 
bifidobacterial cells). Together, these data suggest that enterocyte inflammatory response triggers 
the activation of the B. animalis subsp. lactis BI07 cell surface bound Plg to plasmin, lowering its 
adhesion to HT29 cell surface and shifting bacterial migration to the enterocyte supernatant. 
Evaluation of plasminogen activation by HT29 cells pre-incubated or not with TNF-α 
To determine if a TNF-α mediated pro-inflammatory response enhanced Plg activation by HT29 
cells, a plasmin activity assay was carried out. Untreated and TNF-α pre-treated HT29 cell 
monolayers were incubated with human Plg and activation to the proteolytic form plasmin was 
assessed by measuring the hydrolysis of the plasmin-specific chromogenic substrate D-Val-Leu-Lys 
4-nitroanilide dihydrochloride. TNF-α stimulated HT29 cells displayed a two-fold increase of Plg 
activation compared to untreated enterocytes (P < 0.001), proving the impact of a TNF-α pro-
inflammatory response on the HT29 cell Plg activators system. 
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Fig. 24. Immunofluorescence microscopy visualization of B. animalis subsp. lactis BI07 adhesion to TNF-α stimulated 
HT29 cells. Confluent HT29 cell monolayers were pre-treated with TNF-α and incubated with 5 x 10
7
 CFU of B. animalis 
subsp. lactis BI07 untreated (BI07), pre-treated with Plg (+Plg), pre-treated with Plg and uPA (+Plg+uPA), and with Plg 
or Plg and uPA in the presence of aprotinin (+Plg+aprotinin; +Plg+uPA+aprotinin). Adherent bacterial cells were 
visualized (magnification: X 100) by staining with mouse anti-bifidobacterial antiserum and Alexa-Fluor 488-
conjugated anti-mouse antibody (green). HT29 cells were labelled with Alexa-Fluor 568-conjugated phalloidin (red). 
Assays were repeated three times, and a representative experiment is shown for each experimental condition. 
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Fig. 25. Intracellular invasion assay of B. animalis subsp. lactis BI07 into TNF-α pre-treated HT29 cells. TNF-α pre-
treated confluent HT29 cell monolayers were incubated with 5 x 10
7
 CFU of B. animalis subsp. lactis BI07 untreated 
(BI07), pre-treated with Plg (+Plg) and pre-treated with Plg and uPA (+Plg+uPA). Intracellular and adherent bacteria 
were differentiated by double immunofluorescence microscopy. Adherent B. animalis subsp. lactis BI07 bacteria were 
stained with mouse anti-bifidobacterial antiserum followed by a secondary Alexa-Fluor 488-conjugated anti-mouse 
antibody (green). After a permeabilization step, invading bacteria were stained with mouse anti-bifidobacterial 
antiserum and a secondary Alexa-Fluor 568-conjugated anti-mouse antibody (red). The corresponding phase contrast 
images are shown in the right panel (magnification: X 100). For each experimental condition, the assay was repeated 
three times and a representative experiment is shown. 
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Discussion 
 
The host Plg system can represent an important tool used by Bifidobacterium in the dynamics of 
cross-talk with the human host. To elucidate the significance of this host system in the starting 
events of the interaction process between bifidobacteria and human intestinal epithelial cells, the 
role of human Plg in the Bifidobacterium animalis subsp. lactis BI07-HT29 cells early interaction 
has been studied. As reported in this chapter, human Plg recruited on B. animalis subsp. lactis BI07 
cell surface significantly enhanced the adherence of this microorganism to the host enterocytes. 
Bacterial bound Plg can thus act as a “molecular bridge” between bifidobacterial and human 
enterocytes receptors, increasing bacterial adhesion to the host intestinal epithelium, as 
suggested by Pancholi and co-workers for streptococcal adhesion to pharingeal cells (Pancholi et 
al., 2003). In the presence of host uPA, B. animalis subsp. lactis BI07 acquired a surface-associated 
proteolytic activity that caused a reduction in bacterial adherence to enterocytes surface and 
supported the migration of bacterial cells to the enterocyte supernatant compartment. B. 
animalis subsp. lactis BI07 acquisition of surface-associated proteolytic activity did not result in 
enterocyte internalization or bacterial transmigration through enterocyte monolayers, 
demonstrating the strict commensal nature of this health-promoting species. Thus, even if the 
modality of interaction with host Plg system components is similar both for the probiotic 
microorganism B. animalis subsp. lactis BI07 and pathogenic bacteria (Parkkinen and Korhonen, 
1989; Schaumburg et al., 2004; Lähteenmäki et al., 2005; Sijbrandi et al., 2005; Sun, 2005; 
Sebbane et al., 2006), these findings demonstrate that the outcomes of this interaction with 
regard to host colonization are different. Cell surface bound Plg increases bacterial adhesion to 
host epithelium both for pathogens and B. animalis subsp. lactis BI07 (Pancholi et al., 2003; Attali 
et al., 2008a), but activation of this surface associated Plg to the active form plasmin by host PAs 
determines a different phenotype of interaction with the host. Indeed, B. animalis subsp. lactis 
BI07 acquisition of cell surface-bound plasmin activity does not determine pericellular invasion, a 
common behaviour for pathogenic bacteria, but favours bifidobacterial migration to the luminal 
compartment. The capability to interact with host Plg system cannot be considered a virulence 
factor by itself, as this characteristics is shared among symbionts and pathogens (Antikainen et al., 
2007b; Kinnby et al., 2008). This property could instead be viewed as an ancestral mechanism of 
interaction between bacteria and the host, evolved before the radiation of pathogens from 
commensal microorganisms (Ochman et al., 2000; Blaser and Kirschner, 2007). The ability to 
intervene with this host system becomes a fundamental tool for host invasion only in association 
with other pathogenicity attributes, as it happens for pathogens (Sun et al., 2004). 
The outcome of the interaction Bifidobacterium - host Plg system - intestinal epithelium can be 
modulated by variables present in the intestinal environment, such as the occurrence of intestinal 
mucosa inflammation. To this aim, this interaction has been studied in a simplified model of 
inflamed intestinal epithelium, HT29 cells stimulated with the pro-inflammatory cytokine TNF-α 
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(Ma et al., 2004; Yan et al., 2008). Mimicking the situation in an inflamed human intestinal tract 
(Mondino and Blasi, 2004; Okumura et al., 2008), accordingly to our data TNF-α mediated 
inflammation of HT29 cells enhanced the ability of these cells to activate human Plg, most likely by 
up-regulation of uPA activity. In a recent study, NF-κB activation mediates up-regulation of uPA 
activity in response to pro-inflammatory stimuli in human colorectal cell lines (Killeen et al., 2009); 
thus, in HT29 cell line model, the observed TNF-α-dependent increase of Plg activation capacity 
might be dependent on the activation of NF-κB pathway via TNF-α (Vallee et al., 2004). Our data 
showed that TNF-α modulates the dynamics of the Plg-mediated interaction between B. animalis 
subsp. lactis BI07 and HT29 enterocytes: the TNF-α mediated inflammatory response enhances 
HT29 cell capacity to activate human Plg, promoting the activation of the B. animalis subsp. lactis 
BI07 cell surface associated Plg to plasmin. This reduces Plg-dependent contribution to the 
bacterial adhesion and favours bacterial migration to the lumen compartment. Confirming these 
findings, the presence of the plasmin inhibitor aprotinin was sufficient to restore the Plg-mediated 
adhesion of B. animalis subsp. lactis BI07 to inflamed HT29 cells. Similarly to the results described 
for non-inflamed HT29 cells, no evidence of intracellular invasion or transmigration were observed 
even in TNF-α stimulated enterocytes, further confirming the commensal nature of B. animalis 
subsp. lactis BI07. 
These data suggest that the phenotype of interaction of B. animalis subsp. lactis BI07 with the 
host Plg/plasmin system depends on the physiological status of the intestinal epithelium: in non-
inflamed regions of the gut epithelium, Plg increases B. animalis subsp. lactis BI07 adherence, 
while the presence of an inflammation-dependent epithelial response would activate bacterial 
surface associated Plg to plasmin, favouring bifidobacteria shifting to the luminal compartment. It 
can be hypothesized that this peculiar dynamics of interaction between B. animalis subsp. lactis 
BI07 and the host Plg system could be relevant in the microecology of Bifidobacterium in the 
human gut. In non-inflamed intestinal tissue sites, the suitable ecological niches for B. animalis 
subsp. lactis BI07, this microorganism can make use of the available Plg to enhance adhesion to 
the gut mucosa. In case of inflamed gut regions, the acquisition of surface-bound plasmin activity 
allows the microorganism to shift to the luminal compartment, going away from the inflamed 
sites. Since the host Plg/plasmin system components fluctuate in response to the inflammatory 
conditions of the gut environment, this system can be used by bifidobacteria as a “sensor system” 
to detect the inflammatory status of the surrounding gut microenvironment. As bifidobacteria are 
unable to face an inflamed environment (Stecher and Hardt, 2008), the host Plg system may be 
used to sense and escape gut inflammation, allowing B. animalis subsp. lactis BI07 to get away 
from inflamed regions. The model of interaction described here might be one of the mechanisms 
involved in the reduction of the relative abundance of Bifidobacterium observed in IBD patients 
(Sokol et al., 2009; Veiga et al., 2010). The differences in the phenotype of interaction with the 
host Plg system between B. animalis subsp. lactis BI07 and enteropathogens could become 
relevant in the context of inflammation-dependent dysbiosis in the human gut. It is broadly known 
that enteropathogens, such as S. enterica or Campylobacter jejuni, take advantage of host 
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inflammatory response to overcome symbiont microbiota members, as bifidobacteria (Lupp et al., 
2007; Rawls, 2007; Stecher et al., 2007; Stecher and Hardt, 2008). Enteropathogens utilize the 
inflammation-dependent increase in plasmin availability to invade host tissue (Parkkinen and 
Korhonen, 1989; Schaumburg et al., 2004; Lähteenmäki et al., 2005; Sijbrandi et al., 2005; Sun, 
2005; Sebbane et al., 2006), a behaviour completely different from bifidobacteria, that use 
surface-bound plasmin to escape from inflamed sites. The opposite behaviour of symbionts and 
pathogens with respect to plasmin role in the interaction process with the host may support the 
shift of balance from protective microbiota to pathogens reported in inflamed gastrointestinal 
sites. Nevertheless, this hypothesis needs to be demonstrated by in vivo studies designed to verify 
host Plg system role in the inflammation-dependent dysbiosis in the human gut. 
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Introduction 
 
The capability to interact with the host Plg/plasmin system has been considered as a possible 
novel component in the molecular cross-talk between bifidobacteria and the host (Sánchez et al., 
2008; Gilad et al., 2011), but until now plasmin(ogen) binding to Bifidobacterium has been studied 
only in phosphate-buffered saline (PBS) suspensions, an in vitro and simplified environment. In 
order to determine whether this interaction has some significant relevance in the complex human 
gastrointestinal environmental niche, the capability of the probiotic strain Bifidobacterium 
animalis subsp. lactis BI07 (Turroni et al., 2010c) to recruit Plg from crude protein extracts from 
human faeces has been investigated. Faecal samples have been chosen as an ex vivo model of the 
human gastrointestinal ecosystem for several reasons: they represent a non-invasive sampling of 
the gastrointestinal tract environment, and crude faecal protein extracts reflects the entire 
content of the full length of the colon-rectum, containing proteins and peptides present due to 
leakage, secretion or esfoliation (Ang et al., 2010). 
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Materials and methods 
 
Samples collection and crude faecal extracts preparation 
Faecal samples were collected from 10 healthy Italian subjects aged ≥ 30 years. None of the 
individuals had a history of gastrointestinal disorders at the time of sampling. No dietary 
restrictions was prescribed for at least 4 weeks before sampling, with the exception of functional 
foods, probiotics and antibiotics. From each enrolled subject an informed consent was obtained. 
Crude faecal protein extracts were obtained following the procedure described by Ivanov et al. 
(2006), with minor modifications. In brief, faecal samples were diluted 1:1 (wt/vol) in ice-cold PBS 
(Phosphate-Buffered Saline) in a stomacher bag and homogenized for 2 min at high speed in a 
stomacher (Seward), until a uniform consistency was achieved. Aliquots (10 ml) of each 
homogenized sample were collected in tubes and Complete Protease Inhibitors Solution (Roche) 
was added. 3-mm glass beads (BioSpec Products) were added before treating the samples with 
FastPrep (MP Biomedicals) at 5.5 ms for 1 min 3 times. Glass beads and debris were removed by 
centrifugation at 12000 rpm for 10 min. Protein concentration in supernatants was measured by 
NanoDrop (NanoDrop Technologies). 
Bifidobacterium strains and growth conditions 
For this study, five bifidobacterial strains were selected. Bifidobacterium animalis subsp. lactis 
BI07 was originally isolated from fermented milk, whereas B. longum ATCC 15707, B. breve ATCC 
15700, B. bifidum DSM20456 and B. adolescentis ATCC 15703 were isolated from human intestine 
(Meile et al., 1997; Ventura et al., 2007d; Lee and O’Sullivan, 2010). Bacteria were cultured in de 
Man-Rogosa-Sharpe (MRS) medium (Difco) supplemented with 0.05% (wt/vol) L-cysteine at 37°C 
in anaerobic conditions, obtained in a jar by using Anaerocult A (Merck). Bifidobacteria cells were 
grown for 18 h until they reached the stationary phase. 
Bifidobacterium interaction with human faecal extracts 
Stationary-phase bifidobacterial cells were resuspended at a concentration of 1 × 109 CFU/ml in 10 
ml of crude faecal protein extracts from subjects 1 to 10, or in 10 ml PBS as a negative control. 
After incubation at 37°C for 1 h, bacterial cells were recovered by centrifugation at 6000 rpm for 
10 min at 4°C and washed in 50 mM Tris-HCl (pH 7.6). In order to detect faecal proteins captured 
on the bifidobacterial cell surface, the bacterial cell wall protein fractions were purified as 
reported by Hardie and Williams (1998). Bifidobacterial cells were resuspended in 500 μl of 
protoplast buffer (50 mM Tris-HCl [pH 7.6], 1 M sucrose, 1.4 mM phenylmethylsulfonyl fluoride, 
15 mg/ml lysozyme) and incubated for 90 min at 37°C. The suspension was then centrifuged for 3 
min at 4000 rpm at 4°C and the supernatant, containing the cell wall proteins, was collected and 
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stored at -20°C. In order to remove sucrose excess, cell wall proteins were precipitated with 15% 
trichloroacetic acid (TCA), centrifuged for 10 min at 13000 rpm at 4°C, and resuspended in 
acetone. After 5 min incubation on ice, proteins were centrifuged for 10 min at 13000 rpm at 4°C 
and acetone was completely removed. 
Immunoblot analysis 
To detect Plg presence, Western blotting analysis was performed for both crude faecal protein 
extracts and bifidobacterial cell wall protein fractions after incubation with faecal extracts. As 
positive controls, human Plg (Sigma-Aldrich) and Plg activated to plasmin by urokinase (uPA, 
Calbiochem) were used. Aliquots of 10 μg of proteins were mixed with loading buffer (0.5 M Tris-
HCl [pH 6.8], 4% (wt/vol) SDS, 20% glycerol, 0.1% bromophenol blue, 5% β-mercaptoethanol), 
boiled for 5 min and loaded onto 12% SDS-PAGE gels and resolved for 2.5 h at 160 V using a SE 250 
mini vertical electrophoresis unit (GE Healthcare). Proteins were then blotted onto a nitrocellulose 
membrane (Bio-Rad) using the Minitrans-Blot Electrophoretic Cell (BioRad) at 100 V, 90 mA, at 4°C 
overnight. After transfer, the membrane was incubated for 1 h at 25°C in a blocking solution (4% 
skim milk (Fluka, Sigma-Aldrich) dissolved in TBS-T [20 mM Tris-HCl [pH 7.6], 0.5 M NaCl, 0.15% 
Tween 20]), followed by an incubation with goat polyclonal anti-human Plg IgG antibodies (Kordia) 
for 1 h at 25°C under constant agitation. The membrane was then washed four times in TBS (20 
mM Tris-HCl [pH 7.6], 0.5 M NaCl) and incubated with the horseradish peroxidase conjugated anti-
goat IgG (Sigma-Aldrich) at 25°C for 1 h. After four TBS washings, the membrane was incubated 
with ECL Plus (GE Healthcare) and the chemiluminescent signal was detected by using a 
PhosphorImager Storm system (GE Healthcare). 
Two dimensional gel electrophoresis, comparative proteomic analysis and protein 
identification 
In order to investigate if bifidobacteria can interact with other proteins present in human faeces, 
the cell wall protein fraction of B. animalis subsp. lactis BI07 incubated with crude faecal extract 
from subject 1 or with PBS, and the faecal proteins from subject 1 were analyzed by comparative 
proteomics, following the procedure reported by Candela et al. (2007). Proteins were solubilised 
in IEF solution containing 7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), and 0.005% (vol/vol) 2-mercaptoethanol for two-dimensional 
polyacrylamide gel electrophoresis (2DE) analysis. The estimate of total protein concentration was 
carried out with PlusOne 2D Quant kit (GE Healthcare). Isoelectric focusing was performed using 
Immobiline DryStrips with a linear gradient between 4 and 7 (in 7 cm) on an IPGphor system (GE 
Healthcare). The rehydration of 40 µg of cell wall proteins was carried out for 12 h in 125 µl of 
buffer A (8 M urea, 2% [wt/vol] CHAPS, 2% [vol/vol] Ampholine pH 4.0 to 6.5 [GE Healthcare], 10 
mM dithiothreitol, 0.8% bromophenol blue). Proteins were focused for a total of 10 kV · h. 
Reduced and alkylated IPG strips (Görg et al., 1988) were loaded onto 12% acrylamide separating 
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gels and proteins were resolved by SDS-PAGE at 160 V for 2.5 h using a SE 250 mini vertical 
electrophoresis unit (GE Healthcare). Spots were visualized by silver staining. GS-800 imaging 
densitometer (Bio-Rad) was used for the digital acquisition of gels protein patterns. Comparison 
among gel in order to detect protein spots differently present on the gels was carried out with 
PDQuest v. 8.0.1 software (Bio-Rad). The selected protein spots were excised from the acrylamide 
gel and subjected to in-gel tryptic digestion and extraction of peptides (Shevchenko et al., 1996); 
TipZip (Millipore) was used to purify the extracted peptides. A MALDI-TOF-MS approach was 
employed to generate peptide mass fingerprinting maps of the tryptic peptides, using a Voyager-
DE Pro Biospectrometry work station (Applied Biosistems). All spectra were obtained in reflectron 
mode, with accelerating voltage of 20 kV and 40-ns delayed extraction. Internal calibration with 
peptides derived from trypsin auto-proteolysis was carried out. Peptide fingerprints obtained were 
scanned with Aldente (Gasteiger et al., 2005; http://www.expasy.org/aldente/) and ProFound 
(http://prowl.rockefeller.edu) database searching algorithms for protein spot identification, 
considering positive proteins with a minimum of four matching peptides. 
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Results 
 
Plasminogen detection in human crude faecal extracts 
To evaluate the presence of plasmin(ogen) in human faeces, an immunoblot analysis with 
polyclonal anti-human Plg IgG antibodies was carried out with crude faecal extracts from subject 1 
to 10. As reported in Fig. 26A, with the exception of subject 7, all the faecal proteomes showed 
bands attributable to plasmin heavy chain A and light chain B isoforms. Moreover, subject 1, 3 and 
8 displayed bands corresponding to Plg isoforms. These data prove the presence of Plg and its 
derivatives in the healthy human gastrointestinal tract, each subject with its own peculiar 
band pattern. 
Bifidobacterium capability to recruit plasminogen present in human faecal extracts 
The capability of Bifidobacterium to recruit Plg and derivatives present in human crude faecal 
protein extracts was investigated. At first, the ability of one strain, B. animalis subsp. lactis BI07, to 
capture on its surface Plg and derived molecules from the 10 different faecal extract samples was 
tested. Stationary-phase B. animalis subsp. lactis BI07 cells were incubated with crude faecal 
extracts from subjects 1 to 10. Bifidobacterial cell wall protein fractions were purified and 
examined by immunoblot analysis with anti-human Plg IgG antibodies in order to detect Plg 
captured on B. animalis subsp. lactis BI07 cell surface. As negative control bifidobacterial cells 
were incubated with PBS under the same experimental conditions, and as positive control faecal 
extracts were incubated without bacterial cells. The cell wall protein fractions from B. animalis 
subsp. lactis BI07 incubated with the faecal extracts showed a Plg- and plasmin-related band 
pattern corresponding to the one detected in the respective crude faecal fractions (Fig. 26B). 
Negative controls did not exhibit any Plg- and plasmin-related band pattern (data not shown). 
These data prove the capacity of this bifidobacterial strain to recruit Plg and plasmin isoforms 
present at physiological concentrations in crude protein extracts from human faeces. 
The next step was to investigate whether the capability to capture Plg and derivatives from crude 
faecal extracts was a common trait among different bifidobacteria. To this aim, four human 
Bifidobacterium strains belonging to as many species were chosen: B. longum ATCC 15707, B. breve 
ATCC 15700, B. bifidum DSM20456 and B. adolescentis ATCC 15703. These bifidobacterial cells 
were incubated with faecal extracts obtained from subject 1 under the same experimental 
conditions, and the purified cell wall fractions were analyzed by immunoblot analysis to detect Plg 
and plasmin isoforms presence. As shown in Fig. 27, all the bifidobacterial strains studied were 
able to recruit Plg and its derivatives present in human faeces, with B. animalis subsp. lactis BI07 
and B. bifidum DSM20456 displaying the highest efficiencies in Plg/plasmin recruitment. 
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Fig. 26. (A) Immunoblot analysis of crude faecal extracts from subjects 1 to 10 carried out by using polyclonal anti-Plg 
IgG antibodies. As positive controls, 5 µg (each) of Plg and Plg activated to plasmin by a preincubation with 0.06 
kallikrein inhibitor units (KIU) uPA was loaded. Black arrows indicate protein bands attributable to plasminogen 
isoforms (~90 to 100 kDa). Grey arrows indicate plasmin heavy chain A (~65 kDa), plasmin heavy chain A short form 
(~57 kDa), and plasmin light chain B (~25 kDa) isoforms. Dotted arrow indicates angiostatin (~38 kDa), which 
corresponds to the first four kringle domains of Plg isoforms. (B) Immunoblot analysis with polyclonal anti-Plg IgG 
antibodies of cell wall proteins purified from B. animalis subsp. lactis BI07 cells incubated with faecal extracts from 
subjects 1 to 10. Arrows indicate Plg and plasmin isoforms as reported above. 
Fig. 27. Ten to the 9 CFU/ml (each) of B. 
animalis subsp. lactis BI07 (B. ani.), B. 
longum ATCC 15707 (B. lon.), B. breve 
ATCC 15700 (B. bre.), B. bifidum 
DSM20456 (B. bif.), and B. adolescentis 
ATCC 15703 (B. ado.) were incubated in 
parallel with crude extracts from human 
faeces (FE). Bacterial cell wall proteins 
were purified, and plasmin(ogen) was 
detected by immunoblot analysis with 
polyclonal anti-Plg IgG antibodies. Black 
arrows indicate protein bands 
attributable to plasminogen isoforms 
(~90 to 100 kDa). Grey arrows indicate 
plasmin heavy chain A (~65 kDa), plasmin 
heavy chain A short form (~57 kDa), and 
plasmin light chain B (~25 kDa) isoforms. 
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B. animalis subsp. lactis BI07 interaction with other human faecal proteins 
To investigate the capability of bifidobacteria to interact with other human faecal proteins besides 
plasmin(ogen), the same previously described interaction experiment was carried out using B. 
animalis subsp. lactis BI07 and faecal extract from subject 1 as models. Purified cell wall fractions 
from faecal extract-incubated B. animalis subsp. lactis BI07 cells (BI07-FE) and PBS-incubated 
B. animalis subsp. lactis BI07 cells (BI07-PBS) and the faecal protein extract from subject 1 (crude 
faecal proteins) were examined by comparative proteomics (Fig. 28). The comparative analysis 
allowed the detection of six protein spots specific for the human crude faecal protein fraction in 
the cell wall fraction from BI07-FE, revealing that B. animalis subsp. lactis BI07 is able to capture 
on its cell surface various components present in the human faeces. A MALDI-TOF-MS approach 
was used for the identification of these protein spots (Table 6). Two spots, 1 and 3, were identified 
as human Plg and spot 2 as plasmin heavy chain A, in agreement with Western blotting data. One 
spot, no. 4, was identified as human keratin 8 and spot 6 as an hypothetical protein from rice 
(Oryza sativa), whereas spot 5 remained unidentified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fig. 28. Comparative proteomics of the cell wall fractions from BI07-PBS and BI07-FE and the crude faecal protein extract 
from subject 1. Numbered spots were analyzed by MALDI-TOF MS: protein spots 1 to 6 were specific for the crude faecal 
protein fraction and detected in the cell wall fraction from BI07-FE; protein spots 7 to 10 were detected only in the faecal 
protein fraction. The two-dimensional gel regions where plasminogen spots were identified are magnified in the insets. 
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Table 6 - Protein spots identification by MALDI-TOF MS 
a
: Spots 1 to 6 were specific for the human crude faecal protein fraction and detected in the cell wall fraction from 
BI07-FP; spots 7 to 10 were detected only in the faecal protein fraction. 
b
: Mr, molecular weight, in thousands. 
 
  
Spot 
ID
a
 
  Swiss Prot 
  Accession No. 
Protein Name Source 
Theoretical 
Mr/pI
b
 
Experimental  
Mr/pI
b
 
% sequence 
coverage 
1 B2R7F8 cDNA, FLJ93426, highly similar to Homo 
sapiens plasminogen (PLG), mRNA 
Homo sapiens 91/7.0 100/4.7 26 
2 P00747 Plasmin heavy chain A Homo sapiens 63/6.8 90/4.7 25 
3 P00747 Plasminogen Homo sapiens 88/7.1 80/4.7 25 
4 P05787 Keratin, type II cytoskeletal 8 Homo sapiens 54/5.5 59/4.9 30 
5 / Unidentified / / 40/5.9 / 
6 Q943E1 Putative uncharacterized protein Oryza sativa 73/6.2 70/6.1 27 
7 / Unidentified / / 36/5.2 / 
8 / Unidentified / / 37/5.3 / 
9 / Unidentified / / 37/5.5 / 
10 A1L302 LOC283685 protein Homo sapiens 41/4.8 30/4.5 30 
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Discussion 
 
The capability of Bifidobacterium to recruit Plg molecules on its cell surface has been recently 
demonstrated (Candela et al., 2007), but this interaction has been studied only in an in vitro and 
simplified environment, specifically in phosphate-buffered saline (PBS) suspensions. To investigate 
if Bifidobacterium-Plg binding possesses some relevance in the complex human gastrointestinal 
environment, the presence of plasmin(ogen) in human faeces and the ability of the probiotic strain 
B. animalis subsp. lactis BI07 to capture plasmin(ogen) present in faeces were evaluated. 
The presence of human Plg and its derivatives in the human healthy gastrointestinal tract was 
confirmed, strengthening previous data that reported the presence of plasma proteins in faecal 
extracts (Oleksiewicz et al., 2005; Ang et al., 2010). Analysis of the cell wall protein fractions from 
B. animalis subsp. lactis BI07 cells incubated with human crude faecal extracts allowed the 
detection of Plg and plasmin isoforms in the bacterial cell envelope proteome after the interaction 
with faeces, with band patterns corresponding to those detected in the respective faecal extract. 
This finding demonstrated the capacity of this bifidobacterial strain to recruit plasmin(ogen) 
present at physiological concentrations in crude protein extracts from human faeces: up to now, 
this represents the first experimental evidence of a direct interaction between a bifidobacterial 
strain and a human protein present in a human gastrointestinal tract microenvironment, 
supporting the biological significance of Bifidobacterium-Plg binding in the human gut ecosystem. 
The capability to recruit plasmin(ogen) in a human physiological microenvironment is not specific 
of B. animalis subsp. lactis BI07 strain, but represents a common property shared among 
Bifidobacterium strains that generally inhabit the human gut, as demonstrated by the Western 
blot analysis on four different human bifidobacterial strains incubated with crude faecal extracts. 
A comparative proteomic analysis was carried out to detect faecal proteins recruited on the 
cell wall of B. animalis subsp. lactis BI07. Apart from Plg and plasmin, bifidobacteria were capable 
to recruit human keratin and one hypothetical protein from Oryza sativa. Human faeces contains 
proteins of different origins, and plant proteins associated with food intake have already been 
detected in the human faecal metaproteome (Verberkmoes et al., 2009). 
The interaction with Plg system components can have an important impact on the dynamics of 
Bifidobacterium-host interaction in vivo in the human gut. Inflammatory processes in the 
gastrointestinal tract entail imbalances in the host Plg system (Mondino and Blasi, 2004) and 
fluctuations of the components of the Plg system dependent on the inflammatory status could 
influence the outcome of the interaction between Bifidobacterium and the host. Plg bound on the 
bifidobacterial cell surface can be activated by host Plg activators, endowing the microorganism 
with a host-derived surface-associated proteolytic activity useful in the host colonization process, 
as described by Candela and co-workers (Candela et al., 2008b). Depending on the gut 
environment status, this surface-bound Plg can be more or less activated to plasmin, with 
consequences for the colonization process. 
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he red thread running throughout the years of the PhD period has been the study of the 
relationship between the host plasminogen/plasmin system and Bifidobacterium. 
Bifidobacterium is one important genus of the human gastrointestinal ecosystem, representing 
one of the main health promoting groups present in the human gut microbiota. During millennia, 
the intestinal microbiota, this huge and complex symbiotic microbial community that inhabits the 
human gastrointestinal tract (Turnbaugh et al., 2007), evolved a strict inter-kingdom bionetwork 
that provides the human host with nutritional, metabolic and immunologic benefits (Neish, 2009). 
The magnitude of the interaction between gut microbiota microorganisms and the host is certainly 
huge, but until now only few molecules mediating the host-microbiota relationship have been 
described (Chow and Mazmanian, 2010). Since recent times, the capacity to interact with the host 
has been widely investigated in pathogens, which possess several mechanisms to intervene with 
and invade the host. Some microorganisms evolved different virulence strategies and molecular 
systems for the interaction with the host by their own, such as effector proteins delivered by type 
III secretion system (Sukhan, 2000; Parsot, 2005; Seveau et al., 2007; Dussurget, 2008; Schroeder 
and Hilbi, 2008; Pulzova et al., 2009; Ashida et al., 2012), but others take advantage of systems 
already present in the host, as the Plg/plasmin system (Lähteenmäki et al., 2005; Bergmann and 
Hammerschmidt, 2007). The host Plg/plasmin system has been increasingly recognized as an 
important molecular tool used by lactobacilli and bifidobacteria in the interplay with the host 
(Antikainen et al., 2007a, 2007b; Candela et al., 2007; Hurmalainen et al., 2007). A recent study 
have identified bifidobacterial cell surface Plg receptors, some of which are shared among several 
bacteria, both pathogens and commensals (Lähteenmäki et al., 2005; Antikainen et al., 2007b; 
Candela et al., 2007). 
Molecular and biochemical characterization of one bifidobacterial surface Plg receptor, DnaK, has 
been carried out. The presence of DnaK on the cell surface of the probiotic strain B. animalis 
subsp. lactis BI07 has been demonstrated by means of an immunoelectron microscopy approach. 
The affinity of the interaction between DnaK and human Plg has been investigated through a 
saturation binding analysis: this study revealed that DnaK possesses a high affinity for human Plg, 
with a KD in the nanomolar range (~ 11 nM). DnaK-Plg binding is dependent on lysine residues, but 
similarly to α-enolase, a Bifidobacterium surface Plg receptor already characterized (Candela et al., 
2009), the C-terminal lysine residue is involved in Plg binding to a minor extent, as the deletion of 
this residue in the DnaK protein only slightly affects the Plg binding affinity. Further studies are 
necessary to identify the DnaK residues responsible for the specific interaction with human Plg. 
Some residues have been identified as possible binding sites by means of bioinformatics studies, 
but the construction of mutant proteins appear essential to solve any doubt about this, or these, 
binding site(s). 
An important aspect to take into account for a deeper characterization of the role of host Plg in 
the Bifidobacterium - host interplay is the environment where the interaction takes place. Among 
the components present in the gut environment, bile salts represent one of the major challenging 
factors because of their bacterial toxicity (Begley et al., 2005). The adaptation of Bifidobacterium 
T 
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to these components has been largely illustrated (Sánchez et al., 2005, 2007b) and recent works 
have given more insights on the molecular and genetic mechanisms at the basis of this adaptation 
process (Gueimonde et al., 2009; Ruiz et al., 2012b). Adaptation to such a harsh environment 
involves several changes in the entire proteome; a recent study has reported the bile salts-
dependent changes of the envelope proteome of one bifidobacterial species, Bifidobacterium 
longum (Ruiz et al., 2009). With these premises, the impact of B. animalis subsp. lactis BI07 
adaptation to physiological concentrations of bile salts on host Plg binding has been evaluated, 
considering the important impact that this environmental factor can assume in this interaction. 
The results have shown the up-regulation of important bifidobacterial surface Plg receptors, such 
as α-enolase and DnaK, and the enhancement of the capacity of this microorganism to intervene 
with the host Plg/plasmin system. Thus, the increased capability of Bifidobacterium to intervene 
with Plg/plasmin system as a consequence of adaptation to bile salts, present in the intestinal 
environment, may favour the colonization capability of this microorganism in the gut ecosystem. 
The following aspect investigated has been the importance of this specific interaction between 
Bifidobacterium and the host Plg/plasmin system components present in a physiological 
ecosystem. Until now, the capability of bifidobacteria to interact with Plg/plasmin system 
components has been investigated only in a simplified environment, namely phosphate-buffered 
saline suspensions. To determine if this interaction has some relevance in the complex human gut 
environment, the capacity of Bifidobacterium to recruit components of the Plg/plasmin system 
from human crude faecal protein extract has been investigated. Crude protein extracts from 
human faeces represent a good model for the human gut environment, reflecting the entire 
content of the full length of the colon-rectum and being a simple non-invasive way of sampling of 
the gut environment (Ang et al., 2010). The results of this study have shown the capability of 
different Bifidobacterium strains to capture on their cell surface host Plg and its derivatives 
present at physiological concentrations in these faecal extracts, supporting the significance of this 
interaction in the context of the human gastrointestinal ecosystem. 
The last important point examined has been the role of human Plg in the biology of interaction 
between Bifidobacterium and host enterocytes, in order to elucidate the importance of this host 
system in the cross-talk between this probiotic microorganism and the human host. B. animalis 
subsp. lactis has been chosen as a bifidobacterial model, a subspecies frequently found in the gut 
of healthy adults and infants (Turroni et al., 2009). HT29 cell line has been selected as a model 
system for the human intestinal epithelium: these cells derive from human colorectal 
adenocarcinoma and produce mucin, leading to the formation of a mucus layer on the surface of 
the cellular monolayer that mimics the mucus layer encountered by bacteria in the human colon 
(Fogh and Trempe, 1975; Rousset, 1986). The study illustrated in this thesis has demonstrated that 
Plg acts as a molecular bridge between bacteria and host cells, enhancing bifidobacterial adhesion 
to the enterocytes. In the presence of host Plg activators, the interaction phenotype greatly 
changes, with a marked decrease of bifidobacterial adhesion. However, the acquired cell surface 
proteolytic activity does not promote bacterial intracellular invasion of the enterocytes or 
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transmigration across the epithelial monolayers. Gut inflammation has been regarded as one of 
the principal condition that can have a great impact on the Bifidobacterium-host interaction: 
several studies have reported dysbiosis associated with inflammatory intestinal diseases, where a 
decrease in Bifidobacterium content has been illustrated (Frank et al., 2007; Peterson et al., 2008; 
Sokol et al., 2008, 2009). Gut inflammation implies several host changes, and it has been reported 
that Plg/plasmin system components equilibrium is also affected by inflammatory processes: the 
balance is shifted towards an up-regulation of the plasminogen activators expression, leading to a 
marked increase of plasmin availability in inflamed tissues. Thus, inflammation can play a 
significant role in the Plg-mediated interaction between Bifidobacterium and the host gut. To 
elucidate the impact of inflammation on this interaction, Bifidobacterium - Plg - host enterocytes 
interaction has been studied in a model of inflamed intestinal epithelium, stimulating HT29 cells 
with the pro-inflammatory cytokine TNF-α (Ma et al., 2004; Yan et al., 2008). The TNF-α 
dependent increase of the enterocyte capability to activate Plg has led to a decrease in B. animalis 
subsp. lactis BI07 adhesion to the host enterocytes, showing a low adhesion phenotype 
comparable to the phenotype in the presence of Plg activators. Even in this case, the acquisition of 
a surface plasmin activity did not lead to bacteria internalization into enterocytes or 
transmigration across epithelial monolayers, but favours bacteria migration to the luminal 
compartment. Bifidobacterium shows a different behaviour depending on the inflammation level 
in that particular gut region, leaving the epithelium in case of inflammation; this could be one of 
the mechanisms used by Bifidobacterium that can explain its low presence in inflamed gut regions. 
This behaviour is completely different from that of pathogens, because pathogens use this surface 
associated proteolitic activity to invade tissues: the higher amount of plasmin present in an 
inflamed environment can improve the invasive characteristics of pathogenic bacteria. 
The interaction between microorganisms and the host relies on the capacity of the microorganism 
to find a way to communicate with the host. In this context, the host plasminogen system can be 
viewed as an important and flexible tool used by bifidobacteria in the cross-talk with the host, 
allowing the modulation of the interaction with the host in response to different situations that 
this microorganism can encounter in the intestinal habitat. Bifidobacterium can use this host 
system present in the gut environment for its advantage: in case of favourable 
microenvironmental conditions, it allows the enhancement of bacterial adhesion, outcompeting 
other commensal or pathogenic bacteria in the presence of plasminogen, but 
plasminogen/plasmin system provides the microorganism with a system that allows to escape in 
case of “dangerous gut conditions”, for instance from an inflamed gut niche, since bifidobacteria 
cannot face inflammation. For Bifidobacterium this host system can be seen as a sensor of 
environmental gut conditions, but also a tool that allows the immotile microorganism to evade 
an unfavourable situation for its survival. The interaction with this system can thus enable 
bifidobacteria to better adapt to different human host gut niches. 
Deepening the knowledge about the molecular mechanisms at the basis of the Bifidobacterium - 
host interplay is important to achieve a better comprehension of the symbiotic relationship the 
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human host shares with this probiotic microorganism. The studies illustrated here represent a first 
attempt to shed light on the molecular dynamics of the interaction between Bifidobacterium and 
the host, both in health and disease. Following this path, future researches should be performed 
on in vivo models to elucidate the impact of this host system in the ecology of Bifidobacterium in 
the intestinal tract. An interesting aspect to examine is the role of the host plasminogen system in 
the inflammation-dependent depletion of Bifidobacterium in the gastrointestinal tract. Moreover, 
the role of plasminogen in the biology of interaction of Bifidobacterium with the host should be 
studied in the presence of enteropathogens, as these microorganisms intervene with the host 
plasminogen/plasmin system with a completely different purpose, promoting their dissemination 
within the host tissues. The inflammation-dependent modulation of the host plasminogen system 
can impact the relationship bifidobacteria-enteropathogens-host. Favoring enteropathogen 
colonization, as well as the concomitant bifidobacterial migration to the luminal compartment, the 
inflammation-dependent increase of plasmin availability in the gastrointestinal could concur in 
establishing a pro-inflammatory bacterial community. 
Considering the interaction with enteropathogens, the bifidobacterial capability to recruit 
plasminogen could be also viewed as a probiotic characteristic: acting as a plasmin scavenger, 
Bifidobacterium subtracts plasmin to enteropathogens, reducing their colonization of the 
gastrointestinal tract. This phenomenon would become relevant in the context of the 
inflammation-dependent dysbiosis in the human gastrointestinal tract, such as in inflammatory 
bowel disease (IBD). The awareness of the mechanisms behind probiotic properties of 
bifidobacteria could be important for a more rational use of probiotic preparations in the context 
of emerging gut inflammatory diseases, such as IBD, irritable bowel syndrome (IBS), food allergies, 
colorectal cancer (CRC) and metabolic syndrome. 
These findings can open new outlooks to understand the dynamic of interaction of this probiotic 
bacterium with the human gut in different conditions. On a physiological level, the specific gut 
microenvironment, such as inflamed and not inflamed intestinal areas of IBD patients, has an 
important influence in the interaction between Bifidobacterium and the intestinal epithelium. 
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APPENDIX 1 
  
  
Bifidobacterium animalis subsp. lactis BI07 dnaK gene 
Length: 1866 bp - GenBank accession number: AB514431.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bifidobacterium animalis subsp. lactis BI07 DnaK protein 
Length: 621 aa 
 
 
 
 
 
 
 
   1  ATGGGACGCG CAGTTGGTAT TGATTTGGGT ACCACCAATT CCTGCATCGC AACGCTCGAG 
  61  GGCGGTGAAC CGACCGTCAT CGTGAACGCT GAAGGTGCAC GCACCACACC GTCTGTGGTG 
 121  GCATTCAGCA AGTCCGGCGA GATTCTCGTC GGCGAGGTTG CAAAGCGTCA GGCTGTGACC 
 181  AACGTCGATC GCACGATCAG CTCCGTCAAG CGCCACATGG GCACCGACTG GACCGTTGAC 
 241  ATCGACGGCA AGGAATGGAC TCCGCAGGAG ATTTCCGCAC AGATCCTCAT GAAGCTGAAG 
 301  CGCGACGCCG AAGCTTACCT GGGCGAGCCG GTCACGGACG CCGTGATCAC CTGCCCTGCA 
 361  TACTTCAACG ATGCACAGCG CCAGGCGACC AAGGACGCCG GCACAATCGC AGGCCTGAAC 
 421  GTCCTGCGCA TCATCAACGA ACCGACCGCT GCAGCTCTGG CCTACGGTCT GGAGAAGAGC 
 481  AAGGAAGACG AGCGCATTCT GGTCTTCGAT CTCGGCGGCG GCACCTTCGA TGTCTCCCTG 
 541  CTGGAGATCG GCAAGGACGA CGACGGCTTC TCCACCATCC AGGTGCAGGC TACGTCGGGC 
 601  GACAACCACC TCGGTGGCGA CGATTGGGAC CAGCGCATTA TCGACTGGCT CGTCGGCGAA 
 661  GTGAAGAACA AGTACGGTGT TGACCTGAGC AAGGACAAGA TCGCCCTGCA GCGTCTGAAG 
 721  GAAGCTGCCG AGCAGGCGAA GAAGGAGCTT TCCTCCTCGA TGTCCACCAC GATCAACATG 
 781  CAGTACCTGG CCATGACCCC TGACGGGACC CCGGTGCACC TCGACGAGAC GCTCACCCGC 
 841  GCCCACTTCG AGGAAATGAC CAAGGATCTG CTCGACCGCT GCCGCACGCC GTTCAACAAC 
 901  GTGCTTGCAG ACGCCGGCAT CTCGGTCTCC CAGATCGACC ATGTGATTCT GGTCGGCGGC 
 961  TCCACTCGTA TGCCTGCCGT GAAGGAGCTC GTGAAGGAGC TCGACGGCGG CAAGGAAGCC 
1021  AACCAGTCCG TGAACCCGGA CGAAGTGGTG GCCATCGGCG CTGCCGTGCA GTCCGGCGTC 
1081  ATCAAGGGCG ACCGCAAGGA CGTGCTGCTC ATCGACGTGA CGCCGCTGTC CCTCGGTATC 
1141  GAGACCAAGG GCGGCATCAT GACGAAGCTC ATCGAGCGCA ACACCGCAAT CCCGGCGAAG 
1201  CGTTCCGAGA TCTTCTCCAC CGCCGAAGAC AACCAGCCGT CCGTACTGAT TCAGGTCTAT 
1261  CAGGGCGAGC GTGAATTCGC CCGCGACAAC AAGCCGCTGG GCACCTTCGA GCTGACCGGC 
1321  ATCGCTCCGG CTCCTCGTGG CGTCCCGCAG ATCGAGGTCA CCTTCGACAT CGACGCCAAC 
1381  GGCATCGTGC ACGTCTCCGC AAAGGACAAG GGCACGGGCA AGGAGCAGTC GATGACGATC 
1441  ACCGGTGGCT CCGCACTGCC GAAGGAAGAG ATCGACCAGA TGATCAAGGA CGCCGAGGCC 
1501  CACGAAGCGG ACGACAAGAA GCGTAAGGAA GACGCCGAGA CCCGCAACAA CGCCGAGAAC 
1561  TTCGCATACC AGACCGAGAA GCTCGTCAAC GACAACAAGG ACAAGCTCTC CGATGACGTC 
1621  GCGAAGTCCG TCACCGACGC GATTAACGAG CTCAAGGATG CCTTGAAGGG CGACGACATT 
1681  GAGAAGATCA AGGCCGCCCA GGAGAAGCTG ATGACCGAGG CTCAGAAGAT CGGTCAGGCC 
1741  CTCTACGCCC AGCAGGGTGC CGAAGGCGCT GCAGGCGCCG CCGACAGCGG CTCCGCGAAC 
1801  AACGGTGGCG ACGATGACGT GGTCGACGCC GAGGTCGTGG ATGACGACGA CAAGGACAAC 
1861  AAGTAA 
  1  MGRAVGIDLG TTNSCIATLE GGEPTVIVNA EGARTTPSVV AFSKSGEILV GEVAKRQAVT 
 61  NVDRTISSVK RHMGTDWTVD IDGKEWTPQE ISAQILMKLK RDAEAYLGEP VTDAVITCPA 
121  YFNDAQRQAT KDAGTIAGLN VLRIINEPTA AALAYGLEKS KEDERILVFD LGGGTFDVSL 
181  LEIGKDDDGF STIQVQATSG DNHLGGDDWD QRIIDWLVGE VKNKYGVDLS KDKIALQRLK 
241  EAAEQAKKEL SSSMSTTINM QYLAMTPDGT PVHLDETLTR AHFEEMTKDL LDRCRTPFNN 
301  VLADAGISVS QIDHVILVGG STRMPAVKEL VKELDGGKEA NQSVNPDEVV AIGAAVQSGV 
361  IKGDRKDVLL IDVTPLSLGI ETKGGIMTKL IERNTAIPAK RSEIFSTAED NQPSVLIQVY 
421  QGEREFARDN KPLGTFELTG IAPAPRGVPQ IEVTFDIDAN GIVHVSAKDK GTGKEQSMTI 
481  TGGSALPKEE IDQMIKDAEA HEADDKKRKE DAETRNNAEN FAYQTEKLVN DNKDKLSDDV 
541  AKSVTDAINE LKDALKGDDI EKIKAAQEKL MTEAQKIGQA LYAQQGAEGA AGAADSGSAN 
601  NGGDDDVVDA EVVDDDDKDN K 
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The interaction with the host plasminogen/plasmin system represents a novel component in the
molecular cross-talk between bifidobacteria and human host. Here, we demonstrated that the
plasminogen-binding bifidobacterial species B. longum, B. bifidum, B. breve and B. lactis share
the key glycolytic enzyme enolase as a surface receptor for human plasminogen. Enolase was
visualized on the cell surface of the model strain B. lactis BI07. The His-tagged recombinant
protein showed a high affinity for human plasminogen, with an equilibrium dissociation constant in
the nanomolar range. By site-directed mutagenesis we demonstrated that the interaction between
the B. lactis BI07 enolase and human plasminogen involves an internal plasminogen-binding site
homologous to that of pneumococcal enolase. According to our data, the positively charged
residues Lys-251 and Lys-255, as well as the negatively charged Glu-252, of the B. lactis BI07
enolase are crucial for plasminogen binding. Acting as a human plasminogen receptor, the
bifidobacterial surface enolase is suggested to play an important role in the interaction process
with the host.
INTRODUCTION
Bifidobacteria represent one of the most important health-
promoting groups of human intestinal microbiota (Schell
et al., 2002; Ventura et al., 2009). Even though numerous
health-promoting activities have been related to the
presence of bifidobacteria in the human gastrointestinal
tract (Guarner & Malagelada, 2003), knowledge of the
mechanisms of interaction with the host is still in its
infancy. The understanding of the Bifidobacterium–host
interaction process, as well as its impact on human health,
could be clarified by the identification and characterization
of the bacterial proteins involved. In particular, represent-
ing the first line of contact with the intestinal epithelium,
the proteins of the bacterial cell surface may play a critical
role in the early interaction between microbes and the host
(Klijn et al., 2005). Recently, a proteomic approach
identified five highly conserved cytoplasmic proteins in
the cell wall fraction of Bifidobacterium lactis BI07 as
putative human plasminogen (Plg) receptors: DnaK,
glutamine synthetase, enolase, bile salt hydrolase and
phosphoglycerate mutase (Candela et al., 2007). Plg is the
zymogen of plasmin, a trypsin-like serine protease with a
broad substrate specificity. Plg is a single-chain glycopro-
tein with a molecular mass of 92 kDa and comprises an N-
terminal pre-activation peptide (~8 kDa), five consecutive
disulfide-bonded triple-loop kringle domains (K1–5), and
a serine-protease domain containing the catalytic triad
(Vassalli et al., 1991). It is produced mainly by hepatocytes;
however, other tissue sources for Plg synthesis have been
identified, including the intestine (Zhang et al., 2002). The
active form of plasmin is involved in fibrinolysis (Collen &
Abbreviations: 2-PGE, 2-phosphoglycerate; EACA, e-aminocaproic acid;
PEP, phosphoenolpyruvate; Plg, plasminogen.
The GenBank/EMBL/DDBJ accession number for the enolase
sequence of B. lactis BI07 is DQ117970.
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Verstraete, 1975), homeostasis and degradation of the
extracellular matrix and basement membrane (Saksela &
Rifkin, 1988). The capability to intervene with the Plg/
plasmin system is a strategy for host colonization shared by
several pathogens and commensals of the human gastro-
intestinal tract (Parkkinen & Korhonen, 1989; Schaumburg
et al., 2004; La¨hteenma¨ki et al., 2005; Sijbrandi et al., 2005;
Bergmann & Hammerschmidt, 2007; Hurmalainen et al.,
2007; Candela et al., 2008). With the recruitment of human
Plg on the bacterial cell surface, and its subsequent
conversion to plasmin, the micro-organism acquires a
surface-associated and host-derived proteolytic activity,
useful for facilitating the migration across physical and
molecular barriers and for responding to the nutritional
demands during the colonization process (La¨hteenma¨ki
et al., 2005). Several bacterial receptors for human Plg have
been characterized (La¨hteenma¨ki et al., 2001).
Interestingly, most of them have other important functions
besides Plg binding, such as adhesion, movement, enzymic
activity or nutrient uptake. In particular, glycolytic
enzymes including glyceraldehyde-3-phosphate dehydro-
genase and enolase interact with Plg, as shown for different
bacterial species (Bergmann & Hammerschmidt, 2007). In
spite of the absence of peptides required for secretion and
membrane anchorage, these key cytoplasmic enzymes are
displayed on the bacterial cell surface, where they acquire a
secondary ‘moonlighting’ function (Jeffery, 1999) that has
been shown to be important in the bacteria–host
interaction process.
A dose-dependent human Plg-binding activity was recently
demonstrated in four bifidobacterial strains belonging to
the species B. lactis, B. bifidum and B. longum (Candela
et al., 2007). The complete inhibition of Plg recruitment on
the bifidobacterial cell surface in the presence of the lysine
analogue e-aminocaproic acid (EACA) suggested that the
binding of human Plg to these bifidobacteria was strongly
dependent on lysine residues of surface-exposed Plg
receptors (Candela et al., 2007). However, bifidobacterial
receptors for human Plg have never been characterized. In
an attempt to provide insights into the interaction between
bifidobacteria and human-derived Plg, we assessed here the
role of the bifidobacterial enolase as a surface-displayed Plg
receptor in four bifidobacterial species with Plg-binding
activity. The localization of enolase on the bacterial cell
surface was demonstrated by immunoelectron microscopy
in the model strain B. lactis BI07. The recombinant His-
tagged enolase protein was purified and its Plg-binding
activity was characterized with respect to the dissociation
constant and the mechanism of Plg binding. By function-
ing as a surface receptor for human Plg, enolase may play
an important role in the bifidobacterial–host interaction
process.
METHODS
Bacterial strains, media, and growth conditions. Four bifido-
bacterial strains were studied. B. bifidum S16 and B. longum S123 were
isolated from human faeces, whereas B. breve BBSF and B. lactis BI07
were isolated from dairy products. Bifidobacteria were cultured in
MRS medium (Difco) supplemented with 0.05 % (w/v) L-cysteine at
37 uC in anaerobic conditions, obtained by using Anaerocult A
(Merck) in a jar. The cultures were grown for 18 h until they reached
the stationary phase. Escherichia coli strains OneShot TOP10,
BL21Star(DE3) and XL10-Gold were cultured at 37 uC in Luria–
Bertani (LB) medium with shaking. MagicMedia (Invitrogen) was
used for recombinant protein expression. Kanamycin (50 mg ml21)
was added as a selective agent when appropriate.
Extraction of bifidobacterial cytoplasmic proteins. Cytoplasmic
proteins were extracted from 50 ml bacterial culture in the stationary
growth phase. Cells were collected by centrifugation for 10 min at
3800 g, 4 uC and then washed in 50 mM Tris/HCl (pH 7.6),
resuspended in 500 ml TE buffer (50 mM Tris/HCl pH 7.6, 5 mM
EDTA) and 50 ml Complete Protease Inhibitor Solution (Roche) were
added. The suspension was sonicated for 8 min, power 30 W, pulse
frequency 20 % in a Branson Sonifier 250 and centrifuged for 10 min
at 22 000 g, 4 uC. The supernatant was collected and centrifuged for
2 h at 176 000 g, 4 uC by using a Beckman Ultracentrifuge L7-55. The
supernatant, containing cytoplasmic proteins, was stored at 220 uC.
Resolution of Bifidobacterium cell wall proteins by 2D-
electrophoresis and Plg overlay assay. Experiments were carried
out as reported by Candela et al. (2007). Briefly, 40 mg bifidobacterial
cell wall proteins was resolved by 2D-electrophoresis. Isoelectric
focusing was carried out using Immobiline DryStrips with a linear pH
gradient between 4 and 7 (7 cm) on an IPGphor system (GE
Healthcare) and proteins were separated by SDS-PAGE at 160 V for
2.5 h. For the Plg overlay assay, the resolved proteins were blotted
onto a nitrocellulose membrane (Pure nitrocellulose membrane, Bio-
Rad) by using a Trans-Blot Electrophoretic Cell (Bio-Rad). After
blocking, the membrane was incubated with 4 mg human Plg ml21
(Sigma-Aldrich) in PBS for 1 h at 25 uC. Captured Plg was detected
by incubating the membrane with goat anti-Plg IgG antibody
(Kordia) and a peroxidase-conjugated anti-goat IgG (Sigma-
Aldrich) as secondary antibody. To determine the role of the lysine-
binding site(s) in Plg binding, the experiment was repeated in the
presence of EACA. Primary and secondary antibody alone did not
result in non-specific background binding (data not shown).
Protein identification using MALDI-TOF MS. The selected protein
spots were excised from the acrylamide gel and subjected to in-gel
tryptic digestion and extraction of peptides (Shevchenko et al., 1996).
The extracted peptides were purified with ZipTip (Millipore). Peptide
mass fingerprinting maps of tryptic peptides were generated by
MALDI-TOF MS with a Voyager-DE Pro Biospectrometry work
station (Applied Biosystems), as reported by Candela et al. (2007).
Aldente (http://www.expasy.org/tools/aldente) and ProFound (http://
prowl.rockefeller.edu/prowl-cgi/profound.exe) database search algo-
rithms were used for the identification of the proteins.
Electron microscopy and immunoblot analysis. In order to
visualize bifidobacterial enolase on the B. lactis BI07 cell surface, we
performed pre-embedding immunogold experiments using intact
bacterial cells. Bifidobacterial cells recovered from a stationary-phase
culture were washed in PBS and adjusted to a concentration of 16109
c.f.u. ml21. Cells were resuspended in 100 ml rabbit polyclonal anti-
pneumococcal enolase antiserum (Bergmann et al., 2003) diluted
1 : 250 in PBS/1 % BSA, and incubated for 1 h at 25 uC under
constant agitation. After two washes with 1 ml PBS/1 % BSA, bacteria
were resuspended in 25 ml anti-rabbit IgG coupled to 10 nm gold
particles (Auro Probe, GE Healthcare) diluted 1 : 5 in PBS/1 % BSA,
and incubated for 30 min at 25 uC with constant agitation. Bacteria
were then collected and washed twice in PBS/1 % BSA and fixed with
2.5 % glutaraldehyde in 0.1 M cacodylate buffer for 4 h at 4 uC.
Bifidobacterial enolase plasminogen receptor
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Processing for transmission electron microscopy was carried out as
reported by Candela et al. (2007). Electron microscopic experiments
were repeated four times. For immunoblot analysis, B. lactis BI07
proteins (10 mg) were subjected to SDS-PAGE with 12 % polyacryl-
amide and blotted onto a nitrocellulose membrane by using a
Minitrans-Blot Electrophoretic Cell (Bio-Rad). Post-transfer, the
membrane was blocked in a solution of 4 % skim milk (Biolife) in
TBS-T (0.15 % Tween 20 in TBS) and then incubated with rabbit
polyclonal anti-streptococcal enolase antiserum (Bergmann et al.,
2003). Subsequently, the membrane was washed in TBS-T and
incubated with the peroxidase-conjugated anti-rabbit IgG (GE
Healthcare). After TBS-T washing, the membrane was incubated
with ECL Plus (GE Healthcare), and the signal was detected by using a
PhosphorImager Storm system (GE Healthcare).
Cloning, expression and purification of recombinant B. lactis
BI07 enolase. In order to analyse the nucleotide sequence of the B.
lactis BI07 enolase gene, chromosomal DNA was used as a template
for PCR and the enolase gene was amplified with the primer pair L-
FEno (59-GAAACTCACGCCTTTACGGGCGTT-39) and R-FEno (59-
TCAAGATACACAACCGTTTTAAGGAGT-39), designed against the
nucleotide regions downstream and upstream of the B. longum
NCC2705 enolase gene (1299 bp, GeneID:1022550), respectively. The
PCR product obtained was cloned into the pCRII-TOPO cloning
vector (Invitrogen), following the protocol supplied by the manufac-
turer, and the DNA insert was sequenced using the primer set T7 and
T7-reverse. For cloning and expression, the B. lactis BI07 enolase gene
was amplified by PCR using the primer set EnoTOPO-L (59-
CACCATGGCAGTAATTGAAAGCGTGT-39) and EnoTOPO-R (59-
TCACTTGGCCAGGTACTTCT-39), and the PCR product was cloned
into the expression vector pET200/D-TOPO (Invitrogen) to obtain
the construct pENOwt. Cloning and expression of the B. lactis BI07
enolase gene were carried out in E. coli TOP-10 and E. coli
BL21Star(DE3) (Invitrogen), respectively. The His-tagged fusion B.
lactis BI07 enolase was purified by affinity chromatography under
native conditions on Ni-NTA resin, according to the manufacturer’s
instructions (Invitrogen). The purified proteins were dialysed at 4 uC
using Spectra/Por membranes 6000–8000 kDa (Spectrum
Laboratories) and 20 mM Tris, 120 mM NaCl as dialysis buffer.
The expression of the His-tagged recombinant protein His6-enolase
was verified by Western blot analysis with polyclonal anti-pneumo-
coccal enolase antiserum (Bergmann et al., 2001) and anti-HisTag
(Sigma) antibody.
Site-directed mutagenesis. The QuikChange Multi Site-Directed
Mutagenesis kit (Stratagene) was used to obtain a mutant plasmid
library from pENOwt. Plasmids harbouring mutants of the B. lactis
BI07 enolase gene, deleted of nucleotides encoding the C-terminal
lysine (pENObs1), mutated in the internal Plg-binding site
(pENObs2), or with both the deletion and the internal mutation
(pENOdouble), were created. Primer ENOmutBS1 (59-
AAGAAGTACCTGGCCTGATGAAAGGGCGAGCTCAACG-39) was
designed to replace the C-terminal lysine with a stop codon. Primer
ENOmutBS2 (59-GAGTTCTACAACTTGGGGACCGGCTTGTACC-
GCTTCGACGG-39) was designed to replace Lys-251 and Lys-255
with leucine, and Glu-252 with glycine, as performed by Bergmann
et al. (2003) on Streptococcus pneumoniae enolase. Equal amounts of
each primer were added to a 50 ml PCR, together with 200 ng
pENOwt as DNA template. The mutagenesis reaction was carried out
in a thermocycler with a first denaturation step at 95 uC for 1 min,
followed by 30 cycles at 95 uC for 1 min, 55 uC for 1 min and 65 uC
for 14 min. The DNA template was removed by DpnI treatment at
37 uC for 2 h. The mutant plasmid library was transformed into the
E. coli XL10-Gold strain and a number of clones were sequenced to
isolate the three mutants. Mutant proteins carrying the desired amino
acid substitutions or deletion were expressed and purified as
described above.
Enolase activity of bifidobacterial whole cells and purified B.
lactis BI07 enolase protein. In order to determine the enolase
activity of intact bifidobacterial cells, a direct enzyme assay was
performed (Pancholi & Fischetti, 1998). Briefly, 16109 bifidobacter-
ial cells were washed three times in 100 mM HEPES buffer pH 7 and
equal amounts were resuspended in reaction buffer [100 mM HEPES
(pH 7), 10 mM MgCl2, 7.7 mM KCl, 3 mM 2-phosphoglycerate (2-
PGE)] or in control buffer [100 mM HEPES (pH 7), 10 mM MgCl2,
7.7 mM KCl]. The bacterial suspensions were incubated for 3 min at
37 uC and subsequently centrifuged for 10 min at 19 000 g, 4 uC. The
supernatants were recovered and centrifuged for a further 10 min at
19 000 g, 4 uC. After the second centrifugation step, the supernatants
were recovered and phosphoenolpyruvate (PEP) concentration was
determined by measuring the absorbance at 240 nm in a Jasco
spectrophotometer (model 7800/V-520). The enzyme activity of the
purified His-tagged enolase protein was determined in a single
enzyme assay. Briefly, different amounts of purified recombinant His-
tagged enolase protein were incubated for 3 min at 37 uC in reaction
buffer containing 15 mM 2-PGE. The release of PEP was measured
spectrophotometrically as described above. For kinetics studies,
different amounts of 2-PGE (0.5–15 mM) were used in a single
enzyme assay carried out with 5 mg purified His-tagged enolase
protein. The Km value was calculated from the Lineweaver–Burk plot.
Structural model of B. lactis BI07 enolase. The homology model
of B. lactis BI07 enolase was calculated as reported by Zambelli et al.
(2009). Using the tool BLAST (Altschul et al., 1990, 1997), the amino
acid sequence of B. lactis BI07 enolase (Swiss-Prot accession no.
Q45RT9) was used to search for bacterial enolase structures with a
high identity score. Four enolases with known protein structures were
selected: Strep. pneumoniae enolase (PDB code 1W6T), Enterococcus
hirae enolase (PDB code 1IYX), Methanococcus jannaschii enolase
(PDB code 2PA6), and Escherichia coli enolase (PDB code 1E91).
Multiple sequence alignment was carried out using CLUSTAL W
(Thompson et al., 1994). The prediction of the B. lactis BI07 enolase
secondary structure was carried out using the JPRED tool (Cuff et al.,
1998) and the alignment was manually optimized based on the
secondary structure information. Model structure was calculated with
the program MODELLER 9v5 (Marti-Renom et al., 2000), using the
above indicated enolases as templates. The best model was selected on
the basis of the lowest value of the MODELLER objective function.
Structure validation was performed using PROCHECK (Laskowski et al.,
1993). The program UCSF Chimera (Pettersen et al., 2004) was used
for protein visualization.
Plg-binding analysis. Human Plg (Sigma-Aldrich) was biotinylated
using the EZ-Link Micro Sulfo-NHS-SS Biotinylation kit (Pierce),
following the manufacturer’s instructions. The solid-phase Plg-
binding assay was performed as previously described by Sanderson-
Smith et al. (2006, 2007). Microtitre plates (96-well; OptiPlate-96,
Perkin Elmer) were coated with 150 nM recombinant enolase (50 ml
in 0.1 M NaHCO3) and incubated at 4 uC overnight. After washing
with PBS, the plates were blocked with 200 ml BSA 2 % in PBS for 1 h
at 37 uC. After three PBS washes, increasing concentrations of
biotinylated Plg in PBS (2, 6, 18, 36, 55, 110, 166 and 250 nM) were
added to the plates, in the presence or absence of a 50-fold molar
excess of unlabelled Plg. Plg was allowed to bind to immobilized
proteins for 2 h at room temperature, then the plates were washed
three times with PBS, and 50 ml ExtrAvidin horseradish-peroxidase-
conjugated antibodies (Sigma-Aldrich), diluted 1 : 5000 in PBS/1 %
BSA, was added to each well. Plates were incubated for 2 h at 25 uC
and washed four times with PBS and 0.05 % Tween 20. One hundred
microlitres of Chemiluminescent Peroxidase Substrate for ELISA
(Sigma-Aldrich) was added to each well and luminescence was read
using a Victor3V 1420 Multilabel Counter scanner (Perkin Elmer) and
the software Wallac 1420 WorkStation. As a negative control for Plg
binding, BSA-coated plates were utilized. For each of the recombinant
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proteins, Plg-binding experiments were repeated four times, whereas
for a given Plg concentration, each measurement was repeated in
triplicate. To assess the involvement of lysine residues in the enolase–
Plg interaction, experiments were repeated in the presence of 0.5 M
EACA. For analysis, data were normalized against the highest and
lowest luminescence values, and nonlinear regression analysis was
carried out using Graph Pad Prism (version 5.0, Graph Pad Software).
For calculation of the equilibrium dissociation constant (KD) one-
and two-site binding analysis was performed and the best-fit curve
was chosen.
RESULTS
Enolase is a conserved putative Plg receptor in
Bifidobacterium
In order to screen the putative surface Plg receptors in
Bifidobacterium, the cell wall fractions from the Plg-
binding strains B. longum S123, B. bifidum S16 (Candela
et al., 2007) and B. breve BBSF (data not shown) were
purified and a Plg overlay assay was carried out. To this
end, cell wall proteins were resolved in a two-dimensional
gel, immobilized on a nitrocellulose membrane, incubated
with human Plg, and probed with anti-Plg antibody to
identify bound Plg (Fig. 1). For each strain, the coordinates
of the major putative Plg-binding proteins detected could
be matched to a protein spot on the replica gel stained for
proteins. Plg binding was completely inhibited in the
presence of EACA (data not shown). Among the putative
Plg-binding proteins, two proteins with an apparent
molecular mass of 70 and 50 kDa and a pI of 4.5 and
4.7, respectively, were found to be conserved in the
different bifidobacterial strains analysed. For each strain,
the corresponding spots were excised from the gel and
subjected to trypsin digestion and MALDI-TOF MS
analysis for protein identification. The peptide fingerprints
obtained were scanned with the searching tools Aldente
and ProFound, and an unambiguous identification was
obtained: the protein of 70 kDa and pI 4.5 was identified as
DnaK and the protein of 50 kDa and pI 4.7 as enolase.
DnaK and enolase had been previously identified as
putative Plg receptors in a cell wall fraction of the Plg-
binding strain B. lactis BI07 (Candela et al., 2007). To
investigate the role of bifidobacterial enolase as a receptor
for human Plg, B. lactis BI07 was selected as model strain.
Localization of enolase protein on the B. lactis
BI07 cell surface
At first, the distribution of enolase in cytoplasmic and cell
wall fractions of B. lactis BI07 was evaluated by a Western
blot experiment carried out with a cross-reactive polyclonal
anti-pneumococcal enolase antiserum (anti-Eno)
(Bergmann et al., 2003). Enolase was detected in both the
cytoplasmic and cell wall fractions of B. lactis BI07 (Fig. 2).
In order to visualize the enolase protein on the B. lactis
BI07 cell surface, an immunoelectron microscopy experi-
ment was carried out. Intact B. lactis BI07 cells were
incubated under pre-embedding labelling conditions with
the anti-Eno antiserum followed by the secondary antibody
labelled with 10 nm gold particles. Analysis of ultrathin
sections at a magnification of622 000 (Fig. 3) detected the
enolase (black dots) directly in the bacterial cell wall
region. Non-specific binding of the secondary antibody was
not detected (data not shown). The binding pattern of the
anti-Eno antiserum suggests either that the distribution of
enolase is in the form of a cluster, or that its epitopes are
not uniformly exposed on the cell surface. The enzyme
functionality of the surface enolase was evaluated by
monitoring the conversion of 2-PGE to PEP, when
supplied to viable bifidobacterial cells. Intact cells of B.
lactis BI07 showed a dose-dependent enolase activity (data
not shown).
Fig. 1. Plg overlay assay carried out with the cell wall fraction of
B. longum S123 (a), B. bifidum S16 (b) and B. breve BBSF (c).
For each strain, the 2D-gel stained for proteins and the replicate
2D-gel used for Plg overlay are shown. Four micrograms Plg per ml
was applied as the Plg overlay. Plg-binding proteins were detected
with anti-Plg antibody and peroxidase-conjugated secondary
antibody. The black squares indicate two proteins with an apparent
molecular mass of 70 and 50 kDa and a pI of 4.5 and 4.7, which
are conserved among the different bifidobacterial strains.
Bifidobacterial enolase plasminogen receptor
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Analysis of Plg binding to B. lactis BI07 enolase
In order to characterize the Plg-binding activity of B. lactis
BI07 enolase, the gene was sequenced, cloned, and the
recombinant His6-tagged enolase protein was purified by
affinity chromatography. The nucleotide sequence of B.
lactis BI07 enolase (GenBank accession no. DQ117970)
revealed 98 % identity to the enolase gene of B. longum
NCC2705 (GenBank accession no. AE014295). In Fig. 4 we
show the dose-dependent enzymic activity for the recom-
binant His6-tagged B. lactis BI07 enolase. 2-PGE was
converted to PEP with a specific activity of 1.35 mmol PEP
synthesized per min per mg protein. These data indicate
that B. lactis BI07 enolase was purified in the native 3D
structure. To evaluate the specific Plg-binding activity of B.
lactis BI07 enolase, a solid-phase Plg-binding assay
(Sanderson-Smith et al., 2007) was carried out. The
saturation binding analysis of biotinylated Plg to immo-
bilized recombinant B. lactis BI07 enolase is reported in
Fig. 5. Non-specific binding was determined in the
presence of a 50-fold molar excess of unlabelled Plg, and
specific binding was calculated by subtracting non-specific
binding from the total binding obtained at each concen-
tration of biotinylated Plg. As a negative control, BSA-
coated wells were utilized. According to our data, Plg
binding to immobilized enolase was dose-dependent and
saturable binding was achieved with 250 nM Plg. The best-
fit nonlinear regression analysis allowed calculation of an
equilibrium dissociation constant (KD) for the interaction
of enolase with Plg of 42 nM. The binding was completely
inhibited in the presence of 0.5 M EACA, proving the
crucial role of enolase lysine(s) in Plg binding.
Fig. 2. Immunoblot analysis using anti-enolase antiserum of
cytoplasmic (a) and cell wall (b) fractions of B. lactis BI07
resolved by SDS-PAGE.
Fig. 3. Immunoelectron microscopic localization of enolase on the
cell wall of B. lactis BI07. Enolase was detected on the bacterial
surface by anti-enolase antiserum and a secondary antibody
coupled to 10 nm gold particles in pre-embedding experiments.
An ultrathin section of B. lactis BI07 cells at a magnification of
22000 shows enolase (black dots) localized directly in the cell
wall region.
Fig. 4. Enzymic activity of the recombinant His6-enolase of B.
lactis BI07. The activity was determined using a direct enzyme
assay: different amounts of the purified recombinant His6-enolase
were incubated with 15 mM 2-PGE. The release of PEP was
evaluated by measuring the increase in absorbance at 240 nm.
Fig. 5. Saturation binding analysis of biotinylated Plg to immobi-
lized recombinant His-tagged B. lactis BI07 enolase. Specific Plg
binding ($) was calculated at each concentration of biotinylated
Plg by subtracting non-specific binding obtained in the presence
of a 50-fold molar excess of unlabelled Plg from total binding. A
one-site hyperbolic binding function was fitted to the data and the
KD determined. The experiment was repeated in the presence of
the lysine analogue EACA (0.5 M, grey triangles).
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Homology model of B. lactis BI07 enolase and
identification of the putative Plg-binding sites
In an attempt to identify the putative Plg-binding site(s) of
B. lactis BI07 enolase, a homology model of the protein was
generated using the coordinates of four enolases of known
structure: the enolases of Strep. pneumoniae (PDB code
1W6T) and Enterococcus hirae (PDB code 1IYX), which
share 55 % identity with B. lactis BI07 enolase, and the
enolases of Escherichia coli (PDB code 1E9I) and M.
jannaschii (PDB code 2PA6), which show 52 % identity
with B. lactis BI07 enolase (Fig. 6a). In Fig. 6(b), a model of
the B. lactis BI07 enolase dimer is represented. The
Ramachandran Plot analysis (Willard et al., 2003) of the
model for B. lactis BI07 enolase indicated a good
stereochemical quality (data not shown). The monomer
consists of two domains: the N-terminal domain contains a
three-stranded antiparallel b-sheet followed by six a-
helices, and the C-terminal domain is composed of an a/
b-barrel structure. B. lactis BI07 enolase possesses a C-
terminal lysine at amino acid position 432, which
constitutes a homologue of the pneumococcal Plg-binding
site BS1 (Bergmann et al., 2003). In order to evaluate
whether the surface loop L3 of B. lactis BI07 enolase
contained a peptide region homologous to the internal Plg-
binding site BS2, located on the surface-exposed loop L3 of
Strep. pneumoniae enolase (residues 248–256; Ehinger et al.,
2004), the protein structures were superimposed. A 0.4 A˚
(0.04 nm) root-mean-square distance (r.m.s.d.) between
the Ca atom positions of the B. lactis BI07 and
pneumococcal enolases demonstrated an overall structural
similarity between these two proteins. In particular, the
enolases of B. lactis BI07 and Strep. pneumoniae shared a
significant structural similarity in the loop L3 (r.m.s.d. of
0.64 A˚, 0.064 nm) (Fig. 6c). Residues 248–256 within the
L3 region of B. lactis BI07 enolase and the BS2 region of
pneumococcal enolase displayed high structural homology.
Impact of BS1 and BS2 homologues on Plg
binding to B. lactis BI07 enolase
In order to determine the role of the putative Plg-binding
sites BS1 and BS2 of B. lactis BI07 enolase in Plg binding,
three genetic mutants of the corresponding enolase (eno)
gene were constructed: (i) the enoBS1 mutant gene, deleted
of the BS1 pneumococcal homologue, obtained by the
deletion of the codon encoding the C-terminal lysyl residue
at position 432; (ii) the enoBS2 mutant gene, obtained by
site-directed mutagenesis of the amino acids homologous
to those that were previously demonstrated to be essential
in Plg-binding to the BS2 site of the pneumococcal enolase
(Bergmann et al., 2003; Ehinger et al., 2004), 251
(LysALeu), 252 (GluAGly) and 255 (LysALeu); and
(iii) the enodouble mutant gene constructed by deleting the
C-terminal lysine from the enoBS2 mutant. The recombin-
ant His-tagged enolaseBS1, enolaseBS2 and enolasedouble
proteins were purified and their specific Plg-binding
activity was evaluated in a saturation binding analysis of
biotinylated Plg to the immobilized recombinant proteins
(Fig. 7). The interaction of enolaseBS1 with Plg was dose-
dependent and saturable, with a KD of about 46.2 nM, a
value comparable to that shown by the wild-type B. lactis
BI07 enolase protein. In contrast, neither enolaseBS2 nor
enolasedouble showed specific and saturable interaction with
human Plg, proving the crucial role of the BS2 homologue
in Plg binding to B. lactis BI07 enolase.
DISCUSSION
Plg-binding bifidobacterial strains belonging to the
human-associated species B. longum, B. bifidum and B.
breve (Ventura et al., 2007), as well as the Plg-binding
probiotic strain B. lactis BI07 (Candela et al., 2007), share
the enolase enzyme as one of their putative surface Plg
receptors. Enolase is an essential glycolytic enzyme
catalysing the formation of PEP from 2-PGE. Localized
on the cell surface, it is one of the best-characterized
human Plg receptors in prokaryotes and eukaryotes
(Pancholi & Fischetti, 1998; Bergmann et al., 2001;
Crowe et al., 2003; Schaumburg et al., 2004; La¨hteenma¨ki
et al., 2005; Antikainen et al., 2007b; Knaust et al., 2007). A
single enolase gene is present in the published genomes of
the bifidobacterial species B. animalis subsp. lactis
(accession no. NC_011835), B. longum (accession no.
NC_004307), B. longum subsp. infantis (accession no.
NC_011593), B. adolescentis (accession no. NC_008618)
and B. bifidum (accession no. NZ_ABQP00000000). Thus,
analogously to Streptococcus pyogenes, Strep. pneumoniae
and Staphylococcus aureus (Antikainen et al., 2007a), the
same enolase gene product is both an essential glycolytic
enzyme in the cytoplasm and, localized on the cell surface,
a receptor for human Plg. As reported for several
prokaryotes and eukaryotes that display enolase on the
cell surface (Pancholi, 2001), the bifidobacterial enolase
lacks either predicted or detectable protein-sorting ele-
ments for secretion and anchorage onto the bacterial cell
wall. The mechanisms of secretion and surface localization
of this essential glycolytic enzyme are still under debate.
Recently for Strep. pneumoniae, scavenging of cytoplasmic
proteins released through allolysis was proposed to account
for the presence of enolase on the cell surface (Claverys &
Havarstein, 2007). On the other hand, according to Boe¨l
et al. (2004), the export of enolase may depend on the
modification of the enzyme by covalent binding of 2-PGE
to Lys-341. The role of enolase as a surface Plg receptor was
further studied using B. lactis BI07 as a model strain. In a
Western blot analysis we confirmed that B. lactis BI07
enolase is present in the cytoplasm and in the cell wall
fractions. Moreover, providing direct evidence for the
presence of enolase on the bifidobacterial cell surface,
enolase was visualized on the cell surface of B. lactis BI07 by
immunoelectron microscopy. Similarly to Strep. pyogenes
(Pancholi & Fischetti, 1998), Strep. pneumoniae (Kolberg
et al., 2006) and Strep. suis (Esgleas et al., 2008), the B.
lactis BI07 enolase is displayed on the bacterial cell surface
Bifidobacterial enolase plasminogen receptor
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with relatively low abundance. The ability of intact B. lactis
BI07 cells to convert 2-PGE to PEP in a direct enzyme assay
demonstrated that the surface enolase still retains its
functional enzyme activity. The His-tagged B. lactis BI07
enolase was purified and characterized with respect to its
enzyme activity and, most importantly, its secondary
‘moonlighting’ function as a Plg receptor. In a direct
enzyme assay, the Km for 2-PGE was calculated to be
0.73 mM. This value is in the range reported for other
bacterial enolases, including the Strep. pyogenes
(1.492 mM) (Pancholi & Fischetti, 1998), Strep. pneumo-
niae (4.5 mM) (Bergmann et al., 2001) and Bacteroides
fragilis (0.210 mM) (Sijbrandi et al., 2005) enolases. The
affinity of B. lactis BI07 enolase for human Plg was
calculated in a saturation binding analysis. The purified
His-tagged B. lactis BI07 enolase showed a high affinity for
human Plg, with a KD value in the nanomolar range
(42.8 nM). Compared to the eukaryotic enolase, which
possesses a KD value of about 0.1–2 mM (Redlitz et al.,
1995), the B. lactis BI07 enolase shows a significantly higher
affinity for human Plg. On the other hand, in comparison
with bacterial enolases from pathogenic micro-organisms,
B. lactis BI07 enolase shows a slightly lower affinity to
human Plg. Strep. pyogenes, Strep. pneumoniae and Strep.
suis enolases demonstrated KD values for human Plg of 1–
4, 0.55 and 14 nM, respectively (Pancholi & Fischetti, 1998;
Bergmann et al., 2003; Esgleas et al., 2008). The best-fit
nonlinear regression of data obtained in the saturation
binding analysis to Plg indicated that the B. lactis BI07
enolase possesses only one site of binding to human Plg.
Our data are in general agreement with those reported for
Strep. pyogenes (Derbise et al., 2004) and Strep. pneumoniae
enolases (Bergmann et al., 2005). However, while in the
case of Strep. pyogenes the C-terminal lysines have been
indicated as the Plg binding site, for pneumococcal enolase
Plg-binding mainly depends on the internal Plg-binding
site BS2 (residues 248–256) located on the surface-exposed
loop L3 (Bergmann et al., 2003, 2005; Ehinger et al., 2004),
while the C-terminal lysine residue(s) (BS1) is either not or
only marginally involved. In particular, within the Plg-
binding site BS2 of pneumococcal enolase Lys-251, Lys-254
and Glu-252 are critical for Plg binding (Ehinger et al.,
2004). The homology model of the B. lactis BI07 enolase
indicated that the protein possesses a structural homologue
of both the internal Plg-binding site BS2 of pneumococcal
enolase and the C-terminal lysine that constitutes the Plg-
binding site BS1. Site-direct mutagenesis of Lys-251, Glu-
252 and Lys-255 within the BS2 homologue of B. lactis
BI07 enolase impaired its Plg-binding activity. In contrast,
the deletion of the B. lactis BI07 enolase C-terminal lysine
Fig. 6. (a) Multiple sequence alignment of the sequences of Bifidobacterium lactis BI07 (BI07), Enterococcus hirae (1IYX),
Streptococcus pneumoniae (1W6T), Methanococcus jannaschii (2PA6) and Escherichia coli (1E91) enolases, with the
secondary structure indication (a-helix, yellow; b-strand, cyan) derived from the JPRED prediction for B. lactis BI07 enolase and
from the PDB structure for all the remaining sequences. (b) Ribbon scheme of dimeric B. lactis BI07 enolase model structure,
derived using the sequence alignment reported in (a). In the bottom image the ribbons are rotated 90 6 around the long
horizontal axis. Ribbons are coloured from blue, in the proximity of the N-terminus, to red at the C-terminus. (c) Detailed view of
the superimposed L3 regions of B. lactis BI07 enolase (blue) and pneumococcal enolase (yellow). Lysines 251 and 255 and
the pneumococcal homologue lysines 251 and 254, crucial for Plg binding, are represented in ball and stick notation. The
molecular graphic images were produced using the UCSF Chimera package.
Fig. 7. Saturation binding analysis of biotinylated Plg to immobi-
lized recombinant His-tagged B. lactis BI07 EnolaseBS1,
EnolaseBS2 and Enolasedouble proteins. At each concentration of
biotinylated Plg, specific binding ($) was calculated by subtracting
the non-specific binding obtained in the presence of a 50-fold
molar excess of unlabelled Plg from the total binding. For
EnolaseBS1, a one-site hyperbolic binding function was fitted to
the data and the KD determined. The experiment was repeated in
the presence of the lysine analogue EACA (0.5 M, grey triangles).
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did not have any impact on Plg interaction. Taken
together, our data demonstrate that the interaction
between the B. lactis BI07 enolase and human Plg involves
the internal Plg-binding site homologous to the BS2 site of
pneumococcal enolase. In particular, as in the case of
pneumococcal enolase (Ehinger et al., 2004), the positively
charged residues Lys-251 and Lys-255, and the negatively
charged Glu-252, are vital for Plg interaction. Disruption of
the enolase gene would provide in vivo proof of its role as a
Plg receptor; however, the presence of only one bifido-
bacterial enolase gene, which is essential for bacterial
survival, renders the construction of a viable enolase-
defective B. lactis BI07 mutant impossible.
There is a growing number of reports concerning the
expression of cytoplasmic housekeeping proteins on the
bacterial cell surface of Gram-positive micro-organisms
(Pancholi, 2001; Pancholi & Chhatwal, 2003; Schaumburg
et al., 2004; Sijbrandi et al., 2005; Lee et al., 2006;
Antikainen et al., 2007a; Knaust et al., 2007). Although
their mechanism of secretion still remains unclear,
localized on the bacterial cell surface these multifunctional
proteins acquire a ‘moonlighting’ function (Jeffery, 1999),
with a role in the interaction process with the host. We
believe that this is the first report of the localization of
enolase on the cell surface of four species of
Bifidobacterium, a health-promoting member of the human
intestinal microbiota. Interestingly, the presence of surface
enolase has been recently reported for two species
belonging to the gut commensal genus Lactobacillus
(Antikainen et al., 2007a; Castaldo et al., 2009). However,
while the Lactobacillus crispatus surface enolase is a
receptor for human Plg, the Lactobacillus plantarum surface
enolase is a fibronectin-binding protein. Acting as a human
Plg receptor, the bifidobacterial surface enolase may play a
role in the interaction with the host. Although it will be
necessary to screen for the presence of surface enolases in
other bifidobacterial species, our findings raise the question
of the impact of glycolytic enzymes in the biology of the
Bifidobacterium–host interaction. In particular, concerning
enolase, further studies are justified to investigate its
capability to interact with extracellular matrix proteins
such as laminin and fibronectin, as already reported for
the enolases from Lactobacillus, Streptococcus and
Staphylococcus (Antikainen et al., 2007a).
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Bifidobacterium animalis subsp. lactis lives in the gastrointestinal tract of most mammals,
including humans. Recently, for the probiotic strain B. animalis subsp. lactis BI07, a dose-
dependent plasminogen-binding activity was demonstrated and five putative plasminogen-binding
proteins were identified. Here we investigated the role of surface DnaK as a B. animalis subsp.
lactis BI07 plasminogen receptor. DnaK was visualized on the bacterial cell surface by
transmission electron microscopy. The His-tagged recombinant DnaK protein showed a high
affinity for human plasminogen, with an equilibrium dissociation constant in the nanomolar range.
The capability to tolerate physiological concentrations of bile salts is a crucial feature for an
intestinal symbiont micro-organism. By proteome analysis we demonstrated that the long-term
exposure of B. animalis subsp. lactis BI07 to bile salts results in the upregulation of important
surface plasminogen receptors such as DnaK and enolase. Moreover, adaptation of B. animalis
subsp. lactis BI07 to physiological concentrations of bile salts significantly increased its capacity
to interact with the host plasminogen system. By enhancing the bacterial capacity to interact with
the host plasminogen, the gut bile environment may facilitate the colonization of the human host by
B. animalis subsp. lactis BI07.
INTRODUCTION
Human beings are in coevolution with a complex microbial
community living in their gastrointestinal tract (GIT), the
human intestinal microbiota (Gill et al., 2006; Ley et al.,
2008). Active and metabolizing, the intestinal microbiota
affects several host physiological features and has recently
been considered as an integral component of the human
physiology (Neish, 2009; Round & Mazmanian, 2009).
Bifidobacteria are obligate anaerobes in the Actinomycetales
branch of the high-G+C Gram-positive bacteria and can
be found in the human GIT as both autochthonous and
allochtonous residents (Klijn et al., 2005). As inhabitants of
the human gut they are only a minor component of the
adult intestinal microbiota, but they largely predominate in
the gastrointestinal ecosystem of breast-fed infants until
weaning (Ventura et al., 2009). The presence of bifido-
bacteria in the human GIT has been correlated with several
health-promoting effects (Guarner & Malagelada, 2003);
however, there is only fragmentary information about their
ecology, physiology and interaction with the host.
Originally isolated from fermented milk (Meile et al.,
1997), the species Bifidobacterium animalis subsp. lactis is
commonly found in the guts of healthy adults and infants
(Turroni et al., 2009). The complete genome sequence of
three B. animalis subsp. lactis strains has been recently
determined, and important insights into its genetic basis
for the interaction with the host and the adaptation to the
human gut environment have been provided (Barrangou
et al., 2009). In particular, four genes with a possible role in
the interaction with human epithelial cells have been
identified, including two putative collagen-adhesion pro-
teins, an elastin-binding protein and a fibronectin-binding
protein. Another aspect of the B. animalis subsp. lactis–
Abbreviations: Anti-Eno, anti-pneumococcal enolase antiserum; BSH,
bile salt hydrolase; EACA, e-aminocaproic acid; GIT, gastrointestinal
tract; PA, plasminogen activator(s); Plg, plasminogen; uPA, urokinase
plasminogen activator.
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host interaction was revealed by the dose-dependent
human plasminogen (Plg)-binding activity demonstrated
for the BI07 and DSM 10140 strains (Candela et al., 2007).
Plg is the zymogen of plasmin, a trypsin-like serine
protease with a broad substrate specificity. Plg is a single-
chain glycoprotein with a molecular mass of 92 kDa and
comprises an N-terminal pre-activation peptide (~8 kDa),
five consecutive lysine-binding disulfide-bonded triple-
loop kringle domains (K1–5), and a serine-protease
domain containing the catalytic triad (Vassalli et al.,
1991). It is produced mainly by hepatocytes; however,
other tissue sources for Plg synthesis have been identified,
including the intestine (Zhang et al., 2002). The active
form, plasmin, is involved in fibrinolysis (Collen &
Verstraete, 1975), homeostasis and degradation of the
extracellular matrix and basement membrane (Saksela &
Rifkin, 1988).
The capability to intervene with the Plg/plasmin system
is a strategy for host colonization shared by several
pathogens and commensals of the human GIT
(Parkkinen & Korhonen, 1989; Schaumburg et al., 2004;
La¨hteenma¨ki et al., 2005; Sijbrandi et al., 2005; Bergmann
& Hammerschmidt, 2007; Hurmalainen et al., 2007;
Candela et al., 2008b). The binding of Plg to the bacterial
cell surface depends on the presence of surface Plg-binding
proteins which can interact with Plg by means of a
C-terminal lysine residue(s) or/and lysine-enriched
internal Plg-binding motive(s) (Bergmann et al., 2003,
2005; Bergmann & Hammerschmidt, 2007; Candela et al.,
2009; Sha et al., 2009). With the recruitment of human Plg
on the cell surface, and its subsequent conversion to
plasmin, the micro-organism acquires a surface-associated
and host-derived proteolytic activity useful for facilitating
migration across physical and molecular barriers and for
responding to the nutritional demands during the
colonization process (La¨hteenma¨ki et al., 2005).
Similarly to the bifidobacterial species of human origin
Bifidobacterium bifidum and Bifidobacterium longum, the
probiotic species B. animalis subsp. lactis showed a dose-
dependent binding activity to human Plg (Candela et al.,
2007). In the presence of host-derived Plg activators (PA),
Plg captured on the B. animalis subsp. lactis cell surface was
converted to plasmin, endowing the bacteria with a Plg-
dependent surface-associated plasmin activity effective in
the degradation of physiological host substrates (Candela et
al., 2008b). The complete inhibition of Plg binding to B.
animalis subsp. lactis BI07 in the presence of the lysine
analogue e-aminocaproic acid (EACA) suggested that Plg
binding is strongly dependent on lysine residues of surface
Plg receptors. Five putative human Plg receptors were
identified in the cell-wall fraction of B. animalis subsp.
lactis strain BI07: DnaK, glutamine synthetase, enolase, bile
salt hydrolase (BSH) and phosphoglycerate mutase
(Candela et al., 2007). Analogously to other Gram-positive
bacteria (La¨hteenma¨ki et al., 2001), the B. animalis subsp.
lactis Plg-binding proteins are highly conserved cytoplas-
mic proteins that, expressed on the bacterial cell wall,
acquire a secondary ‘moonlighting’ function different from
the one exerted in the cytoplasm. The glycolytic enzyme
enolase of B. animalis subsp. lactis BI07 was characterized
with respect to surface localization and Plg-binding
activity. Proving its role as a bifidobacterial Plg receptor,
B. animalis subsp. lactis BI07 enolase showed a high affinity
for human Plg, with an equilibrium dissociation constant
in the nanomolar range (Candela et al., 2009).
Adaptation and tolerance to physiological concentrations
of bile salts (usually below 5 mM) is a vital factor for
bacterial colonization of the human gut ecosystem (Ridlon
et al., 2006; Sanchez et al., 2007). Bile salts are detergent-
like compounds that are secreted into the intestine during
digestion. Besides their primary role in the emulsification
and absorption of fats, bile salts also exert a strong
antimicrobial activity by inducing membrane damage and
causing oxidative stress to DNA (Bernstein et al., 1999).
The adaptation of B. animalis subsp. lactis to bile salts
involves a global change in its protein expression profile
(Sanchez et al., 2007), and the issue of whether these
changes could affect the manner of interaction with the
host has been addressed. Very recently, with the attempt to
specifically investigate if bile adaptation could influence the
Bifidobacterium–host interaction, Ruiz et al. (2009) studied
the effect of bile salts on the B. longum cell-wall proteome.
The authors reported that the surface Plg receptors enolase
and glutamine synthetase were upregulated in response to
bile salts, suggesting that the adaptation of B. longum to the
bile environment triggers the production of bacterial
factors for intestinal colonization.
Here we assessed the role of DnaK as a surface Plg receptor
in B. animalis subsp. lactis BI07 and also analysed the effect
of the adaptation to the bile salts environment on the Plg-
binding capacity of this bacterium. Demonstrating the
influence of bile adaptation on the B. animalis subsp.
lactis–host interaction process, the bile salts treatment
induced the upregulation of surface Plg receptors and
significantly increased the ability of the bacteria to interact
with the host Plg system.
METHODS
Bacterial strains, media and growth conditions. B. animalis
subsp. lactis BI07 was cultured in MRS medium (Difco) supplemen-
ted with 0.05% (w/v) L-cysteine at 37 uC in anaerobic conditions,
obtained by using Anaerocult A (Merck) in a jar. The bifidobacterial
cells were grown for 18 h until they reached the stationary phase.
Liquid MRS cultures were also performed with bile salts (oxgall;
Difco) at the final concentrations of 1.2 and 3 g l21. Since human bile
salts are difficult to retrieve, oxgall was used in this study. Oxgall has
higher concentrations of bile salts and phospholipids and lower
phospholipid/bile salts molar ratios than human bile (Coleman et al.,
1979), whereas the ratio of glycine- to taurine-conjugated bile acids is
similar (Hafkenscheid & Hectors, 1975). Escherichia coli OneShot
TOP10, BL21Star(DE3) and XL10-Gold strains were cultured at
37 uC in Luria–Bertani (LB) medium with shaking. MagicMedia
(Invitrogen) was used for recombinant protein expression.
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Kanamycin (50 mg ml21) was added as selective agent when
appropriate.
Extraction of bifidobacterial cytoplasmic and cell-wall frac-
tions. Cytoplasmic proteins were extracted as reported by Candela
et al. (2009). Briefly, stationary-phase cells of B. animalis subsp. lactis
BI07 were collected, washed in 50 mM Tris/HCl (pH 7.6), resus-
pended in 500 ml TE buffer [50 mM Tris/HCl (pH 7.6), 5 mM
EDTA], and 50 ml Complete Protease Inhibitors Solution (Roche) was
added. The suspension was sonicated and centrifuged for 10 min at
14 000 r.p.m. (22 000 g) at 4 uC. The supernatant was collected and
centrifuged for 2 h at 45 000 r.p.m. (176 000 g) at 4 uC by using a
Beckman Ultracentrifuge L7-55. The supernatant, containing cyto-
plasmic proteins, was stored at 220 uC. Cell-wall proteins were
extracted as reported by Hardie & Williams (1998). Briefly, after
washing in 50 mM Tris/HCl (pH 7.6), stationary-phase B. animalis
subsp. lactis BI07 cells were resuspended in 2 ml protoplast buffer
[50 mM Tris/HCl (pH 7.6), 1 M sucrose, 1.4 mM phenylmethylsul-
fonyl fluoride, 15 mg lysozyme ml21]. The suspension was incubated
for 90 min at 37 uC and centrifuged for 3 min at 4000 r.p.m. (1667 g)
at 4 uC. The supernatant, containing the cell-wall proteins, was
collected and stored at 220 uC.
Electron microscopy and immunoblot analysis. In order to
visualize bifidobacterial DnaK on the B. animalis subsp. lactis BI07
cell surface, we performed pre-embedding immunogold experiments
using whole bacterial cells. PBS-washed stationary-phase cells were
adjusted to a concentration of 16109 c.f.u. ml21, resuspended in
100 ml rabbit polyclonal anti-meningococcal DnaK antiserum
(Knaust et al., 2007) diluted 1 : 100 in PBS-1% BSAe (BSA), and
incubated for 1 h at 25 uC under constant agitation. After two
washings with 1 ml PBS-1% BSA, bacteria were resuspended in 25 ml
anti-rabbit IgG coupled to 10 nm gold particles (Auro Probe, GE
Healthcare) diluted 1 : 5 in PBS-1% BSA and incubated for 30 min at
25 uC with constant agitation. Bacteria were then collected and
washed twice in PBS-1% BSA and fixed with 2.5% glutaraldehyde in
0.1 M cacodylate buffer for 4 h at 4 uC. Transmission electron
microscopy (TEM) processing was carried out as reported by Candela
et al. (2007). Electron microscopic experiments were repeated four
times. For immunoblot analysis, B. animalis subsp. lactis BI07
cytoplasmic or cell-wall proteins (10 mg) were subjected to SDS-
PAGE with 12% polyacrylamide and blotted onto a nitrocellulose
membrane (Bio-Rad) by using the Minitrans-Blot Electrophoretic
Cell (Bio-Rad). Post-transfer, the membrane was blocked in a
solution of 4% skim milk (Biolife) in TBS-T (0.15% Tween 20 in
TBS) and then incubated with anti-meningococcal DnaK antiserum
(Knaust et al., 2007). Subsequently, the membrane was washed in
TBS-T and incubated with the peroxidase-conjugated anti-rabbit IgG
(GE Healthcare). After TBS-T washing, the membrane was incubated
with ECL Plus (GE Healthcare), and the signal was detected by using
the PhosphorImager Storm system (GE Healthcare).
Construction of a B. animalis subsp. lactis BI07 genomic
library and screening for the dnaK gene. Three hundred
micrograms of B. animalis subsp. lactis BI07 chromosomal DNA
was partially digested with the restriction enzyme MboI. DNA
fragments of about 20 kb were isolated by ultracentrifugation at
26 000 r.p.m. for 24 h at 18 uC in a sucrose gradient (10–40%),
purified by precipitation with ethanol and ligated to BamHI-digested
Lambda EMBL3 vector (Stratagene). Recombinant lambda phages
were packaged by using the Lambda EMBL3/BamHI Gigapack III
Gold Cloning kit (Stratagene). The library was amplified and titrated
as described in the kit manual. A digoxigenin-labelled DNA probe
targeting the dnaK gene was obtained by amplifying the chromosomal
DNA of B. longum NCC 2705 with the primer set L-DnaK (59-
TTGGCACGTGCAGTTG-39) and R-DnaKwt (59-TCACTTGTTG-
TCCTTGTCG-39) (designed based on the genome sequence of
B. longum NCC 2705) by using the DIG DNA Labelling and
Detection kit (Roche). For screening, the phage library was plated on
120 mm NZY agar plates using E. coli XL1-Blue MRA P2 as host
strain. Plates were blotted onto nylon membrane (Hybond-N+, GE
Healthcare). Neutralization, denaturation, cross-linking, membrane
hybridization with the DIG-labelled DNA probe, and detection were
carried out as described by the DIG-DNA Labelling and Detection kit
manual (Roche). Plaques corresponding to the positive signals in the
original plates were cut out and resuspended in SM buffer to isolate
the recombinant phage population. Phage DNA was extracted by
using the Qiagen Lambda mini kit (Qiagen). Positive clones were
sequenced and the sequence of the B. animalis subsp. lactis BI07 dnaK
gene obtained.
Cloning, expression, purification of recombinant B. animalis
subsp. lactis BI07 His6-DnaK. B. animalis subsp. lactis BI07
chromosomal DNA was used as template in a PCR for the
amplification of the dnaK gene using the primer set DnaK-TOPO-L
(59-CACCATGGGACGCGCAGTTGGT-39) and DnaK-TOPO-R (59-
TTACTTGTTGTCCTTGTCGTCGTC-39). The PCR product was
cloned in the expression vector pET200/D-TOPO (Invitrogen) to
obtain the construct pDKwt. Cloning and expression of B. animalis
subsp. lactis BI07 dnaK gene were carried out in E. coli TOP-10 and E.
coli BL21Star(DE3) (Invitrogen), respectively. The His-tagged fusion
B. animalis subsp. lactis BI07 DnaK was purified by affinity
chromatography under native conditions on Ni-nitrilotriacetic acid
resin according to the manufacturer’s protocol (Invitrogen). The
purified protein was dialysed at 4 uC using Spectra/Por membranes
6000–8000 Da (Spectrum Laboratories) and 20 mM Tris, 120 mM
NaCl as dialysis buffer. The expression of the His-tagged recombinant
protein His6-DnaK was verified by Western blot analysis with
polyclonal anti-meningococcal DnaK antiserum (Knaust et al.,
2007) and anti-HisTag antibody (Sigma).
Plg-binding analysis by solid-phase binding assay. Human Plg
(Sigma-Aldrich) was biotinylated by using the EZ-Link Micro Sulfo-
NHS-SS Biotinylation kit (Pierce). The solid-phase Plg-binding assay
was performed as previously described by Sanderson-Smith et al.
(2006, 2007). Microtitre plates (96-well; OptiPlate-96, Perkin Elmer)
were coated with 150 nM recombinant DnaK (50 ml in 0.1 M
NaHCO3) and incubated at 4 uC. After washing with PBS, plates
were blocked with 200 ml BSA 2% in PBS for 1 h at 37 uC. After three
PBS washings, increasing concentrations of biotinylated Plg (2, 6, 18,
36, 55, 110, 166, 250 nM) in PBS were added to the plates, in the
presence or absence of 50-fold molar excess of unlabelled Plg. Plg was
allowed to bind to immobilized proteins for 2 h at 25 uC. Plates were
washed three times in PBS and 50 ml ExtrAvidin HRP conjugated
(Sigma-Aldrich) diluted 1 : 5000 in PBS-1% BSA was added to each
well. Plates were incubated for 2 h at 25 uC and washed four times
with PBS and 0.05% Tween 20. One hundred microlitres of
Chemiluminescent Peroxidase Substrate for ELISA (Sigma-Aldrich)
was added to each well and luminescence was read by using the
Victor3V 1420 Multilabel Counter scanner (Perkin Elmer) and the
softwareWallac 1420WorkStation. As negative control for Plg binding,
BSA-coated wells were utilized. Plg-binding experiments were repeated
in three biological replicates where, for each Plg concentration, three
technical replicates were performed. To assess the involvement of lysine
residues in the DnaK–Plg interaction, experiments were repeated in the
presence of the lysine analogue e-aminocaproic acid (EACA) (0.5 M).
Data were normalized against the highest and lowest luminescence
value, and non-linear regression analysis was carried out by using
GraphPad Prism (version 5.0). For calculation of the equilibrium
dissociation constant (KD), one- and two-site binding analyses were
performed and the best-fit curve was chosen.
Two-dimensional gel electrophoresis and comparative
analysis of protein expression. Experiments were carried out as
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reported by Candela et al. (2007). Briefly, 40 mg samples of B.
animalis subsp. lactis BI07 cell wall proteins were resolved by
two-dimensional electrophoresis. Isoelectric focusing was carried out
using Immobiline DryStrips with a linear pH gradient between 4 and
7 (7 cm) on an IPGphor system (GE Healthcare) and proteins were
separated by SDS-PAGE at 160 V for 2.5 h. Spots were visualized by
silver staining. Protein patterns in the gels were recorded as digitized
images using a GS-800 imaging densitometer (Bio-Rad). Spot
detection, matching and the examination of differentially expressed
proteins were performed by PDQuest v. 8.0.1 software (Bio-Rad).
Two biological and three technical replicates were made per
condition and formed one replicate group with average normalized
spot intensities. Comparison was carried out between cell-wall
fractions from stationary-phase cells grown in MRS medium and in
MRS in the presence of 1.2 g bile salts l21 (oxgall; Difco). A
threshold of at least two times enhanced or decreased expression
level was chosen to consider the differentially expressed proteins.
The Plg-binding proteins were identified by comparison of the
two-dimensional gels with the reference map reported by Candela
et al. (2007).
MALDI-TOF-MS analysis of Plg binding to B. animalis subsp.
lactis BI07. Plg binding to B. animalis subsp. lactis BI07 cells was
evaluated by using a MALDI-TOF-MS-based approach, as reported
by Candela et al. (2008a). Stationary-phase B. animalis subsp. lactis
BI07 cells (16109 c.f.u.) grown in MRS with and without 1.2 g bile
salts l21 (oxgall; Difco) were incubated with 0, 10, 20, 50, 100 and
200 mg human Plg (Sigma-Aldrich). Subsequently, bifidobacteria
were washed three times with PBS to remove unbound Plg. After
washing, bacterial cells were resuspended in 20 ml 2% NH4Cl for
MALDI-TOF analysis. In order to detect Plg recruited on the bacterial
cell surface, 1.0 ml of each bacterial suspension was spotted, airdried,
and then overlaid with 1.0 ml matrix solution (12.5 mg ferulic acid
ml21 in a mixture of formic acid/acetonitrile/water 17 : 33 : 50). The
resulting droplet was left to crystallize by airdrying and analysed in a
Voyager DE Pro MALDI-TOF mass spectrometer (Applied
Biosystems) operating in linear positive ion mode in the range of
20 000–100 000 Da and equipped with a pulsed N2 laser at 337 nm.
Default operating conditions were as follows: accelerating voltage
25 000 V, grid voltage 22 500 V, extraction delay time 750 ns. All
acquisitions were generated automatically on the instrument software
(Voyager, Biospectrometry Workstation) using a random search
pattern mode and based on overhanging 1600 shots from 20 non-
overlapping positions (80 shots per position). Data were externally
calibrated with a standard BSAe (BSA) solution (67 kDa). As
analytical standard, 200 ng human Plg were spotted. For each Plg
concentration three biological and three technical replicates were
carried out.
In order to evaluate the impact of DnaK and enolase on B. animalis
subsp. lactis BI07 Plg-binding activity, Plg-binding assay of whole B.
animalis subsp. lactis BI07 cells was performed after pre-treatment of
cells with cross-reactive anti-meningococcal DnaK antiserum (Knaust
et al., 2007) or anti-pneumococcal enolase antiserum (anti-Eno)
(Bergmann et al., 2003), respectively. To this aim, 16109 c.f.u.
stationary-phase B. animalis subsp. lactis BI07 cells were washed in
PBS and incubated with anti-meningococcal DnaK antiserum diluted
1/250 or anti-Eno diluted 1/100 in PBS-1% BSA, for 1 h at 25 uC
under constant agitation. After two washings with PBS-1% BSA, cells
were resuspended in PBS and incubated with 100 mg human Plg
(Sigma-Aldrich) for 30 min at 37 uC with constant agitation.
Subsequently, bifidobacteria were washed three times with PBS to
remove unbound Plg. After washing, bacterial cells were resuspended
in 20 ml NH4Cl 2% for MALDI-TOF analysis of Plg binding,
as previously described. For each experimental condition three
biological and three technical replicates were carried out.
Plasmin activity assay. This was carried out as reported by Candela
et al. (2008b). Briefly, stationary-phase B. animalis subsp. lactis BI07
cells grown in MRS with and without 1.2 g bile salts l21 (oxgall;
Difco) were washed with PBS, adjusted to a concentration of
16109 c.f.u. ml21 and incubated for 30 min at 37 uC with 20 mg Plg
ml21 (Sigma-Aldrich) in PBS. After two PBS washing steps, cells were
resuspended in 50 mM Tris/HCl, pH 7.5 (TBS). A volume of 100 ml
of the bacterial cell suspension was added per well of a 96-well
microtitre plate. Plg was activated with 0.06 KIU urokinase PA (uPA)
(Calbiochem), and 30 ml of plasmin-specific chromogenic substrate
solution, containing 0.54 mM D-valyl-leucyl-lysine-p-nitroanilide
dihydrochloride (S-2251) (Sigma-Aldrich), was added. Absorbance
at 405 nm was measured by using a Multiskan Ascent V1.24 (Thermo
Electron Corporation) immediately after the addition of S-2251 and
at intervals of 7 min during 1 h incubation at 37 uC. As negative
control the kinetic experiment was carried out with B. animalis subsp.
lactis BI07 cells not incubated with Plg. Further controls were
performed with B. animalis subsp. lactis BI07 cells incubated with Plg
in the presence of 0.1 M EACA (Sigma-Aldrich) and in the absence of
uPA. Controls for spontaneous hydrolysis of S-2251 were carried out
with the chromogenic substrate alone and in the presence of PA.
Experiments were repeated twice and 10 technical replicates were
carried out for each condition
RESULTS
Localization of DnaK protein on the cell surface of
B. animalis subsp. lactis BI07
The presence of the DnaK protein in the cytoplasmic and
cell-wall fractions of B. animalis subsp. lactis BI07 was
demonstrated by immunoblot analysis using a cross-
reactive anti-meningococcal DnaK antiserum (anti-DnaK)
(Knaust et al., 2007) (Fig. 1). Immunoelectron microscopy
was conducted to confirm the presence of DnaK on the
surface of the bacteria. B. animalis subsp. lactis BI07 cells
were incubated under pre-embedding labelling conditions
with the anti-DnaK antiserum followed by the secondary
antibody labelled with 10 nm gold particles. Analysis of
ultrathin sections at a magnification of 622 000 showed
the presence of DnaK in the bacterial cell-wall region (black
dots, arrowed in Fig. 2). No non-specific binding of the
secondary antibody was detected (data not shown).
Analysis of Plg binding to B. animalis subsp.
lactis BI07 DnaK
A genomic library of B. animalis subsp. lactis BI07 was
constructed and screened for the dnaK gene by using a
digoxigenin-labelled DNA probe targeting the B. longum
NCC 2705 dnaK gene. The nucleotide sequence of B.
animalis subsp. lactis BI07 dnaK (GenBank accession no.
AB514431) showed 100% identity with the dnaK gene of B.
animalis subsp. lactis DSM 10140 (GenBank accession no.
CP001606) and 87% with that of B. longum NCC 2705
(GenBank accession no. AE014295). In order to study the
specific Plg-binding activity of B. animalis subsp. lactis
BI07 DnaK, a His6-tagged DnaK protein was expressed
and, after purification, a solid-phase Plg-binding assay was
carried out (Sanderson-Smith et al., 2007). The binding
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Fig. 1. Immunoblot analysis (right panels)
using anti-DnaK antiserum of cytoplasmic (a)
and cell wall (b) protein fractions of B. animalis
subsp. lactis BI07 resolved by SDS-PAGE.
(right panels).
Fig. 2. Immunoelectron microscopic local-
ization of DnaK on the cell surface of B.
animalis subsp. lactis BI07. DnaK was
detected on the bacterial surface by anti-
DnaK antiserum and secondary antibody
coupled to 10 nm gold particles in pre-
embedding experiments. An ultrathin section
shows DnaK (black dots, arrowed) localized
directly in the cell-wall region.
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assay demonstrated a dose-dependent interaction between
biotinylated Plg and immobilized recombinant B. animalis
subsp. lactis BI07 DnaK (Fig. 3). In the presence of 150
nM Plg a saturation binding was achieved. Non-specific
binding was determined in the presence of 50-fold molar
excess of unlabelled Plg, and specific binding was calculated
by subtracting non-specific binding from the total binding
obtained at each concentration of biotinylated Plg. As
negative control BSA-coated wells were utilized. The best-
fit non-linear regression analysis allowed calculation of an
equilibrium dissociation constant (KD) for the interaction
with Plg of about 11 nM. The pivotal role of DnaK lysine
residues in Plg binding was demonstrated with 0.5 M
EACA as competitor, which completely inhibited Plg
binding (Fig. 3).
Role of surface DnaK and enolase in Plg binding
to B. animalis subsp. lactis BI07
In order to provide experimental evidence of the role of
surface DnaK and enolase as Plg receptors, we evaluated
the impact of pre-treatment with anti-DnaK or anti-
enolase antibodies on B. animalis subsp. lactis BI07 Plg-
binding activity. Bacterial cells were pre-treated with anti-
DnaK or anti-Eno (Candela et al., 2009) antisera and their
Plg-binding activity was compared with that of untreated
bacteria using MALDI-TOF analysis. As a control, B.
animalis subsp. lactis BI07 cells not treated with Plg were
utilized. The results showed that treatment with the anti-
Eno antiserum decreased the Plg-binding activity by about
30%, and treatment with the meningococcal anti-DnaK
antiserum decreased it by about 80% (Fig. 4). In contrast,
no reduction in Plg binding was measured when using
anti-rabbit IgG as blocking antibodies. These results
suggest that both enolase and especially DnaK are of
importance for the sequestration of plasminogen by B.
animalis subsp. lactis B107.
Impact of bile salts exposure on the B. animalis
subsp. lactis BI07–plasmin(ogen) interaction
First, the capability of B. animalis subsp. lactis BI07 to grow
in the presence of bile salts was tested. To this end, B.
animalis subsp. lactis BI07 was grown in batch cultures in
the absence and in the presence of bile salts at concentra-
tions of 1.2 and 3 g l21 (Sanchez et al., 2005). As reported
for B. longum NCIMB 8809, growth rates were very similar
during the exponential phase in each of the three different
conditions (Fig. 5). In contrast, at the end of the
stationary-phase the c.f.u. ml21 were significantly lower
in the presence of bile salts (1.26109, 56108 and 16108
c.f.u. ml21 for bile salts concentrations of 0, 1.2 and 3
g l21, respectively). In order to assess whether the
physiological changes that are a consequence of the long-
term exposure of B. animalis subsp. lactis BI07 to bile salts,
can affect the expression of surface Plg receptors, a
comparative proteomic approach was performed. The
cell-wall proteomes of B. animalis subsp. lactis BI07 grown
in media supplemented or not supplemented with bile salts
at the concentration of 1.2 g l21 were compared by two-
dimensional gel electrophoresis (Fig. 6). Plg-binding
proteins are numbered as reported by Candela et al.
(2007). The expression profiles showed that exposure to
bile salts induced a 2.8-, 2.3- and 10-fold upregulation of
three Plg-binding proteins: DnaK, enolase and phospho-
glycerate mutase, respectively. Surprisingly, the putative
Plg-binding protein BSH was slightly downregulated (by
about 1.7-fold) after bile exposure. A downregulation was
also observed for the as yet unidentified Plg-binding
proteins no. 2 and no. 8.
To investigate whether bile salts adaptation affects the Plg-
binding capacity of B. animalis subsp. lactis BI07, we
compared the Plg-binding activity of stationary-phase cells
grown in the presence or in the absence of 1.2 g bile salts
l21. B. animalis subsp. lactis BI07 cells were incubated with
different concentrations of Plg and the bacterial-bound Plg
was measured by MALDI-TOF (Fig. 7). Although B.
animalis subsp. lactis BI07 showed a dose-dependent Plg-
binding activity independently of bile salts supplementa-
tion, bacteria grown in the presence of bile salts were about
10 times more efficient in Plg binding. In a plasmin activity
assay we compared the capability of B. animalis subsp.
lactis BI07 cells grown with and without 1.2 g bile salts l21
to acquire a Plg-dependent surface-associated plasmin
activity after the addition of host PA. To this end, B.
animalis subsp. lactis BI07 stationary-phase cells were
incubated with 20 mg Plg ml21 and the cell-captured Plg
was then activated to plasmin by the addition of uPA. The
Fig. 3. Saturation binding analysis of biotinylated Plg to immobi-
lized recombinant B. animalis subsp. lactis BI07 His-tagged DnaK.
The black dots represent the specific binding. Specific Plg binding
was calculated at each concentration of biotinylated Plg by
subtracting non-specific binding obtained in the presence of 50-
fold molar excess of unlabelled Plg from total binding. A one-site
hyperbolic binding function was fitted to the data and the KD
determined. The experiment was repeated in the presence of the
lysine analogue, EACA (0.5 M, grey triangles). Values represent
the mean±SD of 9 measurements.
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acquired bacterial surface-associated plasmin activity was
evaluated in kinetic experiments by measuring the
hydrolysis of the plasmin-specific chromogenic substrate
S-2251 at intervals of 7 min over a period of 1 h (Fig. 8).
The B. animalis subsp. lactis BI07 cells grown in the
presence of bile salts showed a significant increase in the
rate of S-2251 hydrolysis, demonstrating a higher rate of
surface-associated Plg-derived plasmin activity compared
with cells grown in standard conditions. As expected, the
lysine analogue EACA was effective in inhibition of the
plasmin formation of the B. animalis subsp. lactis BI07 cell
surface, proving the essential role of the Plg lysine-binding
sites for its recruitment to the bacterial cell surface (Fig. 8).
DISCUSSION
In this work we demonstrate the importance of B. animalis
subsp. lactis BI07 DnaK as a surface receptor for human
Plg. DnaK is a highly conserved primary cytoplasmic
protein of 67 kDa belonging to the heat-shock protein 70
family (HSP70) (Bukau & Horwich, 1998). HSP70s are
chaperones with an important role in protein folding and
transport. By immunoelectron microscopy we documented
the presence of DnaK on the cell surface of B. animalis
subsp. lactis BI07. Similarly to the surface-located B.
animalis subsp. lactis BI07 enolase (Candela et al., 2009),
DnaK lacks predicted protein-sorting elements and
anchorage on the bacterial cell wall. Mechanisms of
secretion and surface localization of these cytoplasmic
enzymes are still under debate. However, for Streptococcus
pneumoniae, scavenging of cytoplasmic proteins released
through allolysis was proposed as a possible mechanism for
surface localization (Claverys & Havarstein, 2007).
Strengthening our findings, DnaK had been previously
shown to be present on the cell surface of several pathogens
such as Neisseria meningitidis, Listeria monocytogenes and
Mycobacterium tuberculosis (Schaumburg et al., 2004;
Knaust et al., 2007; Xolalpa et al., 2007), as well as the
probiotic member of the human intestinal microbiota
Lactobacillus salivarius (Kelly et al., 2005). Although for Lb.
salivarius no information had been provided concerning
the DnaK function on the cell surface, in the case of N.
meningitidis, L. monocytogenes and M. tuberculosis its role
as receptor for human Plg was proved. The His-tagged B.
animalis subsp. lactis BI07 DnaK protein was purified and
its affinity for human Plg was evaluated in a saturation
binding analysis. According to our data, the B. animalis
Fig. 4. MALDI-TOF analysis of Plg binding to B. animalis subsp. lactis BI07 cells untreated (BI07+Plg), and pre-treated with
anti-DnaK (BI07+Plg+anti-DnaK) or anti-Eno (BI07+Plg+anti-Eno). As negative control, B. animalis subsp. lactis BI07 cells
not incubated with Plg (BI07) are shown. Plg [M+H]+ signal at 81 kDa, [M+2H]2+ at 40 kDa.
Fig. 5. Growth curves of B. animalis subsp. lactis BI07 in MRS
with 0 (black), 1.2 (dark grey) and 3 g l”1 bile salts (light grey). For
all the experimental conditions growth curves were performed in
three biological replicates and values represent the mean±SD.
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subsp. lactis BI07 DnaK shows a high affinity for human
Plg with a KD of about 11 nM, a value significantly higher
than that reported for B. animalis subsp. lactis BI07 enolase
(KD542.8 nM) (Candela et al., 2009). The complete
inhibition of Plg binding in the presence of 0.5 M EACA
indicates that DnaK lysine residue(s) are crucial for the Plg
interaction. The pretreatment of B. animalis subsp. lactis
BI07 cells with cross-reactive DnaK-specific antiserum had
a detrimental impact on the bacterial Plg-binding capacity,
demonstrating the importance of DnaK as a surface Plg
receptor. Pre-treatment with anti-Eno also reduced Plg
binding to B. animalis subsp. lactis BI07, but by only 30%,
compared to the 80% reduction seen with anti-DnaK
antiserum. While it would be tempting to speculate that
this difference is due to the higher Plg affinity of DnaK
compared to enolase, we can not exclude that it is the
consequence of a different efficacy in blocking the
respective antigens between the two antisera. Moreover,
the contribution of a single Plg receptor to Plg recruitment
on the bacterial cell surface can be influenced by other
variables alongside the mere affinity for Plg, such as its
availability on the cell surface and the number of binding
epitopes (Knaust et al., 2007).
Adaptation of B. animalis subsp. lactis BI07 to bile salts
induces a complex physiological response which influences
the cell envelope proteome. Similarly to B. longum (Ruiz
et al., 2009), the long-term exposure of B. animalis subsp.
lactis BI07 to bile salts results in the upregulation of the
important surface Plg receptors DnaK and enolase.
Supporting these findings, a recent study of the B. animalis
subsp. lactis protein response to bile salts reported the
upregulation of DnaK (Sanchez et al., 2007). In order to
investigate if the physiological changes as a consequence of
bile salts response could have an impact on the B. animalis
subsp. lactis–Plg interaction, we compared the Plg-binding
activity and surface-associated Plg-dependent plasmin
activity of B. animalis subsp. lactis BI07 cells grown with
and without 1.2 g bile salts l21. According to our data, the
B. animalis subsp. lactis BI07 cells grown in the presence of
bile salts were about 10 times more efficient in Plg binding
Fig. 6. Cell-wall proteome of stationary-phase B. animalis subsp. lactis BI07 cells cultured with (b) and without (a) bile salts at
1.2 g l”1. Cell-wall proteins up- and downregulated as a consequence of bile salts adaptation are marked with circles and
squares, respectively. Plg-binding proteins are numbered: DnaK (1), unidentified (2), glutamine synthetase (3), enolase (4),
BSH (5, 6), phosphoglycerate mutase (7), unidentified (8).
Fig. 7. MALDI-TOF analysis of the Plg-binding activity of
stationary-phase cells of B. animalis subsp. lactis BI07 grown in
the presence (OX) or in the absence (MRS) of 1.2 g bile salts l”1.
The bars represent the response, expressed as Plg amplitude/
reference signal amplitude (RS amplitude), with the standard
deviation, of B. animalis subsp. lactis BI07 cells incubated with
different concentrations of Plg (10, 20, 50, 100, 200 mg ml”1).
Reference signal: 23 000 Da.
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compared to cells cultured in standard medium and, after
the addition of host uPA, these bacteria exhibited a
significantly higher rate of acquired Plg-dependent surface-
associated plasmin activity. Taken together, these data
prove that bile salts enhance the ability of B. animalis
subsp. lactis BI07 to interact with the host Plg system, and
show the potential impact of the GIT bile environment on
the B. animalis subsp. lactis–host interaction process. Even
if the upregulation of surface Plg receptors such as enolase
and DnaK can partially explain this increase in Plg-binding
activity, other mechanisms may be involved. For instance,
affecting the accessibility of Plg receptors, changes in the B.
animalis subsp. lactis cell-surface structure may occur in
response to bile adaptation (Ruiz et al., 2007) and may
influence the bacterial affinity for human Plg (Stie et al.,
2009).
Besides the demonstration of the importance of DnaK as a
surface Plg receptor, in this work we report for the first
time that B. animalis subsp. lactis significantly increases its
affinity for human Plg in response to physiological
concentrations of bile salts. Since the ability of
Bifidobacterium to interact with the plasmin(ogen) system
of the human host may have a role in facilitating the
colonization of the human GIT (Candela et al., 2008b), our
results provide evidence that the adaptation of B. animalis
subsp. lactis to the gut bile environment may favour its
capacity to colonize the human GIT. Further studies will be
necessary to determine the mechanisms underlying the
enhancement of B. animalis subsp. lactis BI07 Plg affinity in
the presence of bile salts, as well as how bile influences the
biology of the interaction process between B. animalis
subsp. lactis BI07 and the host enterocytes. However, our
findings provide some insights into the adaptation of B.
animalis subsp. lactis to the human gastrointestinal
environment. Moreover, the importance of DnaK as a B.
animalis subsp. lactis Plg receptor justifies further studies
to attempt to characterize the mechanisms of Plg binding
in more detail.
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Human plasmin(ogen) is regarded as a component of the molecular cross talk between the probiotic species
Bifidobacterium animalis subsp. lactis and the human host. However, up to now, only in vitro studies have been
reported. Here, we demonstrate that the probiotic strain B. animalis subsp. lactis BI07 is capable of recruiting
plasmin(ogen) present at physiological concentrations in crude extracts from human feces. Our results provide
evidence that supports the significance of the B. lactis-plasmin(ogen) interaction in the human gastrointestinal
tract.
Bifidobacterium animalis subsp. lactis is a Gram-positive lac-
tic acid bacterium belonging to the Actinobacteria phylum.
Originally isolated from fermented milk (13, 14, 22), B. ani-
malis subsp. lactis inhabits the gut of healthy adults and infants
(20, 24). Merging health-promoting activities with technologi-
cal properties, B. animalis subsp. lactis is one of the most
common probiotic bifidobacterial species utilized in commer-
cial dairy products in North America and Europe (3). How-
ever, despite its broad usage as a probiotic, few molecules that
mediate the B. animalis subsp. lactis-host interaction have been
described. We previously reported the capability of this probi-
otic microorganism to bind human plasmin(ogen) (5, 6, 7).
According to our data, the probiotic strain B. animalis subsp.
lactis BI07 (21) possesses a dose-dependent binding activity to
human plasminogen (Plg) in concentrations ranging from 5 to
100 ng/l (7). Plg (92 kDa) is the zymogen of the serine
protease plasmin which is involved in fibrinolysis, homeostasis,
and degradation of basement membranes and the extracellular
matrix (17). Although it is produced mainly by hepatocytes,
other tissue sources of Plg have been identified, including the
intestine (25). Plg activation in human tissues is a process
tightly regulated by the balance between plasminogen activa-
tors (PA), such as the urokinase-type activator (uPA) and the
tissue-type activator (tPA), and their specific inhibitors, PAI-1
and PAI-2.
Plasmin captured on the bacterial cell surface has been re-
ported to favor the bacterial dissemination in host tissues, and
the capacity to intervene with the host Plg system has been
traditionally regarded as a paradigm of bacterial pathogenicity
(4, 12). However, Plg binding to commensal species of Lacto-
bacillus, Bifidobacterium, and streptococci has been recently
reported, raising a debate on the role of Plg binding in bacte-
rial commensalism (2, 7, 11). In a previous in vitro study, we
demonstrated that in the presence of Plg and host PA, B.
animalis subsp. lactis acquires a surface-bound Plg-derived
proteolytic activity effective in the degradation of physiological
substrates (6). Thus, we hypothesized that the interaction with
components of the host Plg system in the luminal compartment
of the human gastrointestinal tract (GIT) would endow B.
animalis subsp. lactis with a surface-associated plasmin activity
useful to gain access to the mucus layer overlying enterocytes,
the ideal habitat for commensal microorganisms (10, 19).
However, even if the intervention with the host plasmin(ogen)
system has been recently regarded as a component in the B.
animalis subsp. lactis-host molecular cross talk (8, 18), plas-
min(ogen) binding to B. animalis subsp. lactis has been studied
only in phosphate-buffered saline (PBS) suspensions, and its
relevance in the complex human gastrointestinal ecosystem
remains an unanswered question. With the intent to shed light
on this last issue, we evaluated the capability of the probiotic
strain B. animalis subsp. lactis BI07 to recruit plasmin(ogen)
present at physiological concentrations in human crude fecal
extracts. Reflecting the entire content of the full length of the
colon/rectum (1), fecal extracts represent the only possibility
for a noninvasive sampling of the human GIT content. In our
study, 10 healthy Italian individuals 30 years of age were
enrolled. None of the subjects had a history of gastrointestinal
disorders at the time of sampling. With the exception of anti-
biotics, probiotics, and functional foods, no dietary restriction
was prescribed for at least 4 weeks prior to sampling. Informed
consent was obtained from each enrolled subject. Fecal ex-
tracts were obtained by following the procedure reported by
Ivanov et al. (9) with slight modifications. Briefly, 6 g of feces
was resuspended in 10 ml of PBS with complete protease
inhibitor (Roche). After the addition of 3-mm glass beads
(BioSpec Products), samples were treated with FastPrep (MP
Biomedicals) at 5.5 ms for 1 min 3 times. Debris and glass
beads were removed by centrifugation at 12,000 rpm for 10
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min. The protein concentration in supernatant was determined
by NanoDrop (NanoDrop Technologies). The presence of hu-
man plasmin(ogen) in the crude fecal extracts was investigated
by Western blotting. For each subject, 10 g of fecal proteins
was resolved by SDS-PAGE and Western blotted with poly-
clonal anti-human Plg IgG antibodies (Kordia) as reported by
Candela et al. (7). As positive controls, Plg (Sigma) and Plg
activated to plasmin by uPA (Calbiochem) were loaded. While
the fecal extracts from subjects 1, 3, and 8 also showed bands
attributable to Plg isoforms, all the fecal extracts analyzed, with
FIG. 1. (A) Immunoblot analysis of crude fecal extracts from subjects 1 to 10 carried out by using polyclonal anti-Plg IgG antibodies. As positive
controls, 5 g (each) of Plg and Plg activated to plasmin by a preincubation with 0.06 kallikrein inhibitor units (KIU) uPA was loaded. Black arrows
indicate protein bands attributable to plasminogen isoforms (90 to 100 kDa). Gray arrows indicate plasmin heavy chain A (65-kDa), plasmin
heavy chain A short form (57-kDa), and plasmin light chain B (25-kDa) isoforms. Dotted arrow indicates angiostatin (38 kDa), which
corresponds to the first four kringle domains of Plg isoforms. (B) Immunoblot analysis with polyclonal anti-Plg IgG antibodies of cell wall proteins
purified from B. animalis subsp. lactis BI07 cells incubated with fecal extracts from subjects 1 to 10. Arrows indicate Plg and plasmin isoforms as
reported above.
FIG. 2. Ten to 9 CFU/ml (each) of B. animalis subsp. lactis BI07 (B. ani.), B. longum ATCC 15707 (B. lon.), B. breve ATCC 15700 (B. bre.),
B. bifidum DSM20456 (B. bif.), and B. adolescentis ATCC 15703 (B. ado.) was incubated in parallel with crude extracts from human feces (FE).
Bacterial cell wall proteins were purified, and plasmin(ogen) was detected by immunoblot analysis with polyclonal anti-Plg IgG antibodies. Black
arrows indicate protein bands attributable to plasminogen isoforms (90 to 100 kDa). Gray arrows indicate plasmin heavy chain A (65-kDa),
plasmin heavy chain A short form (57-kDa), and plasmin light chain B (25-kDa) isoforms.
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the only exception being that of subject 7, showed bands at-
tributable to plasmin heavy chain A and light chain B isoforms
(Fig. 1A). These data confirm the presence of Plg and its
derivatives in the healthy human GIT and strengthen previous
data reporting the occurrence of plasma proteins in fecal ex-
tracts (1, 16). The capability of B. animalis subsp. lactis BI07 to
recruit plasmin(ogen) and derivatives present at physiological
concentrations in crude fecal extracts was next investigated. To
this aim, stationary-phase B. animalis subsp. lactis BI07 cells
(7) were resuspended at a concentration of 109 CFU/ml in 10
ml of crude fecal extracts from subjects 1 to 10. After 1 h of
incubation at 37°C, bacterial cells were recovered by centrifu-
gation and washed in 50 mM Tris-HCl (pH 7.6). In order to
detect the Plg captured on the B. animalis subsp. lactis BI07
cell surface, the bacterial cell wall protein fractions were pu-
rified as previously described (7), resolved by SDS-PAGE, and
Western blotted with anti-human Plg IgG antibodies (Kordia)
as reported above. As negative controls, stationary-phase B.
animalis subsp. lactis BI07 cells were incubated with PBS, and
fecal proteins were incubated without bacterial cells. Interest-
ingly, the cell wall fractions from B. animalis subsp. lactis BI07
cells incubated with the fecal extracts from subjects 1, 3, and 8
exhibited a Plg- and plasmin-related band pattern attributable
to the one detected in the respective crude fecal fractions (Fig.
FIG. 3. Comparative proteomics of the cell wall fractions from BI07-PBS and BI07-FE and the crude fecal protein extract from subject 1.
Numbered spots were analyzed by MALDI-TOF MS: protein spots 1 to 6 were specific for the crude fecal protein fraction and detected in the cell
wall fraction from BI07-FE; protein spots 7 to 10 were detected only in the fecal protein fraction. The two-dimensional gel regions where
plasminogen spots were identified are magnified in the insets.
TABLE 1. Protein spot identification by MALDI-TOF MS
Spot IDa Swiss-Protaccession no. Protein name/description Source
Theoretical
Mr/pIb
Experimental
Mr/pIb
% sequence
coverage
1 B2R7F8 cDNA, FLJ93426, highly similar to Homo sapiens
plasminogen (PLG), mRNA
Homo sapiens 91/7.0 100/4.7 26
2 P00747 Plasmin heavy chain A Homo sapiens 63/6.8 90/4.7 25
3 P00747 Plasminogen Homo sapiens 88/7.1 80/4.7 25
4 P05787 Keratin, type II cytoskeletal 8 Homo sapiens 54/5.5 59/4.9 30
5 Unidentified 40/5.9
6 Q943E1 Putative uncharacterized protein Oryza sativa 73/6.2 70/6.1 27
7 Unidentified 36/5.2
8 Unidentified 37/5.3
9 Unidentified 37/5.5
10 A1L302 LOC283685 protein Homo sapiens 41/4.8 30/4.5 30
a Spots 1 to 6 were specific for the human crude fecal protein fraction and detected in the cell wall fraction from BI07-FP; spots 7 to 10 were detected only in the
fecal protein fraction.
b Mr, molecular weight, in thousands.
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1B). As expected, negative controls did not show any Plg- and
plasmin-related bands (data not shown). These data demon-
strate that B. animalis subsp. lactis BI07 is capable of recruiting
Plg and plasmin isoforms present at physiological concentra-
tions in crude extracts of human feces. As far as we know, this
represents the first experimental evidence of a direct interac-
tion between a probiotic bifidobacterial strain and a human
protein in a human microenvironment. The capacity to interact
with plasmin(ogen) present in crude extract from human feces
was investigated in 4 human Bifidobacterium strains: Bifidobac-
terium longum ATCC 15707, Bifidobacterium breve ATCC
15700, Bifidobacterium bifidum DSM20456, and Bifidobacte-
rium adolescentis ATCC 15703 (13) (Fig. 2). The interaction
experiments were carried out as reported above. Interestingly,
all the bifidobacterial strains studied were capable of recruiting
plasmin(ogen) present in human feces. B. animalis subsp. lactis
BI07 and B. bifidum DSM20456 showed the highest efficiencies
in plasmin(ogen) recruitment.
With the intent to investigate whether B. animalis subsp.
lactis BI07 is capable of interacting with other human fecal
proteins besides plasmin(ogen), stationary-phase B. animalis
subsp. lactis BI07 cells were incubated with the fecal extract
from subject 1 as previously described. Subsequently, the cell
wall protein fractions from fecal extract-incubated B. animalis
subsp. lactis BI07 cells (BI07-FE) and PBS-incubated B. ani-
malis subsp. lactis BI07 cells (BI07-PBS) and the fecal proteins
from subject 1 (FP) were analyzed by comparative proteomics
as reported by Candela et al. (5) (Fig. 3). Six protein spots
specific for the human fecal protein fraction were detected in
the cell wall fraction from BI07-FE, demonstrating that B.
animalis subsp. lactis BI07 is capable of recruiting different
components of the human fecal proteome to its cell surface. A
tentative matrix-assisted laser desorption ionization–time of
flight mass spectrometry (MALDI-TOF MS)-based identifica-
tion of spots 1 to 6 was performed as reported by Candela et al.
(7) (Table 1). Confirming the data obtained by Western blot-
ting, spots 1 and 3 were identified as human Plg and spot 2 as
plasmin heavy chain A. These last data were also confirmed by
two-dimensional Western blot analysis with anti-human Plg
IgG antibodies (Kordia) (Fig. 4). Spot 4 was assigned to human
keratin 8 and spot 6 to a hypothetical protein from Oryza
sativa, whereas no identification was obtained for spot 5. Plant
food-related proteins have already been identified as microbi-
ota-associated proteins in the human fecal metaproteome (23).
Our data provide the first experimental evidence of the B.
animalis subsp. lactis plasmin(ogen) binding activity in the hu-
man GIT microenvironment. Allowing B. animalis subsp. lactis
to acquire a host-derived surface-associated proteolytic activ-
ity, the interaction with components of the host Plg system can
impact the dynamics of the B. lactis-host interaction process in
the human GIT. Since gastrointestinal inflammatory processes
involve imbalances of the host Plg system (15), it can be ex-
pected that the inflammation-dependent fluctuations of the
components of the Plg system can modulate the biological
outcome of the B. lactis-host interaction process. Studies in this
direction should be carried out, leading to a more rational
usage of this probiotic bifidobacterial species in inflammatory
diseases.
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Tumor Necrosis Factor Alpha Modulates the Dynamics of the
Plasminogen-Mediated Early Interaction between
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The capacity to intervene with the host plasminogen system has recently been considered an important component in the inter-
action process between Bifidobacterium animalis subsp. lactis and the human host. However, its significance in the bifidobacte-
rial microecology within the human gastrointestinal tract is still an open question. Here we demonstrate that human plasmino-
gen favors the B. animalis subsp. lactis BI07 adhesion to HT29 cells. Prompting the HT29 cell capacity to activate plasminogen,
tumor necrosis factor alpha (TNF-) modulated the plasminogen-mediated bacterium-enterocyte interaction, reducing the bac-
terial adhesion to the enterocytes and enhancing migration to the luminal compartment.
Bifidobacterium is an important, occasionally dominant, genusof the human intestinal microbiota whose presence in the hu-
man gastrointestinal tract (GIT) has been associated with several
health benefits (12, 17). Merging health-promoting activities and
technological properties, B. animalis subsp. lactis is one of the
most common probiotic species in North America and Europe
(3). Because of the wide probiotic usage of this bacterium, differ-
ent studies with the goal of better comprehending the molecular
mechanisms involved in the bacterium-host interaction process
have been recently carried out (3, 11). In this scenario, the capacity
of this microorganism to intervene with the host plasmin(ogen)
system has been recently regarded as a possible actor in the
interplay with human enterocytes (11, 28). However, the role of
the human plasminogen (Plg) system in the biology of the Bifido-
bacterium-host interaction process is still to be determined. The
92-kDa Plg is the monomeric proenzyme of the serine protease
plasmin. Plg comprises anN-terminal8-kDa preactivation pep-
tide, five consecutive disulfide-bonded kringle domains (65 kDa)
thatmediate binding to lysine-containing protein receptors, and a
serine protease domain (25 kDa). Although Plg is produced
mainly by hepatocytes, other tissue sources of Plg, including the
intestine, have been identified (41). Plg is immobilized onto
lysine-containing cell surface protein receptors such as fibrin as
well as components of the extracellular matrix. Plg activation is a
process tightly regulated by the balance between Plg activators
(PAs), such as urokinase (uPA) and tissue-type (tPA) activators,
and their specific inhibitors, PAI-1/2. Involved in fibrinolysis, en-
hancement of cell migration, and damages of tissue barriers, the
Plg system has a key role in several human physiological and path-
ological processes (27).
We previously reported the capability of B. animalis subsp.
lactis to bind human plasmin(ogen) (8). Plg binding to the bifido-
bacterial cell surface ismediated by five cell wall protein receptors:
DnaK, glutamine synthetase, enolase, bile salt hydrolase, and
phosphoglycerate mutase. According to Candela et al. (7), in the
presence of Plg and host PAs, B. animalis subsp. lactis acquires a
surface-bound Plg-derived proteolytic activity effective in the
degradation of host physiological substrates. This modality of in-
teraction with the components of the host Plg system resembles
the one characteristic of several enteropathogens, such as Salmo-
nella enterica, Listeria monocytogenes, and Escherichia coli (16, 25,
29, 30, 32, 36).Different from the case forBifidobacterium, the role
of Plg in bacterial pathogens has been determined, and the bacte-
rial capacity to intervene with the host Plg system has been tradi-
tionally considered a paradigm of pathogenicity (5, 16, 25, 29, 30,
32, 35). Facilitating the bacterial transmigration through epithe-
lial monolayers, for pathogens, the acquisition of a Plg-dependent
surface-associated plasmin activity is necessary for dissemination
in the host tissues. This process has been defined as bacterial me-
tastasis in analogy to the role of Plg in tumor cell invasion (10, 31).
Originally isolated from fermented milk (19) and commonly
found in the gut of healthy adults and infants (38), B. animalis
subsp. lactis has been shown to possess a mutualistic nature, and
its capacity to intervene with the host Plg system must serve a
different purpose than the bacterial metastasis (7). Consequently,
even if B. animalis subsp. lactis and pathogens show the same
modality of interaction with the components of the host Plg sys-
tem, the outcome of Plg-binding activity in the biology of inter-
action with the host must be different, and comprehension of its
significance in bifidobacterial ecology is needed. In this work, we
studied the role of the human Plg system in the early interaction
process between B. animalis subsp. lactis BI07 and the human
enterocyte line HT29 (26). Moreover, since gastrointestinal in-
flammatory processes involve unbalances of the components of
the host Plg system (14, 20, 23), we investigated the impact of the
proinflammatory cytokine tumor necrosis factor alpha (TNF-)
on the dynamics of the Plg-mediated B. animalis subsp. lactis
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BI07-HT29 cell early interaction. TNF-was selected because this
cytokine has been reported to play a central role in intestinal in-
flammation (18, 40).
HT29 cell culture conditions.HT29 cells were grown in Dul-
becco’s modified Eagle’s minimal essential medium with 4.5 g/li-
ter glucose (DMEM; PAA Laboratories) as reported by O’Hara et
al. (22). For adhesion and intracellular invasion assays, 2.5 105
HT29 cells per well were seeded in 24-well tissue culture plates
(TPP) and 12-mm-diameter glass coverslips and grown to conflu-
ent monolayers. For the transmigration assay, 1  105 cells were
layered on 3-m-pore size transwell inserts (Falcon; BectonDick-
inson) in 24-well tissue culture plates and allowed to grow to
confluent and fully differentiatedmonolayers. The tightness of the
cell layers was verified as described byAttali et al. (2). Twenty-four
hours before each assay, the cell medium was replaced with inter-
action medium (IM) (DMEM, 25 mM HEPES, 1 g/liter glucose
[Gibco], 1% fetal calf serum [FCS]); when necessary, 2 ng/ml
human recombinant TNF- (Thermo Scientific) was added to
induce a proinflammatory response (22).
Role of human Plg in the interaction process of B. animalis
subsp. lactisBI07andHT29cells.Toassesswhether theHT29 cell
endogenous Plg contributed to the early interaction between B.
animalis subsp. lactis BI07 and HT29 cells, the impact of the en-
terocyte pretreatment with polyclonal goat anti-human Plg IgG
(Kordia) (5g/ml) on B. animalis subsp. lactis BI07 adhesion was
determined. B. animalis subsp. lactis BI07 adhesion to HT29
monolayers was measured by quantitative PCR (qPCR) as re-
ported by Candela et al. (9). For each experimental condition, six
independent replica experiments were performed. According to
our data, the anti-human Plg pretreatment resulted in a slight, but
not significant (P 0.05), decrease of the bifidobacterial adhesion
to the enterocyte surface (16%). These data indicated that the
endogenously produced Plg of HT29 cells exerted only a minimal
contribution to the B. animalis subsp. lactis BI07-HT29 cell adhe-
sion process. Consequently, in order to investigate the role of hu-
man Plg in the B. animalis subsp. lactis BI07-enterocyte interac-
tion process, bacterial cells were preincubated with human Plg
(Sigma) as reported by Attali et al. (2) and then subjected to a
conventional HT29 cell adhesion assay (9). Thirty-minute prein-
cubation at 37°C with 100 g/ml human Plg significantly en-
hanced B. animalis subsp. lactis BI07 adhesion to HT29 cells
(225%; P 0.001) (Table 1). The incubation of Plg-pretreated
B. animalis subsp. lactis BI07 cells with 5 g/ml anti-human Plg
IgG resulted in the complete abolition of the Plg contribution to
the bifidobacterial adhesion to the HT29 cell surface. These data
demonstrated that human Plg captured on the B. animalis subsp.
lactisBI07 cell surface significantly enhanced bacterial adhesion to
the host enterocytes. As suggested by Pancholi et al. (24), the bac-
terium-bound Plg can act as a molecular bridge between bacterial
and enterocyte receptors, enhancing bacterial adhesion to the host
epithelium. Incubation of Plg-pretreated B. animalis subsp. lactis
BI07 cells with 1 g/ml uPA (Sigma) decreased the HT29 cell
adhesion by 50% with respect to the value obtained in the ab-
sence of uPA (P 0.001) (Table 1). The addition of 8 U/ml of the
plasmin inhibitor aprotinin (Sigma) (2) was effective in the com-
plete recovery of the Plg-dependent enterocyte adhesion of B. ani-
malis subsp. lactis BI07 cells preincubated with Plg plus uPA (Ta-
ble 1), proving that the acquisition of a cell surface plasmin activity
in the presence of uPA was sufficient to dampen the contribution
of Plg to the B. animalis subsp. lactis BI07 adhesion to the entero-
cyte surface.
Next, we investigated HT29 cell internalization and transmi-
gration of untreated, pretreated with Plg or with Plg and uPA B.
animalis subsp. lactisBI07 bacteria. Enterocyte internalizationwas
analyzed by double immunofluorescence microscopy, which en-
ables a differential staining of intracellular and adherent bacterial
cells, as reported by Bergmann et al. (4). For each experimental
condition, three independent adhesion experiments were carried
out. Antibodies against B. animalis subsp. lactis BI07 were gener-
ated in BALB/c mice according to standard protocols. Micro-
scopic analysis of the whole HT29 cell layer revealed no bacterial
internalization by theHT29 enterocyte cell line in any of the tested
conditions (Fig. 1A). For comparison and as a control, the
internalization of Salmonella enterica serovar Typhimurium by
HT29 cells was determined using a gentamicin protection assay
(13). S.Typhimurium, provided by A. Essig (Department ofMed-
ical Microbiology, University of Ulm, Germany), was cultured as
reported byCandela et al. (9). In accordancewith data reported by
Hess et al. (13), we determined aHT29 cell internalization value of
(9.32 1.58) 104 CFU of S. Typhimurium after 1 h of incuba-
tion with 1 108 CFU of this microorganism. In order to analyze
the B. animalis subsp. lactis BI07 transmigration through HT29
monolayers, a transwell system-based transmigration assay was
performed as reported by Attali et al. (2). Untreated, Plg-pre-
treated, and Plg- and uPA-pretreatedB. animalis subsp. lactisBI07
cells showed no transmigration through the HT29 monolayers
(data not shown). In a control experiment, the transmigration of
S. Typhimurium bacteria across HT29 monolayers was deter-
mined. In accordance with the data reported by Hess et al. (13),
(7.84 1.03) 105 bacteria penetrated from the apical compart-
ment to the basal compartment of HT29 cells after 1 h of coincu-
bationwith 2 107CFU.These last data proved that inB. animalis
subsp. lactis BI07, the acquisition of a surface-associated plasmin
activity did not result in enterocyte internalization or bacterial
transmigration through enterocyte monolayers, supporting the
strict commensal nature of this health-promoting species.
Even if the modality of interaction between B. animalis subsp.
TABLE 1 qPCR quantification of the Plg-mediated adhesion of B.
animalis subsp. lactis BI07 to untreated and TNF--pretreated
HT29 cells
Experimental condition(s)a
No. of bacteria/HT29 cell
(mean SD)
No treatment  TNF-
BI07 18.87 1.20 26.65 2.02
BI07 Plg 61.08 2.85 41.09 2.74
BI07 Plg anti-Plg 19.40 1.24 NDb
BI07 Plg uPA 28.87 1.93 36.57 2.27
BI07 Plg uPA aprotinin 81.15 3.58 79.81 3.52
BI07 Plg aprotinin ND 75.96 5.67
BI07 aprotinin 20.23 2.21 23.55 1.55
a Untreated and TNF--pretreated ( TNF-) confluent HT29 cell monolayers were
incubated with 5 107 CFU of untreated B. animalis subsp. lactis BI07 cells (BI07),
Plg-pretreated BI07 cells (BI07 Plg), Plg-pretreated BI07 cells incubated with anti-Plg
IgG (BI07 Plg anti-Plg), Plg- and uPA-pretreated BI07 cells (BI07 Plg uPA),
Plg- and uPA-pretreated BI07 cells in the presence of aprotinin (BI07 Plg uPA
aprotinin), Plg-pretreated BI07 cells in the presence of aprotinin (BI07 Plg
aprotinin), and BI07 cells in the presence of aprotinin (BI07 aprotinin).
b ND, not determined.
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lactis and the components of the host Plg system resembles the one
described for several pathogens (16, 25, 29, 30, 32, 36), our data
demonstrated that the consequences of this interaction with re-
spect to host colonization are different. In fact, for both B. anima-
lis subsp. lactis and pathogenic bacteria, cell-bound Plg enhances
bacterial adhesion to the host epithelium (2, 24), but in the pres-
ence of host PAs, the phenotype of interaction with the host be-
comes totally different. Different from the case for pathogens, in
B. animalis subsp. lactis, the acquisition of surface-associated plas-
min activity does not result in pericellular invasion but rather
supports bacterial migration to the luminal compartment. Thus,
common to symbionts and pathogens (1, 15), the bacterial capac-
ity to intervene with the host Plg system cannot be viewed as a
determinant of pathogenicity by itself. Instead, it could be re-
garded as an ancestral mechanism of bacterium-host interaction
evolved prior to the radiation of pathogens from commensals (6,
21). Acting in concert with other virulence attributes (2, 21), the
capacity to intervene with the host Plg system appears to be a
fundamental prerequisite for host invasion only for pathogens
(37).
Impact of TNF- on the Plg-mediated early interaction be-
tween B. animalis subsp. lactis BI07 and HT29 cells. To mimic
an inflammatory status, HT29 cell layers were preincubated with
the proinflammatory cytokine TNF-, and their early interaction
with Plg- or Plg- and uPA-pretreated and untreated B. animalis
subsp. lactis BI07 cells was investigated by qPCR and immunomi-
croscopic analysis as reported above. Interestingly, we detected
only a minor increase of B. animalis subsp. lactis BI07 adhesion in
TNF--stimulated HT29 monolayers after Plg pretreatment (Ta-
ble 1). Moreover, after the TNF- preincubation of HT29 layers,
FIG 1 Intracellular invasion assays of B. animalis subsp. lactis BI07 in untreated (A) and TNF--pretreated (B) HT29 cells. HT29 cell monolayers grown to
confluence were incubated with 5  107 CFU of B. animalis subsp. lactis BI07 untreated (BI07), pretreated with Plg (Plg) and pretreated with Plg and uPA
(PlguPA). Intracellular and adherent bacteria were differentiated by double immunofluorescence microscopy. Adherent B. animalis subsp. lactis BI07
bacteria (indicated by arrows) were stained with mouse antibifidobacterial antiserum followed by a secondary Alexa Fluor 488-conjugated anti-mouse antibody
(green). After HT29 cell permeabilization, internalized bacteria were stained with mouse antibifidobacterial antiserum and a secondary Alexa Fluor 568-
conjugated anti-mouse antibody (red). HT29 cells are visualized in the corresponding phase-contrast images shown in the lower panel (magnification,100).
For each experimental condition, the assay was repeated three times. Results of a representative experiment are shown.
Biﬁdobacterium-Enterocyte Plg-Mediated Interaction
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Plg-pretreated and Plg- and uPA-pretreated B. animalis subsp.
lactis BI07 cells exhibited comparable adhesion values (Table 1).
The addition of aprotinin effectively restored the Plg-dependent
B. animalis subsp. lactis BI07 adhesion to TNF--stimulated
HT29 layers for both Plg- andPlg- and uPA-pretreatedB. animalis
subsp. lactis BI07 cells (Table 1). Analogous to the data obtained
with noninflamed HT29 cells, no bacterial internalization (Fig.
1B) or transmigration (data not shown) was detected when TNF-
-stimulated HT29 cells were incubated with Plg-pretreated, Plg-
and uPA-pretreated, and untreated B. animalis subsp. lactis BI07
cells. Taken together, these data indicated that, by enhancing the
enterocyte capacity to activate Plg, a TNF--mediated inflamma-
tory response can modulate the dynamics of the Plg-mediated
early interaction between B. animalis subsp. lactis and human en-
terocytes, lowering bacterial adhesion to the enterocyte surface
and shifting migration to the luminal compartment. Confirming
this hypothesis, in a conventional plasmin activity assay (2, 7), we
demonstrated that the TNF- pretreatment increased by 2-fold
the HT29 cell capacity to activate Plg (P 0.001).
Our data suggest that B. animalis subsp. lactis BI07 shows a
different phenotype of interaction with the host Plg system de-
pending on the inflammatory status of the host GIT epithelium.
While Plg enhances B. animalis subsp. lactis adhesion in a nonin-
flamed GIT epithelium, inflammation would result in the activa-
tion of bacterium-bound Plg and mediate the migration of the
microorganisms to the luminal compartment. We hypothesize
that this particular dynamic of interaction between B. animalis
subsp. lactis and the components of the host Plg system could be of
some relevance in the bifidobacterial microecology in the human
GIT. In noninflamed regions of the human GIT, which represent
the suitable ecological niche for B. animalis subsp. lactis, the mi-
croorganism can take advantage of the host Plg for the adhesion to
themucosal surface. On the other hand, in inflamed tissue sites,B.
animalis subsp. lactis would acquire a surface-associated plasmin
activity that, facilitating the bacterial migration to the luminal
compartment, could function as a bacterial escape mechanism to
circumvent the host inflammatory response. Unable to face in-
flammation (34),B. animalis subsp. lactismay thus utilize the host
Plg system to sense and escape intestinal inflammation, abandon-
ing inflamed gastrointestinal sites in favor of noninflamed ones.
Our in vitromodel of interaction could explain, at least in part, the
observed decrease of the relative abundance of Bifidobacterium in
inflammatory bowel disease (IBD) subjects (33, 39).
Conclusions. Investigating the role of Plg in the bifidobacterial
biology in the human GIT, our experimental work represents a
step forward in the comprehension of the factors that play a role in
the dynamics of Bifidobacterium-host interaction in the human
GIT. However, our in vitro data need to be confirmed by in vivo
studies specifically designed to prove the role of the host Plg sys-
tem in the inflammation-dependent bifidobacterial decrease in
the human GIT. The achievement of this goal will allow a better
understanding of the biology of this health-promotingmicrobiota
component in the human GIT.
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